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Resumo 
Portugal apresenta uma alta prevalência de sobrepeso e obesidade em idade pediátrica, 
sendo que um terço das crianças e adolescentes apresentam excesso de peso.  
A obesidade está associada a doenças tais como a hipertensão arterial, diabetes mellitus 
tipo 2, dislipidemia e aterosclerose e a um risco aumentado de doença cardiovascular no 
futuro. O aumento da prevalência da obesidade infantil tem contribuído para o 
aparecimento dessas patologias em indivíduos cada vez mais novos. 
O tecido adiposo secreta inúmeros mediadores com um papel importante no 
desenvolvimento do estado crónico de inflamação de baixo grau presente nos indivíduos 
obesos. A adiponectina, uma adipocina anti-inflamatória secretada principalmente pelo 
tecido adiposo, está relacionada com uma melhoria do perfil lipídico e da sensibilidade à 
insulina. A adiponectina circula como multímeros de alto, médio e baixo peso molecular 
(APM, MPM e BPM, respectivamente). O multímero de APM, descrito como sendo o mais 
biologicamente ativo e responsável pelas ações benéficas atribuídas à adiponectina, está 
reduzido em pacientes obesos. Pouco se sabe sobre as funções biológicas dos outros 
multímeros. 
Neste projecto estudámos numa população pediátrica obesa Portuguesa diversos fatores 
de risco cardiovascular (novos e clássicos) e polimorfismos genéticos com eles 
associados. Posteriormente, avaliámos o impacto da redução do índice de massa 
corporal (IMC) nesses factores de risco, obtida por dois métodos: um programa de 
modificação do estilo de vida e um programa de intervenção com exercício físico. 
Verificámos que as crianças e adolescentes obesos apresentavam um agravamento do 
perfil de risco metabólico, quando comparado com os controlos normoponderais, 
observando-se: 1) um aumento da resistência à insulina, com o aumento da insulinemia e 
do índice homeostasis model assessment – insulin resistance (HOMAIR); 2) um perfil 
lipídico com modificações de risco, nomeadamente um aumento dos triglicerídeos (TG), 
do colesterol total (CT) e do colesterol das lipoproteínas de baixa densidade (LDLc), e 
redução do colesterol das lipoproteínas de alta densidade (HDLc); 3) uma redução da 
proteção antioxidante nos indivíduos mais obesos, com redução da bilirrubina plasmática; 
4) um estado inflamatório de baixo grau, com aumento da proteína C-reativa (PCR) 
plasmática e da neutrofilia e diminuição da adiponectina. O agravamento do perfil 
metabólico foi particularmente notório com o aumento da obesidade abdominal, um 
componente da síndrome metabólica (SM). Mais ainda, os adolescentes obesos com SM 
apresentavam um perfil de maior risco, quando comparados com obesos sem SM. A 
prevalência da SM na nossa população de obesos foi elevada - 24,8%. 
Na nossa população de adolescentes obesos, o critério do Center for Disease Control 
and Prevention para a classificação do z-score do IMC em populações pediátricas foi um 
melhor preditor da SM do que o critério utilizado pela Organização Mundial da Saúde. 
Os níveis de adiponectina circulante correlacionaram-se inversamente com marcadores 
de adiposidade (IMC, circunferência da cintura e % de gordura corporal), com a 
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dislipidemia (níveis de TG e razão CT/HDLc), com a resistência à insulina (insulinemia e 
o HOMAIR) e com o status inflamatório (níveis de PCR); contrariamente, os níveis de 
adiponectina apresentaram uma correlação positiva com os de HDLc. As diferentes 
formas circulantes de adiponectina apresentaram atividades distintas nos indivíduos pré-
púberes estudados. Enquanto a forma de APM espelhou os efeitos benéficos associados 
à adiponectina total, particularmente em relação ao perfil lipídico, o multímero de BPM 
apresentou resultados opostos. 
Alguns dos polimorfismos genéticos estudados evidenciaram uma associação com um 
perfil de maior risco metabólico; os indivíduos obesos com o alelo E4, do polimorfismo da 
apolipoproteína (apo) E, apresentaram um perfil lipídico de risco mais aumentado 
(aumento do CT, do LDLc e da razão CT/HDLc); os indivíduos obesos com menor 
número de repetições no polimorfismo de repetição pentanucleotídica, (TTTAT)n, da apo 
(a) apresentaram um aumento da lipoproteína (a) sérica; e os indivíduos homozigotos 6/6 
para o polimorfismo UGT1A1*28 da UDP-glucuronosiltransferase apresentaram uma 
redução da bilirrubina plasmática. No entanto, verificámos que o efeito de um perfil 
genético menos favorável sobre os marcadores de risco pode ser modulado pela redução 
da adiposidade e dos mediadores inflamatórios. De facto, identificamos a % de gordura 
corporal como um preditor dos níveis plasmáticos de bilirrubina, independentemente do 
polimorfismo UGT1A1*28; os níveis circulantes de adiponectina também se associaram a 
modificações no perfil lipídico (ex. razão TC/HDLc) independentemente do polimorfismo 
da apo E. 
Relativamente ao estudo longitudinal, os resultados de ambas as abordagens foram 
semelhantes. Uma pequena redução de adiposidade em indivíduos obesos foi associada 
a melhorias nos marcadores de risco cardiovascular, nomeadamente no perfil lipídico 
(redução dos TG, do CT, da LDLc e da razão CT/HDLc), e da sensibilidade à insulina 
(redução da insulina e do HOMAIR). Contudo, as alterações nos mediadores inflamatórios 
não foram significativas, podendo ser necessárias reduções mais pronunciadas no peso 
para serem notadas, visto a redução da adiposidade se correlacionar com o aumento da 
adiponectina sérica (total, de APM e de MPM) e com a redução dos valores plasmáticos 
da PCR. 
Em conclusão, encontram-se alterados vários marcadores de risco cardiovascular em 
idades precoces, em obesos Portugueses. Abordagens de intervenção voltadas para as 
escolas e comunidades são boas opções para reduzir a obesidade e o sobrepeso e, 
assim, o risco de doença cardiovascular na vida futura de crianças e adolescentes. Este 
trabalho demonstrou que mesmo pequenos progressos no IMC já estão associados a 
melhorias no perfil lipídico e na resistência à insulina. Demonstrámos, igualmente, que 
estas mesmas reduções ponderais podem contrabalançar perfis genéticos menos 
favoráveis.  
Palavras-chave: obesidade infantil, síndrome metabólica, inflamação, adiponectina, 
exercício físico. 
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 Abstract 
Portugal has a high prevalence of overweight and obesity in pediatric ages, presenting 
one third of children and adolescents weight excess.  
Obesity is associated with diseases such as hypertension, type 2 diabetes mellitus, 
dyslipidemia, atherosclerosis and an increased risk of cardiovascular disease later in life. 
The increase in pediatric obesity has contributed to the appearance of those pathologies 
in increasingly young individuals.  
The adipose tissue secrets many mediators and have an important role in the state of 
chronic low-grade inflammation described in obese individuals. Adiponectin, an anti-
inflammatory adipokine secreted mainly by the adipose tissue in humans, is related to an 
improvement of insulin sensitivity and lipid profile. Adiponectin circulates as low, medium 
and high molecular weight multimers (LMW, MMW and HMW, respectively). The HMW 
multimer, reported to be the most biological active form and responsible by the benefic 
actions attributed to adiponectin, appears to be reduced in obese patients. Little is known 
about the biological functions of the other circulating forms. 
In this project, we studied in a Portuguese obese pediatric population several 
cardiovascular risk factors (classical and new), and associated genetic polymorphisms,. 
Afterwards, we evaluated the impact of changes in body mass index (BMI), obtained by 
two approaches, in those risk factors: a lifestyle modification program and an 
interventional program involving physical exercise.  
We found that obese children and adolescents presented an increased metabolic risk 
profile, when compared to their lean counterparts, characterized by: 1) a rise in insulin 
resistance, with increased homeostasis model assessment – insulin resistance (HOMAIR) 
and insulin levels; 2) a risk change in lipid profile, namely with increased triglyceride (TG), 
total cholesterol (TC) and low density lipoprotein cholesterol (LDLc), and reduced high 
density lipoprotein cholesterol (HDLc); 3) a reduction in the anti-oxidant protection in the 
more obese individuals, with the reduction of plasmatic bilirubin; 4) a low grade 
inflammatory status, with increased plasmatic C-reactive protein (CRP) and neutrophilia 
and reduced adiponectin. The worsening of the metabolic profile was particularly 
noticeable with increased abdominal obesity, a feature of metabolic syndrome (MS). 
Moreover, obese adolescents with MS presented a worst risk profile, when compared to 
obese individuals without MS. The prevalence of MS in our obese population was high – 
24.8%. 
In our obese adolescent population,  the Center for Disease Control and Prevention 
criterion for the classification of BMI z-score in pediatric populations was a better predictor 
of MS, in our obese adolescent population, than the criterion used by the World Health 
Organization. 
Adiponectin plasmatic levels correlated inversely with adiposity markers (BMI, waist 
circumference and % body fat), with dyslipidemia (TG and TC/HDLc ratio), with insulin 
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resistance (insulin and HOMAIR) and with inflammatory process (CRP); contrarily, the 
levels of adiponectin presented a positive correlation with circulating HDLc). The different 
circulating forms of adiponectin demonstrated different actions in pre-pubertal individuals. 
The HMW form mimicked the beneficial effects of total adiponectin, particularly regarding 
the lipid profile, while the LMW form presented opposite results.   
Some of the studied genetic polymorphisms were associated with increased metabolic 
derangement: individuals with the E4 allele of the apolipoprotein (apo) E polymorphism 
presented a worse lipid profile (increased TC, LDLc and TC/HDLc ratio); individuals with 
lower number of repeats of the apo (a) pentanucleotide (TTTAT)n repeat polymorphism 
presented increased lipoprotein (a) levels, an independent marker of cardiovascular risk; 
and homozygous 6/6 individuals for the UGT1A1*28 polymorphism of UDP-
glucuronosyltransferase presented a reduction of bilirubin levels. Nevertheless, we 
verified that the effect of a less favorable genetic profile on risk markers can be modulated 
by reductions in adiposity and inflammatory mediators. In fact, we identified the % of body 
fat as a predictor of plasma bilirubin, independently of the polymorphism UGT1A1*28; 
also, the circulating levels of adiponectin were associated with changes in the lipid profile 
(e.g. TC/HDLc ratio) independently of apo E polymorphism.  
Regarding the longitudinal studies, the result with both approaches were very similar. 
Small reductions of adiposity in obese individuals were associated to improvements in risk 
markers, namely in lipid profile (reduction of TG, TC, LDLc, TC/HDLc ratio) and insulin 
sensitivity (reduction of insulin and HOMAIR).  However, improvements in inflammatory 
mediators were not significant and might need greater weight improvements to be noticed, 
as the reduction of adiposity was correlated with improvements in total, HMW and MMW 
adiponectin and with a reduction of CRP. 
In conclusion, several markers of cardiovascular risk are changed in early ages, in obese 
Portuguese. Intervention approaches aimed at schools and communities are good options 
to reduce overweight and obesity and, thus, the risk of cardiovascular disease later in the 
life of children and adolescents. This study showed that even small improvements in BMI 
are already associated with improvements in lipid profile and insulin resistance. We also 
demonstrated that the same reductions in weight can modulate less favorable genetic 
profiles. 
Keywords: pediatric obesity, metabolic syndrome, inflammation, adiponectin, physical 
exercise. 
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1. Introduction 
Obesity is increasing worldwide in recent years, both in developed and in developing 
countries, leading many authors to refer to obesity as the pandemia of the 21st century. In 
fact, obesity is now considered as a disease with its own complexity, and has been deeply 
studied in the last years. The modern lifestyle, characterized by increased energy intake 
and reduced energy expenditure, is at the basis of the obesity phenomena (1). 
Pediatric obesity is accompanying the adult trend and has reached high rates in many 
countries. In Portugal around one third of the children are overweight or obese (2, 3).   
The weight excess in young ages is a growing concern nowadays. Besides the related 
comorbidities, both at metabolic and psychological levels, it is  associated with an 
increased risk for the appearance of a number of pathologies later in life, as type 2 
diabetes mellitus (T2DM) and cardiovascular diseases (CVD) (4-6). In fact, obesity, 
namely central obesity, is part of the metabolic syndrome (MS), a cluster of risk factors for 
CVD, which encloses dyslipidemia, hypertension, insulin resistance (IR) and impaired 
glucose metabolism (4, 5). 
The mechanisms underlying the associations between obesity and other diseases are not 
completely understood. Nevertheless, inflammatory mediators are likely to be important 
contributors, as inflammation plays a vital role in the initiation and progression of 
atherosclerosis, IR and dyslipidemia (4-6). Actually, an increase in circulating 
inflammatory mediators is often observed in obesity, contributing to the development of a 
state of chronic low grade inflammation (7, 8). 
The white adipose tissue (WAT) is responsible for the secretion of many molecules, most 
of them related to inflammation and immunity. With the enlargement of the WAT, as 
occurs in obese individuals, the type and proportions of the secreted substances turns to 
pro-inflammatory profile. These mediators will exert their actions not only within the WAT, 
but all over the organism, contributing to the appearance of obese-related comorbidities 
(7, 8). 
Different approaches have been used to overwhelm adiposity. Diet and exercise based 
programs are the traditional strategies, aiming at a more favorable caloric balance.  The 
success rates of these programs are widely variable and suffer the influence of many 
factors, such as the studied population, type of exercise used, and program duration. 
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2. Obesity in Portugal 
Overweight and obesity have increased in Portugal, and all over the world, in the last 
decades, accompanying the rise in sedentarism and unbalanced dietary habits (2, 9).  
Portuguese adult population has a high prevalence of obesity.  In fact, an increase of 
obesity prevalence between 1999 and 2006 was observed, from 12% to 15.2%. The 
prevalence was higher in the age group between 45 and 74 years, presenting a 
prevalence above 20% (10). Similar trends were found in a previous study that reviewed 
available data regarding nutritional status of the adult Portuguese population from 1995-
2005, which reported that the prevalence of overweight and obesity at 50 years of age 
were of 40.5% and 22.6% for women, and 52.7% and 19.0% for men, respectively. In the 
same study men presented a higher prevalence of overweight than women for all ages; 
men also presented an increased prevalence of obesity until 40 years and, after this age, 
higher obesity rates were observed for females (11).  
Childhood overweight and obesity are accompanying this global trend and has increased 
markedly not only in developed but also in developing countries. In Europe, this reality is 
particularly notorious in the Southern countries, including Portugal (1, 2, 9, 12). In fact, 
Portugal, Greece, Italy, Slovenia and Spain, present an increased prevalence of 
overweight and obesity in 6-9 years old children, when compared to the Northern 
countries (2, 9, 12). The adolescents from the Southern European countries also 
presented a higher prevalence of overweight and obesity than those from the Northern 
countries, in a study involving 15 years old adolescents, from countries that are members 
of the Organization for Economic Co-operation and Development (OECD). Actually, the 
prevalence of ponderal excess in Portuguese adolescents was only lower than that of the 
United States of America (USA) and Canada, for girls, and than that of the USA, Canada, 
Greece and Italy, for boys (1).  
In a national survey in 2002-2003 Padez et al. (2) found that Portugal presented a high 
rate of overweight and obesity in children from 7 to 9 years old, with 31.6% of the children 
having weight excess, of whom 11.3% were obese. In Europe, this prevalence of weight 
excess was only second to Italy (36%). A higher percentage of obesity and overweight 
was observed in girls, as compared to boys, in the Portuguese population (2, 12).  
In Évora, Alentejo, pre-school children (2-6 years) presented a high prevalence of weight 
excess and obesity (25.4% and 11.6%, respectively) (13), similarly to what was previously 
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described by Padez at al (2). A peak at 3 years of age was present, with 33.3% of the 
children of this age group being overweight or obese. The prevalence of overweight in 
girls was also higher than in boys. It is interesting to notice that a high prevalence of 
parental obesity was present for these children; about 2/3 of the children had at least one 
of the parents with overweight, although no significant difference was seen between the 
parents of normal and overweight children (13).  
Other studies in cities from different regions of Portugal [Porto (14), Coimbra  (3) and 
Famalicão (15)], involving children with similar ages to the study of Padez at al (2), also 
found a high prevalence of overweight and obesity, although some fluctuations were 
present, partially caused by actual geographic differences and by the use of different 
criteria to diagnose obesity.  
A recent study in the central region of Portugal involving children from 6-12 years of age, 
also found alarming results. There was a prevalence of combined overweight/obesity of 
33,0%, being 10,7% of the studied children obese. Contrarily to the previous studies, boys 
presented increased prevalence of overweight (25.9 vs 19.0%) than girls, while no 
difference was present for obesity prevalence. Boys also presented a worse body fat 
distribution, as measured by the waist circumference / height (WC/H) ratio; 28.1% of the 
boys (vs 19.4% of the girls) presented a ratio higher than 0.5, a cut-off used to identify 
individuals with increased metabolic risk (16). In this study, a trend towards an increase of 
weight excess in the oldest studied children was noted, when comparing to the previous 
values reported by Padez et al. Indeed,  when analyzing only the children between 7-9 
years, an increase of about 10% in the prevalence of overweight/obesity, between the two 
studies, was noticed (2, 16).  
An increase in the prevalence of obesity in older ages (15 years) was also found for 
almost all OECD countries, including Portugal, although for some (few) countries the 
prevalence of obesity in girls appears to be diminishing (1). 
When anthropometric data of Portuguese children through the last 3 decades is analyzed, 
a clear increase in height and weight is notorious (1970-2002). This increase was 
associated with the progress of the living conditions and health system during that period. 
However, although generally positive, this improvement led to the secondary problem of 
obesity as the secular evolution of weight was more marked than that of height, causing 
an increased prevalence of children and adolescents with unbalanced body mass index 
(BMI) (2).  
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The most recent Portuguese national survey was conducted by Rito et al. in 2007-2008 
and involved children from 6 to 8 years old. This survey used 3 of the available references 
to define childhood overweight and obesity: the International Obesity Task Force (IOTF) 
reference; the 2000 Centre for Disease Control and Prevention (CDC) reference 
(recommended by the Portuguese Ministry of Health until 2012); and the World Health 
Organization (WHO) reference, 2007 (the currently accepted reference). The use of the 
different cut-offs lead to different outputs: the IOTF criterion resulted in lower prevalence 
of overweight and obesity and increased rates of thinness; the WHO reference led to 
lower prevalence of thinness and higher prevalence of obesity and overweight; and the 
CDC criterion resulted in an intermediate prevalence, between the other two references. 
In fact, using the IOTF reference, the prevalence of thinness, overweight and obesity in 
Portugal were of 4.8%, 28.1% and 8.9%, respectively; using the CDC reference the 
prevalence values were of 2.1%, 32.2% and 14.6%, respectively; and according to the 
WHO reference, the values were of 1.0%, 37.9% and 15.3%. The complexity of using 
different classifications is not only a matter of moving the distribution curve to the right or 
to the left; indeed, the prevalence is different in absolute values and, sometimes, the use 
of different references can give opposite results as, in this study, using IOTF criterion, the 
girls had increased prevalence of thinness, when compared to boys, while opposite 
results were found when applying the other 2 references. For all references the boys 
presented a higher percentage of obesity and combined overweight and obesity than girls, 
however, gender was not a predictor of the nutritional status (17). 
Rito et al. studied the nutritional status of children across the different Portuguese regions. 
Algarve was the region with the lowest prevalence of overweight/obese, while the islands 
of Açores and Madeira presented the highest prevalence (Table 1, using WHO as 
reference). This study showed that the risk of childhood obesity was related to the 
geographic region, increasing for children living in urban areas, and that obesity was not 
influenced by gender or by age (17). 
The regional distribution of obesity prevalence in Portugal for 6-8 years old children was 
similar to the distribution reported for adults, as presented in Table 1. 
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Table 1. Prevalence of obesity and overweight in children and 
adults from different Portuguese regions 
 Adults Children
1
 
 Obesity (%) Obesity (%) Overweight
2
 (%) 
Norte 14.9 14.4 38.6 
Centro  13.1 16.0 38.1 
Lisboa e Vale do Tejo  16.8 16.0 38.3 
Alentejo  15.5 13.0 31.6 
Algarve  12.0 9.7 21.4 
Açores NA 16.5 39.4 
Madeira NA 15.3 37.9 
Portugal  15.2
3
 15.3 37.9 
NA, not available. 1, 6 to 8 years; 2, combined overweight and obesity; 3,
 
values from 
continental Portugal only. Adapted from (17, 18). 
 
The results of revision studies accessing the prevalence of overweight and obesity in pre 
and primary school children in different Portuguese regions and in two European countries 
(Latvia and Italy) are presented in Table 2. The age range (3-12 years old) was chosen 
because the majority of the prevalence pediatric studies in Portugal has been performed 
within this range. The option of researchers to work in this age range is probably due to 
the fact that it is in this development period that the adiposity rebound takes place; 
therefore, this in an important period for health professionals to intervene and prevent the 
development of obesity; furthermore, the confounding effects of puberty are still not 
present (2, 17). Prevalence from Italy and Latvia are highlighted due to their opposite 
rates: Italy present a high prevalence of childhood overweight and obesity (similar to 
Portugal), while Latvia present one of the lowest prevalence in Europe (9). 
The differences in the prevalence of obesity highlight the importance of the environmental 
factors, namely, socio-economic realities, which might lead to significant variations, even 
in a relatively small country as Portugal. 
It is also important to emphasize that the use of different criteria for the classification of 
the children nutritional status makes difficult the comparison between studies. This has 
also occurred in Portuguese studies.  
In the Netherlands there is also a wide variance in the diagnosis criteria and in the 
treatment strategies followed by different pediatricians. Pediatric specific cut-off values, 
adapted for age and sex, were only used by 60% of the pediatricians (32% used the IOTF 
criterion, while 28% used Netherland population specific cut-off). Surprisingly, around 40% 
of the pediatricians used adult cut-offs for BMI, causing an underestimation of the 
prevalence of overweight and obesity in children and adolescents (19).  
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Table 2. Prevalence of overweight and obesity in pre and primary school children, in different Portuguese regions and 
European countries 
Autor Country Region Period Participants 
Female  
(n) 
Age 
(years) 
Criteria OW+OB (%) OB (%) 
Rito 2006 (3) Portugal 
Coimbra – 
Central 
2001 2350 1168 3-6 CDC 23.6 6.7 
Gomes 2010 (13) Portugal Évora – Central 2007 313 137 2.2-6.8 CDC 25.4 11.6 
Branco 2011 (15) Portugal 
Famalicão – 
North 
2009 207 102 6-7 CDC 46.9 28.5 
Ferrão 2013 (14) Portugal Porto – North 2009 2690 1377 6.7±2.2 IOTF 31.8 10.3 
Albuquerque 2012 
(16) 
Portugal Central 2011 1433 747 9.3±1.8 IOTF 33.0 10.7 
Padez 2005 (2, 12) Portugal National Survey 2002-2003 4511 2274 7–9 CDC 31.6 11.3 
Rito 2008 (17) Portugal National Survey 2007-2008 3765 1871 7.0±0.7 
IOTF 28.1 8.9 
CDC 32.2 14.6 
WHO 37.9 15.3 
Wijnhoven 2012 (9)
1
 Europe 
Portugal 2008 1815 904 7 
IOTF 26.8/28.5
2
 7.9/9.3
2
 
WHO 40.5/35.5
2
 16.7/12.6
2
 
Italy 2008 5144 2515 8 
IOTF 37.2/34.7
2
 13.6/11.8
2
 
WHO 49.0/42.5
2
 26.6/17.3
2
 
Latvia 2008 3249 1598 7 
IOTF 15.3/15.1
2
 4.5/3.1
2
 
WHO 24.0/18.9
2
 8.6/4.6
2
 
CDC, Centre for Disease Control; F, female; IOTF, International Obesity Task Force; M, male; OB, obese; OW, overweight; WHO, World Health Organization; Y, 
year. 1, European survey of 12 Countries: Belgium, Bulgaria, Czech Republic, Ireland, Italy, Latvia, Lithuania, Malta, Norway, Portugal, Slovenia and Sweden; 2, 
percentages for males/females. 
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Obesity has been an important point of discussion in the last years, what might have 
contributed to an increased awareness of the general public to this problem. Actually, the 
increase in the obesity and overweight prevalence, as determined by self-reported 
measurements, in the period of 1995-2005, accompanying the changes in objectively 
measured anthropometric data, might corroborate that awareness. Nevertheless, the 
increasing obesity and overweight rates in young adults in the same period highlights that 
this nutritional problem is far from solved. This fact can be related to an obesogenic 
environment, present since early in life, and that makes unhealthy choices the easier 
ones. Thus, a growth of obesity-related comorbidities can be expected in the next years in 
Portugal, particularly if objective actions to fight it are not taken (11). 
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3. Risk factors for obesity 
The development of overweight or obesity depends on a variety of risk factors, hereditary 
and environmental. The interaction between specific genes and the environment may 
trigger the obese phenotype to emerge. Different factors are known to increase the risk for 
childhood obesity, such as: genetic factors, family habits, socio-economic environment, 
sedentarism and diet (20, 21). The risk factors are, usually, associated with either an 
increase in energy intake or with reduced energy expenditure. Some of the most important 
risk factors for obesity are presented in Table 3. 
Intra-uterine life and early childhood appear to be crucial periods for the development of 
obesity later in life. Differences in growth patterns during intra-uterine life and young ages 
have been associated with increased risk for developing obesity both in childhood and in 
adulthood. Early life development must be linked to structural and physiological changes 
that will modulate the metabolism and influence the development of obesity and other 
diseases later in life (20, 21).  
Although some obesity risk factors are common in different societies due to globalization, 
others are very cultural-specific, such as particular types of food and socio-economic 
development (20, 21). 
Obesity is closely linked to many cardiovascular disease (CVD) and metabolic risk factors, 
each one with particular environmental and genetic determinants. The genetic correlation 
between anthropometric and metabolic risk factors (e.g. lipid profile and glucose 
metabolism) suggests the existence of pleiotropic genes influencing more than one risk 
factor and, thus, leading to their clustering (21).  
Premature children usually experience what is called a catch-up growth, and are referred 
to fully achieve their genetic growth potential; however, the risk of obesity according to 
birth weight seems to follow a U-shaped curve, with increased risk for extreme values (22, 
23). 
In agreement, premature children (2-6 years old) from Évora, presented the greatest odds 
for overweight. Nevertheless, no relation was found between obesity and the absolute 
birth weight or the maternal weight gain during pregnancy. Also, no ponderal differences 
were present between parents of overweight/obese and lean individuals (13). 
 
Genetic contribution and follow up study based on the reduction of the body mass index 
10 
 
Table 3. Risk factors for the development of pediatric overweight and obesity 
Group of risk factors  Risk factors 
Physical (in)activity 
 Increased hours of  screen time (TV watching, video games, computers)  
 Decreased hours of extra-curricular activities  
 Use of passive transport 
 Reduced physical activity habits 
Energy intake 
 General unbalanced diet 
 Snacking and consume of fast food and sweetened drinks 
 Consume of  processed  caloric dense foods 
 Binge eating and bulimia 
 Skipping breakfast 
 Low fiber diet 
 Low number of meals per day and irregular meal schedule 
 Increased meal portion size 
Personal history  
 Maternal gestational diabetes 
 Prematurity 
 Low / high birth weight (adjusted for gestational age) 
 Short duration of breast feeding (< 3 months) 
 Unbalanced diet in first childhood (e.g. protein excess) 
Family factors 
 Parental obesity 
 Family history of obesity and overweight  
 Small families (low number of siblings) 
 Lower parental education 
 Lower socio-economic status 
Environmental factors 
 Geographic region (e.g. living in islands increase the risk of obesity) 
 Living in urban areas* 
 Developing countries* 
 Ethnic minorities 
 Exercise and physical activity unfriendly environment 
* increased risk is not well established. 
 
Padez et al. studied the risk factors associated to ponderal excess in a Portuguese 
children population (12). Girls presented a higher risk of overweight or obesity than boys. 
The risk of obesity also increased with parental obesity (more significantly with maternal 
obesity), lower parental education, smaller families (lower number of siblings), lower 
number of sleeping hours, increased hours of television watching, increased birth weight 
and breastfeeding duration shorter than 3 months (12). In agreement, a study in 
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Famalicão (6 and 7 years old children) also found trends towards increased risk of obesity 
in girls, for children born with increased birth weight, decreased parental education, 
increased hours of television watching and for children living in rural areas (15). Padez et 
al. found no influence of physical activity and energy ingestion on the risk of becoming 
obese (12). The lack of association of these last two variables, commonly associated with 
obesity, might be caused by the fact that they were obtained through a questionnaire, and 
not objectively measured (12). In a similar study in Japanese adolescents, an increased 
risk of obesity was observed for individuals that did less exercise, expended more hours 
playing video games or did not have breakfast (24).  
The importance of the environment on increased risk of childhood obesity is focused in a 
study by Ferrão et al. (14). This study, involving children between 3 and 10 years of age, 
in Porto, found that children were at increased risk of obesity if their parents had a bad 
perception of neighborhood safeness for children to walk or ride a bike during day or 
night, of the local traffic or of the quality of sidewalks (14). Parents that perceive their 
neighborhood as unsafe are less likely to allow their children to engage in outdoors 
activities. Interestingly, Branco et al. found a trend to an increased risk of obesity in 
children leaving in rural areas, which are generally accepted as safer to outdoor activities 
than urban areas (15). Thus, there are different aspects influencing the development of 
childhood obesity. 
Contrarily to the findings of Branco in Famalicão (15), the study by Rito et al. found an 
increased risk of obesity for children living in cities, when compared to children in the rural 
areas (17). Gomes et al., on the other hand, found no difference in the prevalence of 
overweight/obese children from rural and urban areas of Évora (13). The definition used to 
validate a risk factor is crucial for the statistical outcome. The definition used by Rito and 
Gomes was that of the National Institute of Statistic, based on which Alentejo is the only 
rural region in Portugal, while the definition used by Branco is not clear. The fact that 
Évora is a city in Alentejo might have included a bias in the analysis (13). 
The risk factors for the development of obesity described in the Portuguese population are 
similar to other populations. Some differences may, actually, result from socio-cultural 
factors and others might be influenced by study designs and analytical bias (e.g. use of 
questionnaires instead of objective measures). 
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4. Diagnosis and evaluation in pediatrics 
The procedures recommended for the diagnosis of overweight and obesity in pediatric 
patients are standardized, although some differences are seen between pediatricians and 
centers. These differences involve, mostly, the type of measurements and determinations 
made and their valorization. Besides these differences within the same country, the 
differences between different countries are more marked and make it difficult to compare 
different studies (6, 25). 
The Portuguese National Child and Adolescent Health Program (NCAHP) includes 
several medical appointments, at specific time points, to evaluate pediatric development 
at physical, psychological and social levels. In each visit, starting at birth, different check 
points are screened, corrective measures are taken, if necessary, and reevaluated in the 
next appointment. Anthropometric measurements are taken at all medical visits and 
nutritional status is evaluated according to growth charts (18). 
The use of gender and age adjusted growth charts is crucial to evaluate and follow the 
child/adolescent development. Portugal used until 2012 the CDC 2000 growth charts, 
which were built based in the American population. Since 2012, it is recommended the 
use of the WHO “Child Growth Standards”, from birth until 5 years of age, and the “WHO 
Reference 2007” growth charts, from 5-19 years of age. The WHO criterion is reported to 
be more sensitive to identify groups of lean, overweight and obese subjects, each 
presenting different biochemical and vascular characteristics, gradually worsening from 
lean to obese children (6).  
The development of WHO Child Growth Standards (0-5 years) resulted from an initiative 
involving 5 countries (Brazil, USA, Norway, Oman and India). To develop these new 
charts only children in their maximum growth potential were included and followed. These 
children come from normal term pregnancies, were breast-fed for at least 3 months and 
had a correct nutritional diversification. Country specific charts are constructed using, 
usually, a single population without the best development conditions; thus, these charts 
might have limited applicability.  As the WHO growth charts were constructed using a 
multicenter initiative, they can be internationally applied, and used for comparisons 
between different countries. In fact, these charts were first tested in four countries in pilot 
studies and similar results were obtained. Furthermore, a good relation between the 
measured anthropometric variables and other developmental and biochemical markers 
were confirmed. The construction of the WHO reference 2007 (5-19 years) involved the 
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use of the 1977 National Centre for Health Statistics (NCHS, USA) data that included 
children who had reached their full height potential without being overweight, after 
removing the outliers. The NCHS data were merged with the records of the 18-71 year-
olds of the WHO standards sample and used to built the new reference. An objective was 
to obtain a smooth transition from the Child Growth Standards (0-5 years) to the WHO 
Reference 2007 (5-19 years), and from this to the older age group (18, 26).  
The following WHO curves are available and should be used in every pediatric 
appointment in Portugal (18, 26): 
 Head circumference – birth to 2 years; 
 Height/length – birth to 19 years; 
 Weight – birth to 10 years; 
 BMI – birth to 19 years. 
BMI growth charts, adapted to age and sex, are used to evaluate the nutritional status of 
children and adolescents. The cut-offs used for that classification are presented in Table 4 
(26). 
 
Table 4. Cut-offs for nutritional status, according to 
WHO BMI growth charts 
Nutritional Status Lower limit Upper limit 
Extreme thinness - < -3 SD 
Thinness ≥ -3 SD < -2 SD (P3) 
Underweight ≥ -2 SD (P3) < -1 SD (P15) 
Normal ≥ -1 SD (P15) ≤ 1 SD (P85) 
Overweight > 1 SD (P85) ≤ 2 SD (P97) 
Obesity > 2 SD (P97) ≤ 3 SD 
Extreme obesity > 3 SD - 
Adapted from (18). SD, standard deviation; P, percentile. 
 
Other criteria are used to evaluate nutritional status in pediatric patients, leading to 
different classifications. The IOTF criterion, for example, has been used in a considerable 
number of studies (9, 14, 16, 17). This criterion has some disadvantages, as compared to 
WHO or CDC criteria. In fact, the WHO criterion has an increased sensitivity and 
specificity to identify obese children, when compared to IOTF reference. Besides, the 
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IOTF criterion uses references ranges of BMI instead of providing specific BMI z-score (as 
occurs with CDC and WHO references). The use of BMI ranges leads to the inclusion in 
the same classification of children with different BMI percentiles (although the variation is 
not very wide), losing some of the information of the gradual relation between BMI and 
other variables, and the power to detect effects of short-term interventions. Besides, IOTF 
do not have a reference for height measurements (6, 27).  
After the initial diagnosis of obesity it is important to identify the underlying causes. 
Although the majority of obesity cases are secondary to a positive energy balance, other 
causes, such as punctual mutations, syndromic forms of obesity, metabolic diseases and 
iatrogenic causes can underlie obesity and should be excluded. The use of an organized 
anamnesis, focused on the family and individual history, and on the risk factors for the 
development of obesity, might help to clear some doubts (5).  
The NCAHP present a list of check points that should be focused in each visit and that, if 
correctly followed, might provide important information about the cause of obesity, either 
genetic or environmental, and unveil some comorbidities that might already be present, 
such as dyslipidemia, hypertension, IR and nephropathy (5, 18). Some of the points that 
should be addressed at an obesity appointment are listed in Table 5 (5, 18, 25). 
Obese children and adolescents have, usually, a faster development and often present 
increased height and sexual development, particularly in girls. The presence of obesity 
with slower development rates should be further studied, as a hormonal (e.g. lack of 
growth hormone (GH), hypothyroidism) or genetic problem might be present (5, 25). Wrist 
X-ray and dual energy x-ray absorptiometry (DEXA) can evaluate the bone biological age, 
which comparison to the chronological age might help to evaluate changes in the 
development rates and unveil different obesity etiologies (5).  
Obese pediatric patients frequently present altered blood analysis. Thus, several variables 
are routinely assessed during clinical appointments, such as plasmatic triglycerides (TG), 
high density lipoprotein cholesterol (HDLc), glucose and insulin. Adiponectin, an adipokine 
secreted by the white adipose tissue (WAT), with anti-inflammatory and anti-atherogenic 
properties, is reduced in obese individuals. Adiponectin has also been suggested as an 
indicator of metabolic risk in obesity (5).  
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Table 5. Points to address in an obesity pediatric appointment 
Dimension studied  Factors 
Family history 
 
 Birth country and  ethnic background; 
 Family structure – who lives with the children; 
 Socio-economical context; 
 Parents and sibling basic anthropometric measurements; 
 Relatives with T2DM, dyslipidemia, hypertension and other risk factors for 
CVD; 
 Family history of early CVD (< 55 years in man, < 65 years in women); 
Personal history 
 Maternal pregnancy history (maternal weight gain, pre-eclampsia, smoking 
habits, gestational diabetes, term/pre-term pregnancy…); 
 Birth weight, length and head circumference; 
 Period of breast-feeding; 
 Nutritional diversification following breast-feeding; 
 Weight and length/height development; 
Lifestyle habits 
 Sleeping – hours and quality; 
 Dietary habits 
o Types of food eaten, frequency and size of portions; 
o Skipping breakfast; 
o Frequency of meals outside from home; 
o Consume of sweetened drinks and snacks; 
o Meals in family; 
o Binge eating and bulimia; 
 Physical activity habits 
o Sedentary habits (hours of TV watching, video-game playing, ...) 
o Sports playing, other active hobbies; 
o Active transport to school; 
Clinical evaluation 
 Length/height and weight measurement – comparison to growth charts 
adjusted for sex; 
 Waist circumference; 
 Sexual development; 
 Body fat distribution – peripheral (gynoid) or central (android); 
 Blood pressure; 
 Presence of striae, acanthosis nigricans; 
 Blood analysis 
o Lipid profile; 
o Fasting insulin and glucose; 
o Other analysis 
 Thyroid hormones; 
 Growth hormone; 
 Glycated hemoglobin; 
 Hepatic transaminases; 
 Ionogram; 
 Creatinine and urea; 
 Oral glucose tolerance test; 
 Genetic analysis; 
 … 
 Urine analysis 
o Microalbuminuria 
o Glucose 
 Complementary anthropometric measurements 
o Body composition (fat mass, lean mass); 
o Dual energy X-ray absorptiometry, skin folds, … 
o Wrist X-ray 
CVD, cardiovascular disease; T2DM, type 2 diabetes mellitus 
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Besides the diagnosis of total obesity, it is important to assess the body composition and 
the fat distribution, as central obesity is associated with increased CVD risk. BMI and BMI 
z-score can be used in children as an indicator of body fat; however, increasing lean mass 
due to physical fitness can give a false idea of weight excess, especially in adolescents 
practicing sports. Total body fat is physiologically more relevant to determine the risk of 
CVD than BMI, and can be accessed by bio impedance, skin folds and by air 
displacement plethysmography. Body fat distribution and body composition can be 
estimated by using skin folds, however, more specific methods are available, such as 
DEXA, computed tomography and magnetic resonance. Nevertheless, in a pediatric 
routine appointment, waist circumference (WC) and WC/H ratio are good tools for 
indirectly evaluate the presence of abdominal obesity, after comparing the values to 
gender and age adapted charts. Unfortunately, Portugal and WHO do not have population 
representative charts for WC or WC/H ratio; thus, pediatricians need to use international 
cut-offs, with the consequent bias in the classification (5). Indeed, pediatric charts for 
percentage of body fat, abdominal fat and WC would be valuable tools for the diagnosis 
and management of obesity by pediatricians and other health professionals.  
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5. White adipose tissue as an endocrine organ 
The WAT was considered for some time as a tissue for storage of lipid reserves; 
nowadays it is known as an active endocrine organ (5). WAT has several secretory 
functions, namely those associated with the lipid metabolism, such as the release of 
lipoprotein lipase (LpL), an enzyme that breaks circulating TG to fatty acids. Other lipid 
particles secreted by the WAT include steroid hormones, retinol, cholesterol and 
prostanoids (28); however, only some prostanoids are synthesized within the WAT. 
Retinol and cholesterol are just stored in that tissue and released in the sequence of an 
adequate stimulus. Some steroid hormones are activated within the adipocytes, e.g. the 
activation of 11-dehydrocorticosterone (cortisone) into corticosterone (cortisol) (29).  
Besides the important role in the lipid metabolism, the WAT is also a source of many other 
molecules, with several functions.  
In the 1980’s the adipsin, a complement-related factor, was reported as a protein secreted 
by adipocytes (30). Following the timeline, the secretion of the pro-inflammatory mediator 
tumor necrosis factor α (TNF-α) by the WAT was described in the early 90s (7). TNF-α is 
increased in obesity and has been closely associated with the development of insulin 
resistance (IR), one of the most common metabolic derangements in obesity (31). TNF-α 
also influences the lipid metabolism by stimulating lipolysis and apoptosis within the WAT, 
processes that are intensified in obese individuals (32, 33). 
The turning event that definitely changed the way WAT was faced occurred in 1994, with 
the discovery of leptin. A mutation in the gene responsible for the expression of leptin led 
to obesity in ob/ob mice (obese / hyperglycemic mice). The homologous human gene was 
later described as the Obese (Ob) gene (8). Leptin acts in the hypothalamus and helps to 
control energy intake and expenditure. The absence of leptin increases appetite and 
decreases energy expenditure, leading to obesity. The discovery of a molecule with such 
a global influence in the metabolism raised, finally, the WAT to the category of endocrine 
organ. Later, it was discovered that leptin was secreted by other tissues and cells. Even 
so, the WAT is the main source of leptin in humans (34). Furthermore, although elevated 
in obesity, leptin action is deregulated in this disease.  
Since the report of adipsin, more than 50 other molecules secreted by the adipose tissue 
have been described. The secretory function of the WAT is so important that the group of 
the secreted molecules, the WAT secretome, was named “adipokines” (28, 35).  
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The adipokines have the most varied functions, and are involved in many biological 
processes, such as in the lipid metabolism [e.g. adiponectin, apolipoprotein – (apo) – E], 
angiogenesis [e.g. vascular endothelial growth factor (VEGF)), hepatocyte growth factor 
(HGF)], energy intake [e.g. leptin, interleukin (IL) -6], hemostasis [e.g. plasminogen 
activator inhibitor (PAI) -1], blood pressure (e.g. angiotensinogen), and insulin signaling 
(e.g. adiponectin, leptin, TNF-α) (35).  
Several adipokines are also linked to immune and/or inflammatory functions. Indeed, it 
has been suggested that adipocytes have functions similar to immune cells, and that pre-
adipocytes have the capacity of acting, in certain conditions, as macrophages (36).  
The secretion of some adipokines can influence the production and action of others in a 
paracrine, autocrine or endocrine ways (28, 35). 
The adipocytes are not the only secreting cell in the WAT; other cells, as the 
macrophages, vascular endothelial cells and pre-adipocytes, have a relevant role in 
adipokine production (37).  
Considering the large number of substances secreted by the WAT, and their function, it is 
clear that in the center of obesity related inflammation is the WAT. Table 6 presents some 
of the most relevant adipokines released by the WAT, the cell(s) type responsible for their 
synthesis and respective functions. 
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Table 6. Adipokines produced in the WAT, biological function, association with obesity and with other markers 
Adipokines 
Plasma 
levels 
WAT 
locals/cells of 
synthesis 
Biological action Relation with obesity 
Role in obesity related 
diseases 
Relation with other markers or 
mediators 
Adiponectin 
(24, 38-57) 
5-30 μg/ml 
Adipocytes 
VAT > SAT* 
- Anti-inflammatory/oxidant 
- Energy homeostasis 
↑ Insulin sensitivity 
- Improve lipid metabolism 
↓ Atherogenesis 
↑Adipocyte differentiation 
↓ With obesity 
↑ After weight loss* 
 
↓ in IR, dyslipidemia, NAFLD, 
MS, T2DM, atherogenesis, 
CVD 
↑with renal failure, in women. 
↓with TNF-α, IL-6, CRP, PAI-1, 
fibrinogen, UA, age, puberty. 
Leptin 
(4, 24, 55-71) 
2-11 ng/ml 
Mainly in 
adipocytes 
SAT > VAT 
-Food intake, energy expenditure and 
fat storage through central action 
(Hypothalamus) 
- Angiogenesis, hematopoiesis 
↑ With obesity 
↓ After weight loss 
↑ in IR, T2DM, dyslipidemia, 
NAFLD,  MS atherosclerosis, 
CVD 
↑with TNF-α, IL-1, CRP, insulin, 
estrogens women 
↓with glucocorticoids and androgens 
Resistin 
(24, 49, 57, 70-
84) 
5-25 ng/ml 
Mainly 
mononuclear 
cells. 
Also adipocytes 
-In mice: leads to IR; interferes with 
glucose metabolism 
-Humans: not well defined 
↑ Adipocyte differentiation 
↑ with obesity* 
↓ after weight loss* 
↑ in IR, NAFLD, T2DM, MS, 
atherosclerosis, CVD* 
↑with TNF-α, IL-1, IL-6,IL-12, CRP, 
VCAM, ICAM, women 
↓with adiponectin* 
 
TNF-α 
(7, 31, 55, 57, 
65, 85-90) 
0,5-2,0 
pg/ml 
Mainly 
mononuclear 
cells 
Also adipocytes 
SAT > VAT 
-Pro-inflammatory cytokine 
-Studies point to a more local action 
within the WAT 
↑ With obesity 
↓ After weight loss 
↑ in IR, T2DM, atherogenesis 
↑ with resistin, visfatin, IL-1, IL-6, CRP 
MCP-1, 
↓ adiponectin and leptin 
IL-1 
(55, 91-94) 
IL-1α and 
IL-1β 0,1-
0,5 pg/ml 
Mainly 
mononuclear 
cells. Also by 
adipocytes  
VAT > SAT 
-Pro-inflammatory cytokine 
-IL-1α seems to have a more positive 
effect in glucose´s metabolism, 
contrarily to IL-1β 
↑ With obesity 
↓ After weight loss* 
↑ in IR, T2DM 
 
↑ with leptin, resistin, TNF-α, CRP 
↓ adiponectin 
IL-6 
(51, 55, 68, 70, 
71, 95-105) 
0,5-20 
pg/ml 
Mainly vascular 
stromal 
fractions 
VAT > SAT 
-Pro-inflammatory cytokine 
-Impairs insulin effect 
-Anti-obesogenic* 
- ↓ fat mass, ↑ energy expenditure in 
mice 
↑ With obesity 
↓ After weight loss* 
↑ in IR, dyslipidemia, MS, 
T2DM, atheriosclerosis 
↑ with resistin, TNF-α, IL-1 
↓ adiponectin 
IL-18 
(57, 106-108) 
120-270 
pg/ml 
Adipocytes and 
vascular stromal 
fraction 
VAT ≈ SAT 
-Pro-inflammatory cytokine 
-Body weight control and glucose 
metabolism 
- positive effect in the lean 
↑ With obesity ↑ in T2DM 
↑ TNF-α, CRP 
↓ adiponectin 
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Adipokines 
Plasma 
levels 
WAT 
locals/cells of 
synthesis 
Biological action Relation with obesity 
Role in obesity related 
diseases 
Relation with other markers or 
mediators 
Chemokines 
MCP-1 
(88, 109-117) 
70-300 
pg/ml 
Mainly vascular 
stromal fraction 
Also by 
adipocytes 
VAT > SAT 
-Chemiotatic for monocytes and 
lymphocytes 
-Leads to macrophage infiltration in 
the WAT 
-Possible role in regulating food 
intake (centrally) 
↑ With obesity 
↓ After weight loss 
↑ in IR, dyslipidemia, 
hypertension, NAFLD, MS, 
atherogenesis 
↑ TNF-α, leptin, age 
↓adiponectin 
Angiogenic factors 
VEGF 
(57, 118-121) 
50-900 pg/ml 
Platelets Also 
by hypoxic pre-
adipocytes 
VAT > SAT 
-Angiogenic factor – vascular 
remodelling 
-Important in growing WAT 
vascularization 
↑ With obesity ↑ in atherogenesis ↑ insulin, AT II 
Acute-Phase Proteins 
CRP 
(4, 24, 40, 70, 
99, 122-129) 
0,5-10 μg/ml 
Mainly by 
hepatocytes 
Also adipocytes 
VAT IL-6 
induces hepatic 
secretion 
-Acute phase protein 
-Elevated levels are related to bad 
CVD prognostic 
 
↑ With obesity 
↓ After weight loss 
↑ in IR, dyslipidemia, 
hypertension, T2DM, MS, 
atherosclerosis, CVD 
↑ IL-6, man 
↓adiponectin, oral anti-diabetics, anti-
hypertensive, anti-cholesterolemics 
Other Factors 
RBP-4 
(57, 130-137) 
12-48 μg/ml 
Mainly 
hepatocytes 
Also adipocytes 
VAT > SAT 
-Linked to retinol metabolism 
(delivery to tissues, prevent renal 
depuration, stabilize extra and intra 
cellular retinol) 
↑ With obesity 
↓ After weight loss 
↑ in IR, NAFLD, MS, T2DM, 
Atherogenesis 
↑ age*, man 
PAI-1 
(49, 57, 138-
145) 
0,75-15 ng/ml 
Mainly 
endothelial cells 
and platelets 
Also adipocytes 
VAT > SAT 
-Protein of the hemostatic process 
-Inhibitor of tissue plasminogen 
activator 
- Elevated concentrations lead to a 
pro-coagulation state 
-Reduces adipocyte differentiation 
↑ With obesity 
↓ After weight loss 
↑ in IR 
↑ leads to atherogenesis, CVD 
↑ insulin 
↓ adiponectin 
*, association is not well established. AT-II, angiotensin II; CRP, C-reactive protein; CVD, cardiovascular disease; ICAM, intercellular adhesion molecule; IL, interleukin; IR, 
insulin resistance; MCP-1, monocyte chemoattractant protein 1;  MS, metabolic syndrome; NAFLD, non-alcoholic fat liver disease; PAI-1, plasminogen activator inhibitor 1; 
RBP-4, retinol binding protein 4; SAT, subcutaneous adipose tissue; T2DM, type 2 diabetes mellitus; TNF-α, tumor necrosis factor α;  VAT, visceral adipose tissue; VCAM, 
vascular cell adhesion molecule; VEGF, vascular endothelial growth factor; WAT, white adipose tissue.  
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6. Adiponectin 
Adiponectin is an adipokine with multiple positive effects on metabolism, such as 
increasing insulin sensitivity and reducing oxidative stress, inflammation, atherogenesis 
and vascular remodeling (42, 146).  Adipocytes are the main source of adiponectin, 
however its levels are paradoxically reduced in obese individuals (147).  
Due to its biological actions, and reduced circulating levels in obesity, adiponectin has 
been deeply studied by the scientific community, particularly regarding the relation 
between lower adiponectin levels in obese individuals and obesity-related diseases and 
comorbidities. Adiponectin levels seems to be already reduced in young obese subjects, 
nevertheless, the relation between adiponectin and other metabolic markers are not well 
established, particularly before puberty (42, 148). Moreover, the influence of weight loss 
therapies, with or without an exercise program, on adiponectin levels is not clear and 
needs further investigation (42, 51, 148).     
Adiponectin is a 244 amino acid protein with 28 kDa, and with 4 domains: a signal peptide 
in the N terminus, a short variable region, a collagenous domain and, finally, the globular 
domain in the C-terminal that is homologous to complement C1q (147, 149) (Figure 1).  
The adipokine that is now called adiponectin had different names in the past, as it was 
discovered simultaneously by different groups, working in humans and in mouse: adipose 
most abundant gene transcript and gelatin-binding protein of 28 kDa (GBP28), in humans; 
adipoQ and adipocyte complement-related protein of 30 kDa (ACRP30), in mouse (147, 
150).  
In humans, adiponectin is a protein that is mainly secreted by adipocytes and its gene is 
mostly expressed in adipocytes (147, 149); its expression increases over 100 times 
throughout adipocyte differentiation (151). Adiponectin gene is located at the 
chromosomal band 3q27, a particularly susceptible locus for diabetes and CVD (152).  
Adiponectin represents 0.01 % of human plasma proteins and its normal plasma level 
ranges between 2 to 30 mg/l (51, 151). 
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6.1. Adiponectin circulating forms 
Three different types of adiponectin complexes are formed before secretion from 
adipocytes: trimers, hexamers (formed by two trimers) and larger structures, resulting 
from the combination between trimmers and hexamers: 9mers, 12mers and 18mers. The 
trimers are usually referred as low molecular weight (LMW) adiponectin, the hexamers as 
medium molecular weight (MMW) adiponectin, and the higher forms as high molecular 
weight (HMW) adiponectin (153). In humans, the three main forms found in circulation are 
trimers, hexamers and 18mers. Usually, monomers are not present in circulation (147). 
The biosynthesis of adiponectin multimers is a complex process involving extensive post-
translational modifications, which are critical for the intracellular assembly and stabilization 
of its oligomers (147, 154). Close to the N terminus exists, in a conserved region, a 
cysteine residue, cysteine 36 in humans, that is also crucial for adiponectin 
multimerization (151). Figure 1 presents a resume of the post-translational multimerization 
process and the mediators influencing it. 
 
Figure 1. Multimerization process of adiponectin and related mediators 
Adapted from (147). DsbA-L, disulfide-bond-A oxidoreductase-like protein; Ero1-Lα, endoplasmic reticulum 
oxidoreductin-1-Lα; ER, endoplasmic reticulum; ERp44, endoplasmic reticulum resident protein 44. 
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Trimers are formed by the interaction between the globular domains forming a highly 
hydrophobic interior in the area where the three monomers interact. Trimers present a 
ten-strand jelly-roll topology, presenting an interesting homology to TNF-α structure, 
especially when considering their opposite biological activities (147, 151). Following the 
interaction of the globular domains, the collagenous domains form triple helix, further 
stabilizing the trimer. For interaction and stabilization of the triple helix, the hydroxylation 
of proline residues within the collagenous domain is important (151). The resulting 
structure resembles a lollypop.  A mature trimer, the form found in circulation, presents an 
intra-trimer disulfide bond in a conserved region close to the N terminus. Theoretically, 
there is still a free cysteine residue from the third monomer, however, probably due to 
conformational changes, this cysteine is not available to interact with other adiponectin 
multimers while still in the endoplasmic reticulum (ER) and, if the dissulfide bond is not 
reduced, the secretion will happen in the form of a trimer (147).  
Hexamers are formed by two trimers in a head-to-head and tail-to-tail configuration and 
also involve the formation of disulfide bonds between cysteine in the conserved region 
close to the N-terminus of the molecule. A mature hexamer usually present 3 disulfide 
bonds, 2 intra-trimer and 1 inter-trimer, presenting no free cysteine for further formation of 
disulfide bonds (147). 
The formation of HMW multimers needs the interaction between trimers and hexamers 
that are not completely oxidized, still having available cysteine residues to form disulfide 
bonds. The disulfide bonds are important for stabilizing the intermediate structures. HMW 
adiponectin has a bouquet-like structure, with all the globular domains in the same side. In 
fact, the HMW adiponectin form, 18mers, the most common in humans, is in fact a group 
of three hexamers stabilized by non-covalent bonds. A very important contribution for the 
non-covalent bonds and formation of 18mers is the glycosylation of amino acid residues. 
Proline and lysine from the collagenous domain, are extensively hydroxylatated, 
consisting on the first step to the glucosyl-galactosyl disaccharide glycosylation of the 
hydroxyl groups of four conserved lysine residues. A cooperative effect is present 
regarding the relation between lysine glycosylation and the oligomerization of adiponectin, 
leading to a sigmoidal type curve. In this way, the substitution of one lysine residue has 
almost no effect, the substitution of 2 residues lead to a medium reduction on HMW 
adiponectin forming and the substitution of 3 residues drastically reduce HMW levels. The 
interaction with Ca2+ ions also increase HMW stability (147).  
The ER is the place where adiponectin oligomerization takes places. The redox state 
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within the ER can affect both the non-covalent interactions and the disulfide bond 
formations. ER stress affects the redox state and can interfere with adiponectin 
oligomerization. Chaperones, oxidoreductases and molecules with redox potential will 
influence the interaction between adiponectin multimer and consequently their 
association. The secretion of adiponectin multimers from adipocytes is tightly controlled by 
a chaperone in the endoplasmic reticulum, the endoplasmic reticulum resident protein 44 
(ERp44). ERp44 has the capacity to bind to cysteine residues in adiponectin, increasing 
the time of retention in the ER and preventing the formation of disulfide bonds in all 
cysteine residues and, thus, increasing the formation of HMW forms. In fact, increased 
ERp44 in the ER is linked with increased HMW form (147, 155). Endoplasmic 
oxidoreductin-1-Lα (Ero1-Lα), is an oxidoreductase that leads to an oxidizing environment 
in ER, favoring disulfide bond formation. It catalyzes the transfer of electrons from thiol 
groups to molecular oxygen during disulfide bond formation, generating hydrogen 
peroxide. It is a preferred partner for ERp44, as it generates disulfide bonds which it 
transfers to proteins such as ERp44, releasing adiponectin from ERp44 (151). Ero1-Lα 
promotes the formation of HMW adiponectin (147, 155). Another interesting molecule is 
the Disulfide-bond-A oxidoreductase-like protein (DsbA-L), a member of the kappa class 
of glutathione S-transferase family, presenting a thioredoxin like domain. Increased DsbA-
L ER levels are associated with increased HMW adiponectin. The DsbA-L oxidoredutase 
activity is not well established, however, a putative mechanism of action could include the 
protection of cysteine residues form excessive oxidation and early intra-trimer disulfide 
bond formation, by the interaction between DsbA-L thio-redoxin like domain with the thiol 
groups. Alternatively, the glutathione S-transferase activity associated with DsbA-L might 
protect cysteines by glutathionylation (147). These ER molecules are known to be 
regulated by the metabolic state of the cell and peroxisome proliferator-activated receptor-
γ (PPAR-γ) agonists (e.g. thiazolidinediones), and to display sexual dimorphism, what can 
help to understand changes in multimer proportions existing in some diseases or between 
genders (147, 155). 
Adiponectin succination is a process by which S-(2-succinyl)Cys is formed, by a non-
enzymatic reaction of fumarate with cysteine residues. In the case of human adiponectin, 
succination occur at cysteine 36 of adiponectin monomers, blocking the oligomerization of 
adiponectin. As a consequence, a lower amount of adiponectin is secreted. The extent of 
succination is increased in states as diabetes or high glucose levels, due to accumulation 
of Krebs cycle intermediates. Increased adiponectin succination might be part of the 
explanation for the reduction in adiponectin levels in states associated with IR, particularly 
the levels of HMW adiponectin (151). 
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The addition of sialic acid is a common post-translational modification to O- and N-linked 
oligosaccharides present on secreted and cell-surface proteins (147, 151). The addition of 
di-sialic acid residues to two threonine O-linked oligosaccharides on the variable region of 
adiponectin have been associated with an increase in the half-life of the molecule in 
circulation, although no influence on multimerization was detected (147, 151). In fact, 
desialylation of adiponectin resulted in increased clearance and uptake into primary 
hepatocytes. The activity of enzymes responsible for adding (sialyltransferases) and 
removing (sialidases/neuraminidases) sialic acids are upregulated in inflammatory states, 
including diabetes and CVD. Thus, the hypoadiponectinemia associated with those 
pathologies might result from a reduced adiponectin synthesis/secretion, and, also, to an 
increased clearance from the circulation (151).  
 
6.2.  Adiponectin receptors 
There are two main transmembrane domain receptors for adiponectin: adiponectin 
receptor 1 (AdipoR1) and adiponectin receptor 2 (AdipoR2). AdipoR1 gene is located in 
chromosome 1q32 and is expressed predominantly in skeletal muscle, while adipoR2 
gene is located in chromosome 12p13 and is expressed mainly in the liver (156, 157).  
Yamauchi et al. proposed that both receptors mediate anti-diabetic metabolic effects 
(156). However, an elegant work in mice found that, although these receptors mediate 
most of the biological functions of adiponectin related to glucose and lipid metabolism, 
they seem to act in opposite directions. Knock-out mice for each of the receptors were 
used, and AdipoR1-/- mice showed increased adiposity associated with decreased glucose 
tolerance, spontaneous locomotor activity and energy expenditure. However, AdipoR2-/- 
mice were lean and resistant to high-fat diet-induced obesity, presented improved glucose 
tolerance, higher spontaneous locomotor activity and energy expenditure, and reduced 
plasma cholesterol levels. Thus, AdipoR1 seems to have more beneficial effects than 
AdipoR2 (157). T-cadherin has been also considered an adiponectin receptor (158). 
Besides these receptors, an adiponectin adaptor protein, AAP1, has been described (71, 
156).  
Adiponectin receptors were also described in other organs and tissues where particular 
biological actions have been studied, e.g. in the central nervous system, where they may 
influence eating behavior and body weight regulation (159, 160). Animal studies have 
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identified adiponectin receptors in the intestine, indicating that adiponectin present in 
breast milk might influence the energy balance and growth in the first period of life, 
probably with impact in future metabolism (161).  
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7. Obesity as an inflammatory disease 
As the WAT grows, the adipocytes accumulate lipids, becoming hypertrophic. 
Hypertrophic adipocytes increase the secretion of mediators that activate resident 
macrophages. These activated macrophages further produce cytokines and attract other 
macrophages, helping to sustain a pro-inflammatory cycle. The WAT macrophages are, in 
fact, the main producers of some adipokines (37).  
The growth of WAT leads to the development of areas that become far from vasculature 
and are under a local hypoxic environment. Thus, it is necessary to create new blood 
vessels to irrigate the growing areas (angiogenesis). The action of angiogenic factors (e.g. 
VEGF, HGF) is crucial in this process, but these mediators are, usually, deregulated by 
the local inflammatory environment and might promote, themselves, inflammatory 
pathways (118-121).  
Adipokines are generally increased in obesity, particularly pro-inflammatory ones, leading 
to a local increase and, afterwards, to a low-grade inflammatory state (28, 37). Such is the 
case of IL-6, TNF-α and CRP (28). 
This general adipokine increase has an important exception, adiponectin, an anti-
inflammatory and anti-oxidant protein. Adiponectin is the most transcript gene in 
adipocytes and its levels are paradoxically reduced in obese individuals (51).  
The rise in the pro-inflammatory mediators and the concomitant decrease of anti-
inflammatory defenses, as adiponectin, contributes to the development of the chronic low 
grade inflammation, common in obese individuals (123, 162). Table 6 summarizes some 
of the obesity-related changes in adipokines. 
The association between obesity and a pro-inflammatory, pro-oxidant and pro-atherogenic 
profile is evident after weight loss, as the levels of pro-inflammatory markers decrease 
(125), while circulating anti-inflammatory adiponectin increases (51). 
The WAT has an almost limitless growing capacity. The increased mass of WAT in 
obesity, together with the increase of circulating adipokines suggest that the WAT might 
be the main source of those molecules. Actually, this is true for some of the circulating 
adipokines, while for others, there is a more complex mechanism that involves a cross-
talk between the WAT and other tissues and organs. For example, PAI-1 is increased in 
obese individuals and its main source seems to be, in fact, the WAT (139);  CRP, for 
Genetic contribution and follow up study based on the reduction of the body mass index 
30 
 
instance, is mainly produced in the liver. Nevertheless, the production of CRP by the liver 
is stimulated by the IL-6 produced in the WAT, particularly by the visceral adipose tissue 
(VAT), that will stimulate the hepatic CRP synthesis through the venous portal system (95, 
123).  
Hence, the communications between the WAT and other organs have an important role in 
the metabolism, with considerable relevance in obesity (5). Another example is leptin 
control of energy intake and expenditure through the hypothalamus. In obesity, a state of 
leptin resistance, as observed for insulin, may develop and cause the loss of the control 
mechanism over energy homeostasis. The resistance to leptin action causes a positive 
feedback mechanism increasing its circulatory levels and contributing to the pro-
inflammatory state (162).  
In synthesis, the cross-talk between WAT and other organs contribute to the global 
metabolic changes happening in the obese body, including chronic inflammation (5). The 
study of each individual product secreted by the WAT is crucial to unveil the global picture 
and to better understand many of obesity related comorbidities.  
 
7.1. Inflammatory changes in pediatric obesity 
The pro-inflammatory changes in childhood obesity are similar to those observed in 
adults. An increase in WAT, together with increased production of circulating pro-
inflammatory mediators, and a decrease in anti-inflammatory molecules, as adiponectin, 
occurs (44). CRP, a classical marker of inflammation, is 3 to 5 fold increased in obese 
children, when compared to lean controls (148). Weight loss is generally associated with 
an improvement of the inflammatory status in children and adolescents (55). 
The pro-inflammatory status in obesity increases with the severity of the disease. In fact, 
an increase in circulating CRP, leptin, resistin and IL-6, and a reduction in anti-
inflammatory adiponectin, was observed in severe obese children and adolescents when 
compared with individuals with moderate obesity. Nevertheless, no difference was found 
for TNF-α (70).  Ogawa et al. also found a reduction in adiponectin with increasing 
severity of obesity in 8 to 13 years old boys (44).  
The correlation with adiposity markers is positive for most of the inflammatory mediators. 
The body fat distribution is particularly important and the correlation with inflammatory 
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markers is even stronger in case of central obesity (increased VAT), when compared to 
the correlation with the absolute body mass (4, 24, 56). Indeed, visceral fat accumulation 
has been linked with a worse metabolic and inflammatory profile characterized by 
increased leptin, liver transaminases and uric acid, and reduced adiponectin and ghrelin. 
Leptin is, in fact, a predictor of the visceral fat depot (24).  
Besides the association with inflammatory status, VAT is also linked to increased risk of 
CVD. Leptin, a marker of visceral fat, is also a predictor of MS features in adolescents. 
Thus, leptin is a potential interesting clinical tool to monitor fat distribution and CVD risk in 
pediatric populations (4). 
Puberty and gender interfere with the inflammatory status in children and adolescents. 
Before puberty the differences in inflammatory markers according to gender are, usually, 
moderate or absent. After puberty, besides a less atherogenic lipid profile, females seem 
to have a different inflammatory profile, with increased leptin and adiponectin, and 
reduced CRP (4, 24). For the other mediators, as ghrelin, there are no gender related 
differences, even after puberty (4, 24). Sexual hormones seem to have a significant role of 
in these post-pubertal changes. Testosterone and derivatives are known to diminish the 
production and secretion of adiponectin from adipocytes, while leptin increases body fat in 
post-pubertal females (24).   
Several studies reported that pediatric obesity is also associated with an increase in 
circulating levels of resistin (71, 163), IL-6 (70), IL-8 (55, 57), IL10 (55, 164), IL-18 (57), 
homocysteine (148), HGF (57), uric acid (6, 24), alanine aminotransferase (ALT) (24, 54), 
aspartate aminotransferase (AST) (54), complement C3 (163), and with a reduced 
concentration of ghrelin (4, 24). However, other studies found no differences between 
overweight/obese individuals and lean controls for circulating levels of ghrelin (148), 
adiponectin (57, 148, 165), resistin (24, 57), adpsin (57), IL-6 (57), IL-10 (57), PAI-I (57), 
TNF-α (57), homocysteine (6), retinol binding protein 4 (RBP-4) (57), VEGF(57), soluble 
vascular cell adhesion molecule (sVCAM) (57), soluble intercellular adhesion molecules 
(sICAM) (57) and CRP (24, 165).      
A moderate increase in bilirubin circulating levels has been reported to be associated with 
lower inflammation and oxidative stress (166, 167), both in adults and in children (168), 
and to reduce the incidence of CV events (169, 170). Increased adiposity, in particular 
central adiposity, has been also associated with lower plasmatic bilirubin (168, 171). 
However, few reports have addressed bilirubin at pediatric ages.  
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Increased leukocyte count is positively associated with total and central adiposity in 
children and adolescents (172, 173) and subcutaneous adipose tissue (SAT) might also 
have a role in that relation (173). The positive relation between total adiposity and 
leukocytes appear to be mainly due to an increase in neutrophils. In fact, lymphocyte and 
basophil counts were reported to be negatively related to BMI and waist circumference 
(173).  Pro-inflammatory adipokines known to be increased in obese individuals, such as 
leptin, IL-1, IL-6 and TNF-α, were related to increased circulating leukocytes (174-177). 
Nevertheless, it is still somehow uncertain which leukocyte populations are altered in 
obese children, how early these changes appear, and the relation with other inflammatory 
and CVD risk factors.  
When different inflammatory mediators cluster, a particular inflammatory profile develops 
which will interfere with other CVD markers, as IR. These profiles are modulated by 
genetic and/or environmental factors.  
The pro-inflammatory changes in pediatric obesity have a broad effect on metabolism and 
might underlie obese associated comorbidities and diseases. Thus, it should be clear 
which variables are indeed altered, and which health consequences are associated with 
such modifications. 
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8. Obesity and other associated diseases  
In adults, obesity has been associated with type 2 diabetes mellitus (T2DM), CVD, 
metabolic syndrome (MS), infertility, steatohepatitis, gallbladder changes, asthma, dental 
problems and psychological disorders (5, 19). Consequently, it is not surprising that in 
Portugal, the patients that use the national health system have an increased prevalence of 
obesity, when compared to the general population (178).  Some of these comorbidities are 
already present in obese pediatric patients (5, 19, 179, 180). A study in a Dutch pediatric 
population showed comorbidities in 11% of the overweight and 37% of the obese 
individuals (19); in another study, in Turkish children, 80% of the obese children 
presented, at least, one feature of MS (180). Ethnic minorities seem to be particularly at 
risk for increased prevalence of both obesity and MS (180).  
Some of the mechanisms underlying the association of obesity with these pathologies are 
still unknown and are subject of intense investigations, however, inflammatory and 
oxidative stress mechanisms are accepted as a common denominator. In fact, 
inflammation is known to play a vital role in the initiation and progression of many of the 
referred diseases (181, 182), and the association between increased inflammation and 
metabolic abnormalities, as increased IR or low density lipoprotein cholesterol (LDLc) 
concentration, are present since early in life of obese individuals (44). In Table 6 are 
highlighted associations between changes in some inflammatory mediators, present in 
obesity, and their influence in diseases as T2DM and CVD. 
The link between obesity-related inflammation and comorbidities are already present in 
early childhood. Children with decreased adiponectin, and thus, with a worse inflammatory 
profile, seem to present increased prevalence of severe obesity, VAT accumulation, high 
LDLc, hyperinsulinemia, MS and acanthosis nigricans (44). Moreover, studies in obese 
children and adolescents showed that the worsening of CV risk markers, such as 
dyslipidemia, hypertension and IR, is associated to an increase in adiposity (5, 70) and in 
obese-associated inflammation, presenting the more obese individuals a worse 
inflammatory and CVD risk profile (70). The worsening of the metabolic profile with 
increased inflammation highlights that the metabolic derangement in obesity is not only a 
question between obese/lean individuals, but also that adiposity has a proportional and 
direct effect (4, 5, 70).  
The body fat distribution, besides the influence on inflammatory mediators, has also an 
impact on metabolic changes. A study in a Mediterranean pediatric cohort reported that a 
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worse inflammatory profile (e.g. increased leptin and decreased adiponectin levels) was 
associated with central obesity, high BP, dyslipidemia and IR. Moreover, as the increased 
inflammatory status correlated with increased adiposity, namely with central adiposity, the 
relation between the inflammatory mediators (leptin and adiponectin) and the number of 
MS features presented were associated to an increase in BMI z-score (56).  
In addition to the influence of increased adiposity, there is a clustering effect of CVD risk 
factors in children and adolescents, in a way that the presence of one risk factor facilitates 
the appearance of another (4, 5). In agreement, similar results were found in a 
Portuguese pediatric overweight population, presenting increased blood pressure (BP), 
hyperinsulinemia, IR, dyslipidemia (increased TG, apo B and reduced apo A1), higher 
levels of leptin, CRP and homocysteine (148).  
The importance of the association between obesity, inflammation and IR are even more 
relevant in children and adolescents, as the presence of obesity in these ages seems to 
increase the risk of developing T2DM and CVD in adulthood. Actually, overweight is 
associated with increased CVD mortality (5, 20, 179) and there is an increase in all-cause 
mortality in adulthood, in case of pediatric obesity (20). 
Features of MS are already observed at young ages in obesity (2, 5, 25, 179, 183). The 
chronic exposition to metabolic abnormalities (e.g. dyslipidemia) might be the link between 
pediatric obesity and increased risk for CVD and metabolic diseases later in life (5, 179). 
However, the effect of pediatric adiposity on the onset of the diseases in adults is difficult, 
as the influence of adult BMI has to be also considered. The tracking of adiposity into 
adulthood leads to the persistence of risk factors, with a crescendo of metabolic risk (20).  
Thus, it is complicated to analyze separately those two phases of life.  
 
8.1.  Insulin resistance and type 2 diabetes mellitus 
Closely linked to the rise in inflammation, IR is also associated with the genesis of many 
of the obesity-related diseases. Actually, in the development of IR, a critical step towards 
the appearance of T2DM and dyslipidemia, an important cross-talk exists between the 
WAT, the skeletal muscle and the liver (5, 33, 179).  
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In obesity, the increased inflammatory mediators, mainly secreted by adipocytes and 
macrophages, interfere with insulin signaling and promotes the development of IR. As a 
consequence of IR, lipolysis within the WAT is augmented (5, 33, 179).  
In the skeletal muscle there is also an increase in cytokine secretion and macrophage 
infiltration, in part due to the increase of inflammatory mediators in the extramyocellular 
WAT. An increase in free fatty acid uptake is associated with these changes in the 
skeletal muscle (5, 33, 179).  
In the liver occurs an increase in the lipid content, mainly in TG, causing steatosis, an 
increase in the recruitment and activation of Kupffer cells, and also an amplified cytokine 
production. In the three referred organs/tissues endoplasmic reticulum stress (ERS) is 
also present, and has an important part on inflammation perpetuation (5, 33, 179).  
Thus, the pro-inflammatory status that appears first at local levels, within WAT, evolves to 
the whole body, through this metabolic cross-talk. The changes that accompany obesity in 
these organs, and their relation to IR, are presented in Figure 2. 
 
 
Figure 2. Mechanisms underlying the development of insulin resistance in obesity 
Adapter from (33). 
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A central factor in the relation between obesity related inflammation and IR might be the 
pro-inflammatory TNF-α. TNF-α is highly increased in obese individuals and is known to 
interfere and impair insulin signaling (33).  
In obese individuals the IR and the consequent hyperinsulinemia, develops earlier than 
the increase in glucose levels. Solid evidence exists relating childhood obesity with T2DM 
in adulthood (5). The risk is even stronger when considering obese adolescents, relatively 
to obese children (20).  The risk of evolving from IR to T2DM depends on the duration and 
magnitude of obesity (5, 20, 25, 179). 
T2DM presents nowadays a high prevalence in obese adolescents, particularly when their 
BMI z-score is above the equivalent to 30 kg/m2 in adults (179). In the USA, the 
prevalence of T2DM in children is 0.4%, more than the double of the type 1 diabetes 
mellitus (T1DM) prevalence. In these ages T2DM is often asymptomatic and it is 
necessary to pay attention to unspecific symptoms, such as glycosuria or vaginal 
candidiasis (25). The real predictive power of pediatric onset of T2DM for future CVD in 
adolescents is not well established (179). 
 
8.2.  Dyslipidemia  
Risk changes in the lipid profile are a common finding in obese individuals, and are 
closely connected to IR. As IR develops there is an increase in the hepatic production of 
very low density lipoprotein (VLDL), contributing to increasing levels of circulating TG and 
LDLc. Furthermore, peripheral IR reduces the action of local LpL, increasing the plasmatic 
TG, and reducing HDLc by increasing its degradation and reducing its synthesis (4, 5, 25, 
179).   
The increase of obesity in children and adolescents is associated with a worse lipid profile 
(5, 6), with increased TG, decreased HDLc, and normal to moderately elevated total 
cholesterol (TC) and LDLc (184, 185). These changes in the lipid profile are somehow 
stable and, without intervention therapy they will persist into the adulthood, together with 
obesity (25, 179). 
Apo E by regulating the hepatic uptake of remnant lipoproteins through the LDL-receptor 
and LDL-receptor-related protein, and by facilitating cholesterol efflux from foam cells, has 
an important role in the cholesterol metabolism and in atherosclerosis development (186). 
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Apo E presents a genetic polymorphism on the gene exon 4, the E2/E3/E4 apo E 
polymorphism that influence the circulating levels of TC. Individuals carrying the E2 allele 
present lower values of TC than individuals carrying the E4 allele (187). Thus, besides the 
increase of TC cholesterol in obesity, the individuals with some specific polymorphisms, 
such as E4 carriers, might be at increased risk for future CVD and present a worse 
metabolic profile. The effect of the same polymorphism on TG levels has also been 
addressed but available results are contradictory; however, it seems that E2 carriers 
present increased circulating TG in comparison to E4 carriers  (188, 189).   
Lipoprotein (a) (Lp(a)) is an independent risk factor for CVD (190, 191). It is structurally 
similar to LDL but presents a different apolipoprotein - apo (a) – that binds to apo B 
particle in the LDL-like domain of Lp(a), preventing Lp(a) from binding to the LDL receptor 
and, thus, limiting the catabolism of Lp(a) (191). As a consequence, circulating Lp(a) 
levels, although widely variable between individuals, are relatively stable in the same 
subject across time, as its concentration is mainly determined by the synthetic rate, which 
is mostly genetically determined (191-193). Lp(a) presents a pro-atherogenic role that can 
be explained by different characteristics of this particle: apo (a) from Lp(a) presents a 
plasminogen-like domain that prevents fibrinolysis, leading to a pro-coagulant state; Lp(a) 
has also been reported to function as an oxidant scavenger, preventing the oxidation of 
LDL and other lipoproteins; nevertheless, the resulting oxidized Lp(a) is an atherogenic 
factor itself, which is deposited in the arterial walls, contributing to the formation of foam 
cells. The Lp(a) may circulate in different sizes, being the smaller more atherogenic. The 
Lp(a) particle size is inversely related the size of the apo (a) (190, 191).  The apo (a) 
particle size is influenced by different genetic polymorphisms that, ultimately, influence the 
Lp(a) circulating levels. For example, a pentanucleotide repeat (PNR) polymorphism, 
(TTTTA)n, 1.4 kilobases upstream from the gene reading frame, has been reported to 
influence Lp(a) levels, presenting individuals with more repeats lower circulating Lp(a) 
(193). Despite the existing data on lipid profile changes in obesity, little is known about the 
influence of Lp(a) in the CV risk in pediatric populations, and its relation with other risk 
markers. 
It is important to identify individuals with genetic profiles that associate with increased 
metabolic risk as these individuals could benefit more from an early intervention. 
Moreover, a better understanding of the genetic factors might help to identify the individual 
CVD risk. 
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8.3.  Hypertension 
In obese individuals, hypertension is associated with increasing weight and percentage of 
body fat. Weight loss, usually, induces BP reduction (4, 25). The vascular damages, due 
to dyslipidemia and the consequent atherosclerosis, have an important part in the 
increased prevalence of hypertension in obese individuals (194-196). Hyperinsulinemia, a 
consequence of IR, also has an important and direct role in the development of 
hypertension. It was proposed that increased circulating insulin causes an increase in 
sodium retention in the kidneys, and in sympathetic activity and promotes the growth of 
vascular smooth muscle, thus increasing BP (4, 25).  
Increasing BMI is directly linked with increased BP and, consequently, hypertension has 
accompanied the increase in overweight prevalence in pediatric subjects in the last years 
(180). Hypertension is one of the most common features in obese children and 
adolescents, and usually continues until adulthood. In fact, the risk of hypertension in 
adulthood increases with persistence of pediatric obesity from childhood to adolescence 
(4, 6, 25, 179).  
 
8.4.  Metabolic Syndrome 
MS is a cluster of CVD risk factors including obesity, hypertension, dyslipidemia (high TG 
and low HDLc) and IR (4, 5, 197). These features of MS were, until some years ago, 
exclusive of adults, but are, nowadays, appearing at younger ages, partially caused by the 
increased prevalence of obesity in children and adolescents (2, 4, 179, 183). 
The prevalence of MS in children and adolescents is high in case of overweight, and even 
more higher in obese individuals, when compared with lean subjects (179). In fact, MS 
prevalence seems to be adiposity dependent as by each 0.5 increase in BMI z-score, 
there is a 50% increase in the probability of developing MS (179); the MS prevalence is 
increased in severely obese children, when compared with moderately obese individuals 
(44, 70). 
Worsening of the inflammatory profile has been associated with increased MS prevalence 
in children (44, 70). Actually, in Latin overweight/obese children with a family history of 
T2DM, lower adiponectin levels were observed and were predictors of MS, independently 
of gender, age, insulin resistance and visceral obesity; moreover, in overweight children 
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with MS the adiponectin levels were 25% lower than the values presented by children 
without MS (53). Plasmatic bilirubin levels, a potential marker of inflammation and 
oxidative stress, are also decreased in children with MS (168). 
The reported MS prevalence in the adolescent general population is 4%, while in 
overweight adolescents it can rises to values of 30 to 50%. Nevertheless, the prevalence 
varies widely based on the criterion used to define MS and the studied population (179). 
A small study in Portuguese children, 7-9 years old, using the National Cholesterol 
Education Program (NCEP) criterion, reported a high prevalence of MS in individuals with 
weight excess (16%),  while no cases were found in normal weight individuals (148). In 
this study MS was predicted by decreased levels of apo A1 (the main protein content of 
HDL particles), increased circulating insulin and leptin, and by higher Tanner stage (148). 
In another study, in a pediatric Mediterranean population (Greek), the prevalence of MS, 
according to the International Diabetes Federation (IDF) criterion, was 0.7% for the whole 
population and 7.7% for the obese individuals. Moreover, as observed in the Portuguese 
study (148), all individuals with MS had increased adiposity. The most common MS 
features found in this cohort were increased BP (33.3%) and low HDLc (12.3%); 
surprisingly, no children presented increased TG (56).   
A protective effect of normal weight against MS is suggested by the almost absence of 
normal weight children with MS (56, 148). Actually, in lean individuals there is a sharp 
drop in the percentage of individuals presenting one MS feature, to individuals presenting 
two MS features (56). However, the presence of one CVD risk factor (one MS feature) 
increases the probability of the appearance of a second risk factor. The increased 
adiposity and consequent hyperinsulinemia and inflammation are basic events that induce 
the appearance of other MS features (179); abdominal obesity is particularly related to 
clustering of MS features (4).  
Other protective factors, besides low BMI, have been suggested. For example, it was 
shown that 16 years old obese girls presenting with high adiponectin levels did not 
develop MS for seven years afterwards. Indeed, the healthy obese phenotype, 
characterized by healthy values of MS markers in an obese subject, has been associated 
with the presence of high adiponectin levels (198).  
Bilirubin might also work as a protective factor due to its anti-inflammatory and anti-
oxidant properties. In fact, a mild hyperbilirubinemia, as occurs in individuals with the 
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Gilbert Syndrome, has been associated with a reduced incidence of CVD, inflammation,  
oxidative stress (169, 170, 199) and MS (168, 171). The levels of plasmatic unconjugated 
bilirubin are controlled by the uridine diphosphate glucuronosyltransferase (UGT) 1A1, a 
microsomal enzyme responsible for bilirubin glucuronidation, necessary for its excretion 
(200). A TA duplication polymorphism in the TATA box region of the gene promoter 
affects the activity of UGT1A1 and, consequently, the bilirubin levels (201). The relation 
between bilirubin levels and MS features, and the influence of genetic polymorphisms, 
need further investigations, particularly in individuals at increased risk of developing MS, 
such as obese children.  
 
8.5.  Atherosclerosis 
Atherosclerosis is a chronic disease that begins early in life, and obesity is an important 
risk factor for its development. In fact, atherosclerotic lesions have been described in the 
vessels of increasingly younger subjects (4, 5, 179). Hyperinsulinemia and dyslipidemia 
are often present in obese individuals, increasing the formation of atherosclerotic plaques 
(4, 5, 179, 194, 195).  
Circulating TG-rich lipoproteins inflict oxidative damage to vascular endothelium. 
Furthermore, hypertriglyceridemia, shifts the spectrum of LDL sub-fractions towards 
smaller, denser species, which are believed to be more atherogenic (185, 196), and the 
spectrum of HDL to smaller, less stable particles that limits the reverse transport of 
cholesterol (185).   
The deposit of lipids in the vascular walls leads to the formation of foam cells.  These cells 
secret cytokines (e.g. IL-6, TNF-α and CRP) that recruit more macrophages, causing local 
inflammation, vessel injury and, therefore, the development of atherosclerosis (185, 196, 
202). 
Atherosclerosis is increased in young obese individuals and has been correlated with the 
number of MS features (179, 184). Fatty streaks, a pre-clinical manifestation of 
atherosclerosis, has been identified in children as young as 2 years, presenting a 
prevalence of around 50% in children until 15 years (184). Obesity itself is particularly 
relevant, as the increase of the atherosclerotic process with increased BMI is independent 
from the other risk factors. In fact, coronary artery calcification in young adults was 
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positively correlated with weight, in childhood, and with BMI, in adolescence. IR was also 
associated with vessel changes in youth (179).   
Leukocytosis, particularly neutrophilic leukocytosis, is also often associated with 
atherosclerotic disease and an increased risk of CVD (203-205). In fact, activated 
leukocytes might participate in endothelial injury (203), and monocyte and lymphocyte 
recruitment to the artery wall is present in the atherosclerotic process (176). The 
association between obesity related reactive leukocytosis and the development of 
atherosclerosis needs further clarification. 
 
8.6.  Cardiovascular events 
Chronic hypertension is associated with left ventricular hypertrophy. In adults, left 
ventricular hypertrophy is linked to increased risk of coronary heart disease (CHD), 
sudden death and stroke (179).  High BP, increased BMI and fat mass are positively 
correlated with increased left ventricular hypertrophy in children and adolescents (179). In 
agreement, a positive association between childhood obesity and increased risk for CHD 
later in life has been reported. This association is more evident in males than in females, 
however, it loses some statistical strength when adjusted for adult BMI (20).  
The link between the risk of stroke in adulthood and increased adiposity in childhood is 
not clear. Some studies have reported an increased association, however, other studies 
did not find any association or have found a reduction in stroke events (20).  
 
8.7.  Steatohepatitis and non-alcoholic fatty liver disease 
Steatohepatitis and non-alcoholic fatty liver disease (NAFLD) are common in obese 
individuals. About 30% of obese adults present hepatic fatty changes (5, 25). The 
increase in obesity, particularly visceral obesity, is associated with changes in liver 
transaminases and hepatic insulin sensitivity. IR is the main responsible for the 
development of NAFLD, by causing a rise in lipid (mainly TG) deposits in hepatocytes, 
and changes in the hepatic lipoprotein production towards TG-rich particles (4, 25, 33). 
NAFLD is a silent disease and, by affecting liver function, is closely associated with all the 
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MS classic features. Some authors defend, in fact, that NAFLD should be considered as a 
part of MS (24, 54).  
A study in healthy Japanese adolescents found a high prevalence of fatty liver (23.3% in 
boys and 30.4% in girls) (24); in another study involving a pediatric population, including 
only obese and overweight individuals, the prevalence was 35.6% (54). The prevalence of 
NAFLD is higher in obese children and adolescents (54), and particularly higher in 
individuals presenting visceral fat accumulation (24). Reduced adiponectin and HDLc 
levels, characteristic findings in obesity, are further reduced in overweight/obese individual 
with NAFLD, increasing the overall metabolic risk (54).  
 
8.8.  Sexual Hormone changes 
Obesity related changes in hormone metabolism are associated with an increase in the 
bioavailability of sex hormones through increased cortisol production and reduced 
concentration of the sex-hormone binding globulin, a protein that binds to estrogens and 
androgens, controlling hormone availability. The increased availability of circulating sex 
hormones in obesity supports the increased skeletal maturation for chronologic age 
(although usually adequate for bone age) (5). An increased aromatization of androgens 
into estrogens is responsible for the increased sexual maturation in girls, while in boys it is 
responsible for a decreased sexual maturation and gynecomastia. This sexual hormone 
excess in obese girls favors the development of polycystic ovary syndrome, characterized 
by acne, hirsutism, and menstrual irregularity  (5). 
 
8.9. Asthma and allergic diseases 
Many studies have addressed the relation between obesity and the development of 
asthma in children. Actually, the concomitant increase in asthma and obesity in the last 
years suggest a linkage between them, which has been considered by many authors (20, 
180). The pro-inflammatory state and leukocyte activation present in obesity might cause 
the increase in allergic manifestations. In agreement, besides asthma, allergies and 
eczemas are also reported in association with obesity. Nevertheless, conclusive results 
have not been reached, especially in some specific populations. Differences in eating 
habits might underlie the differences in asthma prevalence found in different cohorts. The 
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causual relation of asthma and obesity is not clear. Indeed, asthmatic children may reduce 
physical activity to avoid asthma symptoms and the reduced activity leads to weight gain; 
or obese children develop more asthmatic symptoms, due to the inflammatory process 
associated with obesity (180). The relation between increased adiposity in pediatric ages 
and an increase in the incidence of asthma later in adulthood is also not clear, with 
studies reporting opposite results, especially after adjusting for adult BMI (20).  
 
8.10. Orthopedic comorbidities 
Orthopedic comorbidities are, in general, a direct result of weight excess, especially in 
morbidly obese children. The knees are a particularly susceptible joint (25).  The weight 
excess on the locomotor apparatus, especially during growth phases, is associated with 
orthopedic pathologies that will persist into adulthood. Orthopedic compensatory changes, 
to balance adiposity excess and distribution, are frequently present and might include 
curving of the femur (genu valgo), changes in the normal column curvature (with 
associated back pains and disc degeneration), slipped capital femoral epiphysis, pain in 
the lower members and foot problems (5, 180). Furthermore, the increased mass makes, 
per se, harder to execute physical exercise, and even daily activities, and may cause pain 
with certain movements. As a consequence, obese individuals, usually, respond to the 
referred limitations with lower activity levels, creating a vicious cycle towards sedentarism 
(25).  
 
8.11. Obstructive sleep apnea 
Increased BMI has been associated to an increased risk of obstructive sleep apnea in 
both adults and children (179).  The excess weight in the thoracic wall and the increased 
size of the tongue in obese individuals make more difficult to breathe normally, particularly 
when lying down.  During sleep, the reduction of the muscular tonus, together with the 
mentioned changes, increases the risk of obstructive sleep apnea (25, 179). The sleep 
duration and its quality were reported to be decreased in obese children and adolescents, 
with lower number of sleeping hours and of sleep spent in rapid eye movement phase, a 
sleep phase important for energy recovery and cognitive functions (180). Nevertheless, 
this same report found no relation between increased prevalence of sleeping apnea with 
the quality of sleep and obesity (180). 
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8.12. Psychological comorbidities  
It is not clear the relation between obesity and psychological comorbidities. A direct 
association between increased BMI and depression or lower self-esteem in obese 
individuals has been reported, however, it is not clear which is the cause and which is the 
consequence (25). 
Obese children have lower self-esteem, lower number of friends and higher incidence of 
depression, when compared to their lean counterparts (25, 179); moreover, adults with 
increased BMI are more likely to have been diagnosed with depression in youth. In 
agreement, adolescents with depressions tend to increase BMI through time (179). Some 
studies, however, found no difference between lean and overweight children regarding 
depression (180). In addition, a decrease in anxiety and depression in extremely obese 
children was reported (180). 
Bullying might be an important part of the problem. Overweight children and adolescents 
victims of bullying are more prone to have suicidal idealization and attempts (179). The 
lower satisfaction with their body makes difficult for obese children to engage in physical 
exercise and group activities, fearing rejection or bulling from pairs and, therefore, 
persisting with inactivity and obesity (25, 179).  
Regarding other psychological disorders, the prevalence of attention deficit hyperactivity 
disorder (ADHD) was reported to be higher in obese and overweight children and 
adolescents. The increase in deregulation of the behavior of those patients would extend 
to their eating habits and contribute to obesity. However, some studies found no 
association or even a decreased prevalence of this disease in overweight youth (180).  
The cause-consequence order between behavior problems and obesity is also not clear. 
Obese children presented increased incidence of behavior problems in school, and 
behavior problems were associated with the development of overweight in lean children 
(180).  
In synthesis, there is controversy regarding the linkage of obesity and psychological 
disturbances. Nevertheless, an interesting work in Chinese youth, studying the 
interactions between psychological factors and obesity, reported that it is not the BMI but 
the individual perception of weight excess that should be associated with psychological 
disorders (206). 
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8.13. Other associated diseases and comorbidities 
Childhood and adolescent obesity have also been associated with different types of 
cancer. Increased pediatric overweight and obesity have been linked to increased risk for 
colorectal, kidney, cervical and ovarian cancers (20, 207-209). On the other hand, breast 
cancer presents opposite trends, namely, a reduced risk in case of adolescent obesity. 
However, other studies found no association between pediatric obesity and cancer 
development in adulthood (20). Other factors influencing the development of cancer, such 
as genetics, lifestyle and environment, can modulate and mitigate the effect of obesity, 
particularly at young ages. 
Biliary lithiasis is also common, particularly in obese women following diet-induced weight 
loss, due to an increase in biliary saturation of cholesterol, dehydration, vesicular 
hypomotility (due to low fat diets) and estrogenic action (25).  
Obesity and overweight have been associated with worsening of dental health, with an 
increase in the development of caries. Nevertheless, results are not conclusive. The usual 
sugar rich diet followed by obese children, associated with poor hygiene, could be key 
factors linking weight excess and caries. Other factors, such as age, race, poverty and 
income ratio might also influence that association (180).   
Other comorbidities reported in obese and overweight pediatric patients include increased 
gastro-esophageal reflux, pseudotumor cerebri, glomerulopathy and respiratory infections, 
among others (5, 180). 
Figure 3 resumes some of the most relevant obese associated comorbidities. 
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Figure 3. Obesity associated comorbidities. 
CHD, coronary heart disease; cIMT, carotid internal media thickness; NAFLD, Non-alcoholic fatty liver 
disease; PCOS, polycystic ovarian syndrome; SCFE, slipped capital femoral epiphysis. 
 
The association of obesity with many diseases is a very relevant issue nowadays, as the 
prevalence of overweight and obesity is growing markedly. The majority of the 
comorbidities present in pediatric obese patients are the same observed in obese adults 
(179). The severity of the comorbidities is positively linked with the excess of adiposity. 
The chronic exposure of the body to metabolic derangements might have a cumulative 
effect and represent a fundamental problem, probably more important than obesity itself, 
particularly in pediatric patients. Thus, investing in health programs nowadays, is most 
likely to invest in the future, both at human and financial levels, by reducing the 
prevalence of obesity and its comorbidities, as well as by reducing the associated costs. 
Intervention of decision makers is crucial to change this paradigm. 
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9. Diagnosis of Metabolic Syndrome in children 
The diagnosis of MS in children is not consensual, even less consensual than in adults. 
Particularly difficult is to find cut-off values, as those usually used in adults are not 
adapted for children and adolescents. In fact, features of MS, as lipid profile, fat 
distribution, blood pressure, insulin sensitivity, vary through pediatric ages, with a 
particularly strong fluctuation during puberty (5, 210, 211). 
There are several MS criteria, varying on how the variables are used (age and sex 
adjusted percentiles or their absolute values), on the use of specific established cut-offs 
and on ethnicity of the studied population. These variations in MS definition make difficult 
to compare the results from different studies, particularly the prevalence of MS in pediatric 
population (5, 56, 210, 211).   
A study involving an obese pediatric population, that was classified as presenting or not 
MS, according to three of the existing criteria, showed the variability of the obtained 
results.  The prevalence of MS, by any of the criteria, was 3 fold higher in the severely 
obese individuals than in the moderately obese. Nevertheless, the prevalence of MS 
ranged from 8% in moderately obese to 25% in the severely obese using IDF criterion, to 
21% and 57%, respectively, using Ferranti’s criterion (70).  
Some attempts to find a more consensual characterization of pediatric MS have been 
made. The IDF criterion divides the pediatric population in 4 groups: bellow 6 years, from 
6 to 10 years, from 10 to 16 years and above 16 years. It uses the WC percentile as an 
indicator of visceral obesity, and establishes that central obesity is a necessary condition 
for the diagnosis of MS. The 90th percentile of WC, adjusted for age and sex, was chosen 
as the cut-off value. Regarding the remaining MS components, the IDF recommended cut-
offs are close to those used for adults. The IDF does not recommend the diagnosis of MS 
in children under 10 years of age; however, it is recommended lifestyle intervention and 
further examination for those children, when they present a high WC, for age and gender. 
For children under 6 years, cut-off values are not available due to scanty data. Adult cut-
off values are used in adolescents over 16 years old (210). The fact that for the diagnosis 
of MS using the IDF criterion is mandatory the presence of central obesity, accompanied 
by other two MS features, is the main reason why MS prevalence using this criteria is 
lower (56). Indeed, other criteria accept the presence of 3 MS features as equally relevant 
for the MS diagnosis. In Table 7 are resumed the IDF criterion for the diagnosis of MS. 
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Table 7. International Diabetes Federation criterion for diagnosis of Metabolic 
Syndrome 
Age (years) ≥6 and <10 ≥10 and <16 ≥16 
Obesity (WC)  ≥90
th
 percentile 
 ≥90th percentile 
(or adult cut-off if 
lower) 
 Male: ≥94cm 
 Female: ≥80cm 
(ethnicity specific 
values should be 
used for other 
groups if available) 
 
Triglycerides (mM) 
MS should not be 
diagnosed but child 
follow up should be 
done, especially if other 
risk factors are present. 
 ≥1.7 (≥150mg/dl) 
 
 ≥1.7 (≥150mg/dl) 

HDLc (mM)  <1.03 (<40mg/dl) 
 Males: <1.03 
(<40mg/dL) 
 Females: <1.29 
(<50 mg/dL) 
 Treatment for lipid 
abnormalities 
 
Blood pressure 
(mmHg) 
 Systolic ≥ 130 or 
diastolic ≥ 85 
 Systolic ≥130 or 
diastolic ≥85 
 Treatment of 
previously 
diagnosed 
hypertension 
 
Glucose (mmol/l) 
 ≥ 5.6 (≥100 mg/dl) 
 Previously 
diagnosed T2DM 
(If ≥ 5.6 an OGTT 
is recommend) 
 
 ≥5.6 (≥100 mg/dl) 
 Previously 
diagnosed T2DM 
(If ≥ 5.6  an OGTT 
is recommend) 
 
Adapted from (165, 167). HDLc, high-density lipoprotein cholesterol; OGTT, oral glucose tolerance test; 
T2DM, type 2 diabetes mellitus; WC, waist circumference.  
 
Brambilla et al., in a study involving the European Childhood Obesity Group (ECOG), 
suggested a totally different set of factors regarding the identification of children with 
metabolic risk. This approach was called by the authors “MIRACLE” (metabolic individual 
risk factor and clustering estimation) and involves the study of the individual and family 
history (past), the clinical data (present) and the potential future outcomes (future). The 
MIRACLE approach includes the selection of 10 variables that are easy to determine in 
routine medical appointments, involving family and individual history, clinical features and 
the presence of metabolic abnormalities of the glucose metabolism. Some variables, 
usually used in other studies, such as WC, TG, HDLc and insulin, were not used, as the 
authors argued that neither the scientific evidence supporting their association with 
metabolic risk is clear, nor the reference values for children and adolescents are available 
(211). Table 8 lists the relevant data used in the MIRACLE (ECOG) approach. 
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Table 8. Factors used in the MIRACLE approach to define Metabolic Syndrome 
Factors Criteria 
Family history 
o Early cardiovascular diseases – one relative with cardiovascular 
disease before 55 years (man) or 65 years (woman); 
o T2DM - one first-degree relative affected; 
o Hypertension - one first-degree relative affected.  
Individual history 
o Small for gestational age - birth weight for length <10th 
percentile for gender and gestational age; 
o Ethnic origin - Indo-Asians, Hispanics, African-Americans.  
Clinical features 
o BMI - corresponding to adult value of ≥30 kg/m2;  
o Waist circumference - ≥90th percentile for age, gender, ethnic-
specific; 
o Hypertension - systolic or diastolic BP ≥ 95th percentile for age, 
gender and height-specific; 
o Acanthosis nigricans - one lesion.  
Metabolic abnormalities  
o IGT - fasting glucose 100–126 mg/dl or glucose at 120 min. 
140–200 mg/dl (OGTT);  
o T2DM - fasting glucose ≥126 mg/dl or glucose levels at 120 
min ≥ 200 mg/dl (OGTT). 
Adapted from (211). BMI, body mass index; BP, blood pressure; IGT, impaired glucose tolerance; OGTT, oral 
glucose tolerance test; T2DM, type 2 diabetes mellitus. 
 
Correct and accurate anthropometric measurements and specific data from blood analysis 
are mandatory for the correct diagnosis of MS. The lack of guidelines for pediatricians 
might influence and under-estimate the diagnosis of MS in children and adolescents. A 
study in the Netherlands verified that although all of the pediatricians measured height 
and weight, and almost all measured BP, only 42% of them measured WC, blood 
sampling was only taken in 2/3 of the cases, and different analysis were requested; about 
70% of the children were tested for lipid profile and fasting glucose, while less than 50% 
had fasting insulin measured. Insulin is particularly important, as abnormalities in fasting 
insulinemia appear before changes in glucose levels in the pathway of IR (19). 
The traditional definition of MS has some gaps, both in adults and children: the lack of 
NAFLD in the criteria, a factor involved with all the classical MS features; the lack of 
consideration for the family and individual history; the lack of use of new markers of 
adipose tissue and chronic low grade inflammation (e.g. CRP);  and the way the factors 
have all the same weight in the classification, although it is unlikely that they all influence 
the development of MS in the same way, among other flaws (56, 211). 
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Thus, further studies are needed to clarify which factors should be used and their relative 
weight when analyzing metabolic risk in pediatric patients. It is also necessary to clarify 
the associations between metabolic changes in childhood and comorbidities in adulthood 
and to construct age and gender adjusted databases of risk factors, in order to provide 
evidence-based guidelines for pediatricians, to perform a correct risk assessment.  
 
9.1. Portuguese recommended values for Metabolic Syndrome risk factors 
The international guidelines for the classification of MS in pediatric patients are 
standardized and facilitate comparisons between different studies and countries. 
Nevertheless, each country may choose to use specific pediatric cut-offs for MS features, 
even when there is not an official criterion to define MS.  
In Portugal, the clinical entity of pediatric MS has not an official definition. Nevertheless, 
the NCAHP highlights the importance of screening dyslipidemia and hypertension in 
youth, starting at young ages. The values that establish an increased risk differ from those 
stipulated for MS diagnosis by the IDF.  
 
9.1.1. Lipid profile assessment in Portuguese children and adolescents 
The National Heart, Lung and Blood Institute (NHLBI; USA) guidelines recommend 
universal screening of dyslipidemia in children between the ages of 9 and 11 years. 
Children 2 to 8 years old with increased risk for dyslipidemia (with diabetes, hypertension, 
BMI > 95th percentile, another relevant medical condition or family history associated with 
CVD risk) are also target for screening of dyslipidemia (184).  
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The recommendations in Portugal are not much different from that of NHLBI. According to 
the NCAHP, a screening of dyslipidemia should be performed in the following situations 
(18): 
 In children between 2 and 4 years old, with family history (first and second degree 
relatives) of: 
o Early CVD (before 65 years in women and 55 in men) 
 Stroke or CHD  
 Sudden death 
 Peripheral vascular disease 
 Cerebral vascular accident 
o Dyslipidemia: TC >240 mg/dl and/or LDLc >130 mg/dl and/or TG >170 
mg/dl and/or HDLc < 35 mg/dl  
 Any child or adolescents with personal history of: 
o Weight excess or obesity 
o Diabetes 
o Hypertension 
o Renal or cardiac disease 
o Hormonal or metabolic disease 
o Taking medicines that interfere with the lipid profile (corticosteroids, 
anticonvulsants, antidepressives, …) 
 
Even in children and adolescents without risk factors is desirable to perform a screening 
above 2 years of age. At least one analysis of the lipid profile in each decade of life should 
be performed in all children (18). 
A good clinical practice is to perform “opportunist” analysis and to introduce the study of 
lipid profile when other analysis are made with a different purpose (e.g. pre-surgical 
analysis) (18).  
A list of the lipid variables that should be screened and the reference values are 
presented in Table 9. Due to the absence of reference values for the Portuguese pediatric 
population the recommended cut-offs at the NCAHP are based on values of the NCEP 
(TC and LDLc) and the American Heart Association (AHA) (TG and HDLc), both entities 
from the USA (18).  
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Table 9. Reference values for dyslipidemia screening in 
Portuguese children and adolescents 
 TC* LDLc* HDLc* TG* 
Normal (<P75)  < 170 < 110 > 35 < 150 
Borderline (P75-95)  170-199 110-129   
High (>P95)  < 200 < 130   
*, values in mg/dl. HDLc, high density lipoprotein cholesterol; LDLc, low 
density lipoprotein cholesterol; P, percentile; TC, total cholesterol; TG, 
triglycerides. 
 
The pediatrician or family doctor should recommend the children and adolescents with risk 
changes in the lipid profile, as follows (18): 
 Children with dyslipidemia: advised to follow a healthier diet, to increase 
physical exercise levels and to be referred to a specialist;  
 Children with borderline risk changes: advised to follow a healthier diet and 
physical exercise. After four to six months, if the values do not normalize, the child 
should be referred to a specialist. 
The risk values for TG and HDLc in Table 9 are very similar to those used by IDF to 
classify MS in children, with a slight difference in HDLc (IDF presents a higher cut-off) 
(18), 165, 167).  
Although the used values are in agreement with the values from other countries, the use 
of cut-offs built specifically for the Portuguese population could increase the accuracy of 
the identification of individuals at increased risk of MS. 
 
9.1.2. Glycemia assessment in Portuguese children and adolescents 
There is no specific screening schedule for the determination of glycemia and insulinemia 
in children and adolescents in Portugal (18). However, fasting glycemia is suggested to be 
analyzed together with the lipid profile screening recommended in the NCAHP, due to the 
high prevalence of diabetes in our country and the confluence of dyslipidemia and 
diabetes risk factors. (18).  
Although the changes in insulin levels are the first to appear in childhood obesity, before 
abnormal levels of glucose can be detected, insulinemia is not usually used as a routine 
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determination for tracking changes in glucose metabolism. Only the evaluation of glucose 
levels are, usually, used in routine clinical practice (19). 
Portugal uses the cut-off levels of glycemia recommended by the American Diabetes 
Association (ADA). These reference values, the same used for adults, are presented in 
Table 10. 
 
Table 10. Reference levels for plasma glucose 
Criteria Normal Pre-diabetes Diabetes
1
 
Fasting plasma glucose (mg/dl) < 100 ≥100;<1262 ≥126 
Casual plasma (mg/dl)   ≥2003 
OGTT 2 hour plasma (mg/dl) <140 ≥140;<2004 ≥200 
Adapted from (212). 1, In the absence of unequivocal hyperglycemia with 
acute metabolic decompensation the diagnosis should be confirmed, on a 
subsequent day, by any one of the criteria. 2, classified as impaired fasting 
glucose. 3, with classic diabetes symptoms: polyuria, polydipsia and 
unexplained weight loss. 4, classified as impaired glucose tolerance. 
 
In the absence of unequivocal hyperglycemia with acute metabolic decompensation, the 
diagnosis of diabetes should be confirmed, on a subsequent day, by any of the three 
criteria presented on the third column of Table 10. Nevertheless, fasting glucose is the 
preferred test, due to its simplicity and applicability (212). 
The ADA recommends the screening of glucose levels in children above 10 years, or at 
onset of puberty, if puberty took place in an earlier age, in children with increased 
metabolic risk. Increased risk is defined as an overweight child (BMI ≥85th percentile for 
age and sex, weight for height ≥85th percentile, or weight ≥120% of ideal weight for height) 
together with any of the following risk factors: 
• Family history of T2DM in first-or second-degree relatives; 
• Race/ethnicity: Native American, African American, Latino, Asian American, Pacific 
Islander; 
• Signs of IR or conditions associated with IR (acanthosis nigricans, hypertension, 
dyslipidemia, or PCOS). 
The screening should be repeated every 2 years (212). 
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The use of the same cut-off values for glycemia in children and adults is widely accepted. 
Nevertheless, more studies are necessary to analyze the sensibility of these values to 
identify IR onset before T2DM is clinically diagnosed. A good option would be to use 
insulin plasmatic values, as insulinemia is more sensible for detecting early IR changes in 
pediatric patients. 
 
9.1.3. Blood pressure assessment in Portuguese children and adolescents 
The guidelines of NCAHP for hypertension screening in children and adolescents follow 
the international recommendations and should be performed in routine appointments in all 
children, starting at 3 years old. 
BP measurements should be compared against tables presenting systolic blood pressure 
(SBP) and diastolic blood pressure (DBP) values adapted for gender, age and height 
percentile. These tables present cut-off values for specific BP percentiles that are used in 
the classification of BP; the limits defining BP are presented in Table 11. 
 
Table 11. Blood pressure evaluation in children and adolescents 
– cut-off values. 
 DBP
1
 SBP
1
 
Normal (P) < 90
th
 < 90
th
 
Pre-hypertension (P)
 3
 
≥ 90th; < 95th 
or 
≥ 80mmHg2 
≥ 90th; < 95th 
or 
≥ 120mmHg2 
Hypertension grade I (P)
3,4
 ≥95th; <99th+5mmHg ≥95th; <99th+5mmHg 
Hypertension grade II (P)
 3,4
 ≥99th+5mmHg ≥99th+5mmHg 
P, percentile. 1, blood pressure values should be adjusted to gender, age and height. 
2, even if the values fall under the adjusted 90
th
 percentile. 3, for the diagnosis of pre-
hypertension or hypertension is sufficient that SBP or DBP fall above the maximum 
limit of the previous category. 4, hypertension should be confirmed in three separate 
occasions.  
 
The diagnosis of hypertension should be confirmed in 3 separate occasions. The standard 
technique to measure the BP is the auscultatory. Digital measurement can be used, but 
must be confirmed by the auscultatory method if BP values are high. The measurement in 
the right arm, contrary to the general habit, is recommended (18). 
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Similarly to the lipid profile, Portugal does not have reference BP tables for children and 
adolescents. The recommended tables are those from the National High Blood Pressure 
Education Program (NHBPEP) Working Group on High Blood Pressure in Children and 
Adolescents, USA. The use of reference values based on populations from different 
countries might misdiagnose or underdiagnose this problem in Portuguese youth (18). 
The cut-offs IDF recommends for BP, to use in the classification of MS, are higher than 
those used in Portugal, what could lead to underdiagnosis of MS, when following IDF 
guidelines  (18), 165, 167). 
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10. Therapeutic strategies for pediatric obesity  
The use of therapeutic strategies in obese children aims weight normalization and 
reduction of the future risk of CVD. A behavioral approach, towards lifestyle modification, 
is the main pillar of obesity treatment, both in children and adults. The main objectives are 
to increase physical activity and improve diet in order to obtain an enhanced energy 
balance. Two strategies are usually used: non-interventional programs, involving 
nutritional counseling and motivation to exercise; and interventional programs, involving 
the use of diets and/or physical exercise programs. Pharmacological drugs have also 
been tested as adjuvants in the treatment, with limited but consistent results (e.g. orlistat 
and metformin) (210, 213-215). 
To improve weight, three points are common to adults and children’s treatment: 
motivation, diet and physical exercise. Usually, childhood obesity is treated by a regular 
pediatrician. As obesity increases, and comorbidities or psychological consequences 
appear, a multidisciplinary approach becomes necessary, including a nutritionist, behavior 
modification specialist, psychologist and an obesity specialist pediatrician (210, 213-215).    
The treatment of obesity is a long process presenting different phases that should not be 
hurried. In the beginning of the treatment, several visits might be necessary, to build the 
trust between the doctor/team and the child. Also, it is beneficial for the children to be 
followed by the same doctor throughout the treatment (5).  
The IDF 2007 recommendations for the prevention and treatment of MS in children and 
adolescents focus on weight improvement and management, tackling obesity as a MS 
underlying cause. IDF recommendations  are (210): 
 Moderate caloric restriction;  
 Moderate increase in physical activity;  
 Change dietary composition. 
According to IDF, the use of adjuvant pharmacologic therapy should also be considered, if 
safety is proved (210). IDF recommendations are similar to other international guidelines, 
such as those recommended by the WHO, the American Association of Pediatricians 
(AAP), and the Associacíon Española de Pediatría (AEP) (25, 214, 216).  
Obesity reduction programs in children should be adapted to age, degree of obesity and 
presence (or not) of comorbidities. The treatment should start immediately and do not wait 
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for older ages (5, 179, 210, 214). Children and young adolescents have a linear growth 
potential that can help on BMI normalization and should be considered when defining a 
treatment strategy (5, 210, 215). 
Depending on the age and the levels of adiposity, children with a BMI higher than the 85th 
percentile and lower than the 95th percentile (overweight children), or above 95th percentile 
but without comorbidities (obese children without complications), could follow 3 basic 
options (179, 214, 215):  
 Slow the rate of weight gain – used in very young children (2-4 years old), 
as they present a very rapid growth rate that might lead to BMI normalization; 
 Weight maintenance – used for children over 4 years; 
 Gradual weight loss (1 to 2 kg/month) to improve BMI. 
For children with BMI above the 95th percentile with comorbidities, an approach based on 
the severity of the situation should be used. Weight loss is usually necessary but, even in 
severe obesity, the weight loss program should be gradual for several reasons (5, 179, 
215):  
 It should be used a goal that the children can achieve to avoid 
demotivation; 
 Even slow weight gain involves a great reduction on habitual caloric intake, 
especially if the children is still growing; 
 Treatment of weight excess is a long term process and gradual weight loss 
is easier to be sustained for longer periods. 
Adolescents who have reached growth limit and have a BMI higher than 30 Kg/m2 should 
be submitted to a program similar to that used for obese adults, to minimize CVD risk 
(179, 213).  
It is necessary to approach the child/adolescent in his culture, social and family 
environment, as it would be harder to tackle childhood obesity without the help of parents 
and caretakers (165, 179, 213-215). 
The NCAHP provide guidelines and check points to follow the pediatric development that, 
if correctly followed, might help to identify obesity and associated comorbidities while still 
in early stages, when the chances for a successful treatment are higher (18).  It also 
focuses on the promotion of healthy lifestyle habits, improving diet and increasing physical 
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activity. Moreover, anticipatory care instructions are provided to parents and caretakers to 
guaranty that they are aware of the most common health issues in each particular age, or 
of any particular health problem of the child, and have the skills and knowledge necessary 
to support the child along the treatment. A gradual responsabilization, first of the parents 
and, afterwards, of the child or of the adolescent, by their health maintenance  and 
success of therapy should be done (18). 
In Portugal, there are no clear guidelines on how the pediatric obesity should be 
approached, only general recommendations are given for a healthier lifestyle. 
Nevertheless, many hospitals in Portugal have specialized pediatricians and provide 
obesity appointments to which children can be referred. The obese appointments, usually, 
involve besides the doctor, a visit to a nutritionist. 
Clearer guidelines regarding obesity and overweight treatment and prevention should be 
provided worldwide, and particularly in Portugal. It seems unreasonable that the NCAHP 
focus on dyslipidemia, hypertension and oral health programs, known comorbidities of 
obesity, while obesity is only referred twice along the 121 pages of the document. 
 
10.1. Prevention and interventional programs 
The prevention of overweight and obesity can be considered as population based 
programs, involving national or global initiatives, regional or community interventions, or 
individualized programs (179, 215). According to the WHO, the use of population based 
programs to prevent obesity in combination with local-based community, school or 
individual programs are successful in fighting obesity (151, 170).  
The population based programs intend to promote and support healthy habits, by reducing 
unhealthy habits and by interfering with the social determinants of health. The use of 
local-based actions is helpful, but needs the support of national government policies to 
ensure their sustainability and efficacy. Thus, population based prevention of obesity 
transfers part of the responsibility on reduction of health risks, from the individual to the 
government (151, 170). The main stakeholders in this kind of approach are the 
governments, who are responsible for creating policies, implementing interventions, and 
monitoring their results (179, 215). The WHO itself is responsible to provide technical and 
scientific basis, the necessary tools and resources for the government’s actions (216). 
Genetic contribution and follow up study based on the reduction of the body mass index 
60 
 
Other key stakeholders include regional and local level administration, non-governmental 
organizations, academic and civil society (216). 
The government, usually through the Ministry of Health, is responsible for the coordination 
of the various stakeholders and for the development of different approaches that must 
globally influence the society, allowing the achievement of optimal results: the upstream 
approach refers to the improvement of the economic physical and social environments; 
the midstream approach is to increase the efficacy in influencing individual behavior and 
lifestyle; and the downstream approach, is related to the availability of health services 
(216). By coordinating the population based programs through these different approaches, 
the government objective is to make a change in the social paradigm and make the 
healthier choices the easier ones (179, 216). The WHO Technical Meeting for Population 
Based Prevention of Childhood Obesity in 2009 highlighted some points, key issues, 
which should be addressed by governments while tackling obesity: 
 Globalization – driving force responsible for much of the changes in diet: 
o To redefine policies with food supply, focusing on quality and quantity.  To 
give particular attention to food marketing directed to child and 
adolescents; 
 Urbanization – urban environments are, in general, associated with unhealthy 
lifestyle. However, increasing obesity occurs both in rural and urban areas: 
o Create friendly environments that facilitate healthy options. Political options 
include building and maintaining in good conditions bicycle and pedestrian 
pathways; offering a good network of public transportation; providing the 
schools with adequate sports equipment, among others; 
 Socioeconomics and demographics – many issues affecting obesity can be 
included in this group. Children of ethnic minorities and low-income families are in 
increased risk of obesity. Furthermore, children from low-income families appear to 
achieve worse responses in interventional programs. Also, the risk of obesity can 
vary, depending on the gender in some societies.  
Early personal history can influence body weight. Children of obese mothers, of 
mothers who had gestational diabetes, or children who were exclusively 
breastfeed for a period shorter than 6 months present a higher prevalence of 
weight excess: 
o Identify and direct interventions to children in higher risk (risk factors can 
be specific of a certain society). A healthy beginning of life should never be 
denied to a children, due to their social status; 
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o The lifecycle approach to obesity consider that to guaranty health in the 
future life the prevention of disease should start early, still during 
pregnancy and continue afterwards; 
 Children with disability – these children are in greater risk of obesity due to 
physical, environmental and psychological limitations, and to the lack of knowledge 
about real capacities of health professionals, parents and the children themselves: 
o Build directed programs and encourage disabled children to do physical 
activity, if possible integrated with non-disabled children; 
 Cost-effectiveness – the cost-effectiveness of programs in inducing changes in 
lifestyle and lowering obesity prevalence is not well established, limiting evidence-
based policies changes:  
o Most of the programs are cost effective. Intervention success is increased 
when large populations are approached and the target is not set in small 
groups or individuals. Considering this, the national health system, due to 
its broad reach, can achieve maximum results. 
The other stakeholders, besides the government, also have an important function, to 
transform and apply the guidelines in the field. While national governments are 
responsible for the design of the programs, regional and local governments should adapt 
the general guidelines to their particular context, in order to increase success rates (216).   
The private sector should help to create and support healthy environments. A very specific 
social role is that of the food industry, by enabling healthy food options and supply. 
Partnerships with commercial entities, regarding the programs funding, can be done and 
might increase the sustainability and quality of those programs. Nevertheless, they have 
to be carried carefully as conflicting interests might be present. Thus, the WHO advises 
that the commercial partners should be more involved in the delivery of the objectives 
than in their lining (216). 
Non-governmental associations should advocacy towards policies tackling obesity, good 
practices, transparency and resourcing of programs. Universities and researchers, on 
their turn, should provide scientific evidence for the development of more effective 
programs (216).   
Successful implementation also depends on other players, as parents, health 
professionals, and teachers. These players are in the field and interact directly with the 
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obese children and adolescents, being the real face of the struggle against obesity (151, 
170). 
To face this public health problem, the best approach is to act early and prevent the 
development of weight excess. Besides general prevention, directed programs can still act 
in other levels of the population, including the prevention of overweight children to become 
obese - primary prevention; and in the treatment of obese children, to prevent and reduce 
obesity-related comorbidities – secondary prevention (179). Community based prevention 
programs can be more or less geographically embracing, presenting maximum effect with 
minimum cost. On the other hand, individualized prevention of overweight and obesity has 
much higher costs and is less likely to have a great impact in public health (179, 215). 
When developing a program is essential to do the “tailoring” of the strategies, adapting 
them to the socio-cultural reality of the target group. Approaches for preventing obesity in 
school age should not be only focused on the obese youth and weight loss, but also to 
encompass cultural aspects, community, schools, family and peers. Afterwards, and as 
the program is applied in the ground, it is necessary to pay attention to individual 
differences that were not considered in the first approach, but might compromise the 
program success (179, 215). 
Interventional strategies to treat obesity are using nowadays a behavioral approach, 
particularly in children. The behavioral modification is aimed to create, or increase, healthy 
habits, by changing diet and physical activity routines and increasing motivational levels 
(5).  
One of the first steps in the behavioral treatment of obesity is to detect unhealthy habits 
and identify the favoring situation, the driving force, and clarify the conditional link 
between them (for example, nutritional excesses and television watching).  Afterwards, it 
is necessary to break the perverse association and build new ones with healthy habits (5, 
216). Through a process of conditioning, it is important to associate the new habits with 
enjoyable experiences and good outcomes, proportioning a positive reinforcement, as 
gratifying experiences are more likely to be repeated. Stress, on the other hand, is a 
potential source of unhealthy behaviors. The identification and prevention of stress 
sources in obese individuals under treatment is crucial. An important point to avoid 
unnecessary stress is to target realistic objectives regarding weight improvements (5). 
Several interventional programs to reduce overweight and obesity have been conducted 
with various results. Different study protocols, designs and studied population are on the 
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basis of this variation. An interesting study in Australia found that multi-angled school-
based programs involving a physical active component were (together with reduction in 
TV advertising of high fat and/or high sugar foods and drinks and laparoscopic adjustable 
gastric banding) the interventional measures with the greatest health benefit in the 
prevention of childhood obesity (216).  
There are international and national guidelines towards fighting obesity and a variety of 
approaches are used, even within the same country. In a small country as Netherlands 30 
different interventional programs were identified, 28 of them were used exclusively in one 
pediatric department. The strategies in those interventional programs varied broadly, 
though the majority lack established scientific basis, or methods to evaluate the efficacy 
(19). 
Regarding the effectiveness of interventional programs there are still doubts in many 
areas, to define which is the best strategy for weight reduction. Pedrosa et al., studying 
overweight Portuguese children (7-9 years) response to weight losing therapy, based in 
nutritional counseling and motivation to exercise, found a greater impact of group (family) 
therapy, when compared to the individual approach. Although both treatments lead to the 
improvement in body weight and lipid profile, the effects of the group based treatment in 
the reduction of adiposity, IR, leptin and in the improvement of lipid profile were more 
marked (148). Children, especially in young ages, are included in family and school 
environment having access almost only to food in the extent that is allowed by parents or 
caretakers, and apply just to the physical activities that the parents are willing to promote 
(5, 148). In this way, a group or family intervention, in which is transmitted information 
about healthier lifestyles, are more likely to promote lasting results, even after the end of 
the intervention (165). This interconnection between the individual and the group/family is 
more complicated in adolescents, as they are in a phase of personality forming and have 
more freedom of choice, regarding diet and physical activities (165). 
 
10.2. Diet 
Unbalanced diet and increased energy intake is a common problem nowadays and a 
major contributor to the epidemic obesity. Lower income families have particularly 
increased difficulty on having a healthy diet, as it is more expensive than other unhealthy 
options (179, 213, 216). 
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Obtaining data about a patient’s diet can involve different strategies. The use of 
questionnaires is common, but lacks objectivity; moreover, obese children and their 
parents, usually, underreport diet excesses, introducing analytical bias. Weekly tables to 
discriminate the number of servings and respective amounts can also be used, as can the 
24 hour food recall. However, both share the lack of objectivity of questionnaires (25).  
Some interventional programs, in order to better control energy intake, choose to provide 
at least one balanced meal per day. Although this is a good strategy, it has the predictable 
logistic, children compliance and financial problems, particularly in longer studies (25). 
To design a healthy diet the children’s nutritional habits and their socio-cultural reality 
should be considered. The basic idea of the diet in the obese pediatric patient is to adjust 
the energy intake to their necessities, in order to allow the correct development, as 
children and adolescents are in a period of constant changes, both physical and 
psychological. Thus, providing an adequate nutrition, to allow the child to reach his full 
development potential is essential (25, 179, 215). The traditional recommendations are, 
usually, overestimated in obese, due to the decreased physical activity, and should be 
adjusted (25). 
The first approach in obese children and adolescents is to reduce the traditional nutritional 
mistakes. Over the last decades it has been observed a trend to increase the caloric 
density of foods, the percentage of fat and carbon hydrates (CH), and to reduce the 
content of micronutrients and fibers. Thus, there is an absolute and relative increase in fat 
intake. Many children, for example, do not have breakfast. It is known that skipping 
breakfast increases the incidence of obesity and decreases school performance (24). 
Other common mistakes include an excessive amount of candies and pastries, particularly 
as the mid-morning and afternoon snack, and an excessive intake of soft drinks with a 
high concentration of CH (25, 213, 215). The substitution of this type of snacks by other 
healthier options, e.g. a fruit, is beneficial (5).   
Not only the type of food is inadequate, but also the number of meals, the daily energy 
distribution, the serving sizes and their weekly basis (5, 25). In western cultures there is 
an excess of meat intake, especially red meat, with a reduction of fish based meals. The 
intake of meat should be reduced to 3 times a week, preferably lean meat (e.g. turkey, 
chicken), and the intake of fish should be of at least of 2-3 meals per week (25). Fruit and 
vegetables intake usually do not reach the recommended 4-5 portions per day (25, 214) 
and the consumption of whole grains is also reduced (25). Due to the reduced intake of 
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fruits, vegetables and cereals there is a lower intake of fibers, a macronutrient that is 
associated with the reduction of obesity and with other beneficial effects, as the regulation 
of intestinal function, reducing the risk of colon-rectal cancer (25). In adolescents, the 
importance of alcohol ingestion in the energy balance should be considered (25).  
Other healthy changes in food habits include the reduction of serving sizes and the 
increase in the time reserved for meals as, by prolonging the length of the meal, there is 
an increase in satiation through the release of anorexogenic and satiation mediators, as 
some gastro-intestinal peptides (e.g. Y peptide) (5). 
The way food is prepared is important to stimulate children to eat healthy. Cooking with 
less fat and the substitution of frying by grilling and baking help to reduce fat intake (25, 
215). It is also important to reduce the use of oil and industrial sauces (e.g. mayonnaise, 
ketchup). The use of salt should be limited, as many of the obese children have increased 
BP; aromatic herbs are a good substitute. Food presentation should not be forgotten, as it 
motivates children to eat better and forget that they are in a diet, if that is the case (25).  
The majority of the diets target changes in the amount and percentage of macronutrients. 
When the approach to reduce nutritional mistakes in overweight and moderated obesity is 
not successful, a nutritionist can prescribe a hypocaloric diet, with the reduction of daily 
energy intake of about 30%. A balanced hypocaloric diet might also involve the increase 
in fiber intake, the reduction of CH with high glycemic levels and the substitution of 
saturated by mono and poly-unsaturated fats (25, 215). Hypocaloric diets and low CH 
diets have shown similar results in short term studies (5). 
In the last years a great number of fast diets and supplements have become available to 
help weight loss. The scientific data supporting these treatments are scanty and they 
should not be used by pediatric patients. Adolescents are a particular vulnerable group 
due to their autonomy to make some decisions (5). 
The nutrition committee of the AEP recommends a mixed, balanced and quantitatively 
limited diet to treat obese individuals. In Spain, to help children to learn the best nutritional 
options, different strategies have been used, as the traffic light diet. In this diet the foods 
are classified according to their content in fat. The foods labeled green are low in fat and 
could be consumed freely, while the consumption of food of the red group, high in fat, 
should be limited. Similar campaigns have been used in Portugal with interesting results 
(5).  
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When a weight-losing diet is followed, besides the decrease in fat mass, a decrease in 
lean mass also occurs and, consequently, a reduction of the energy expenditure. Thus, it 
is important to add protein sources of high biological value to diet and to increase physical 
exercise levels, in order to maintain and improve the lean mass throughout the diet (25).  
In overweight and moderately obese younger children the main objective is to maintain 
the body weight without compromising the normal body development, as the BMI, usually 
normalizes with height increase (25, 215). Also, the energy restriction should be 
moderate, in a way that it can be sustained in time (5).  Very low caloric diets (500-600 
kcal/day) and the use of liquid formulas to substitute entire meals should not be used in 
children and adolescents, and are only recommended in cases of increased health risk 
and morbid obesity (25). In fact, some centers specialized in the treatment of morbidly 
obese or obese with comorbidities have successfully used that approach (5). These diets 
need special attention to avoid the development of acidosis, through an adequate CH 
intake, and to prevent the extensive loss of lean mass, by controlling the protein ingestion 
(5, 25). 
 
10.2.1. Biochemical outputs of diet 
Diet restriction is associated with improvements in adiposity and in lipid profile, namely a 
reduction in TC and LDLc. The influence of diet in HDLc appears to be limited, presenting 
physical exercise more pronounced effects (217). This fact might be explained by a small 
impact of diet on IR (217). 
An improvement in inflammation, following diet-induced weight loss has also been 
reported. In fact, following a diet restriction program, total adiponectin levels were 
increased, while inflammatory mediators such as leptin, MCP-1, IL-15, and IL-18, were 
reduced (218, 219). A cumulative effect of diet and physical exercise on the improvement 
of the inflammatory status was reported (218), however, there are conflicting results (219). 
The use of specific components in the diet, besides the energy restriction, might lead to 
different outcomes regarding metabolic changes. The different types of fats, for instance, 
are associated with different effects. Increased fat intake is associated with a reduction of 
adiponectin (220), while children receiving n3 fatty acids supplementation presented an 
improvement of the inflammatory status (increased adiponectin and reduced TNF-α and 
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leptin). The improvement in inflammation is probably on the basis of the reduction in IR 
(221).  
The type of diet recommended its caloric content and individual components should be 
defined according to the individual degree of obesity, presence or not of comorbidities and 
specific metabolic risk profile, in order to obtain the expected benefit from it. 
 
10.3. Physical activity 
Southern European countries, including Portugal, present lower physical activity levels, 
among children and adolescents, than countries from Centre and Northern Europe.  Part 
of the increased prevalence of obesity in the Southern countries might be related to this 
fact (222). 
An inadequate energy intake accompanied by reduced physical activity is very likely to 
result in weight excess. The increase of the physical activity levels is mandatory in obesity 
treatment and has multiple benefits. To achieve an improvement, two points should be 
considered: to reduce the time spent on sedentary behaviors and to increase physical 
activity levels.  
The daily energy expenditure is calculated by the sum of the energy expended in rest, the 
diet induced thermogenesis and the energy expended on physical activities (25). Physical 
activity, besides the energy used during the activity itself, increases lean mass and, 
consequently, increases the energy expend during rest (25).  
The strategies to access information about individual physical activity levels are similar to 
those used for diet. Questionnaires, filled by children or parents, do not have enough 
accuracy, as there is a trend to underestimate sedentary behaviors. Also, questionnaires 
do not discriminate different levels of energy expenditure that can occur in the same type 
of activity, depending on the engagement of each individual (25). The use of 
accelerometers is a good option for objectively control the level of physical activity, even 
during entire days. Its use has, however, considerable financial costs (25). 
Strategies and interventional programs to increase the physical activity among pediatric 
populations have flourished in the last years. School based programs might be particularly 
interesting as they take advantage of children availability and school sports equipment 
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(25, 213). However, programs involving physical exercise should choose stimulating and 
new activities, especially for the younger children, as their interest is harder to maintain 
(179, 215). The simple increase of the hours spent on curricular physical exercise do not 
present significant improvements (179).  
The guidelines for physical activities in children and adolescents state that 30 to 60 min a 
day should be dedicated to moderate or intense physical activity (25, 179, 213, 214). 
Physical activities should be adequate for age and gender, and should also be stimulating, 
in order to prevent the loss of interest. The general recommendations have to be adjusted 
for each children and the exercise plan adequate to their socio-cultural-economic 
background  (25, 179, 213-215).  
Increasing activity levels with everyday activities, as gardening, walking to school, riding a 
bicycle and traditional children games, as hide and seek, might be effective in increasing 
the metabolic level and should be encouraged (5, 179, 215). On the other hand, sports 
groups, although helpful, may not provide enough activity, due to the limited training 
period and weekly schedule. Moreover, the ingress in a sport group of an unfit obese child 
might have harmful results caused by the initial incapacity to perform requested exercises 
and by eventual bulling of their peers, what could, somehow, traumatize the child and lead 
to withdraw. Thus, group sports should be considered carefully, or postponed until the 
patient has reached minimum skills (179, 215). 
Nevertheless, there are conflicting results regarding the success of interventional 
programs involving exercise alone or combined with diet. Doubts exist, particularly 
regarding the long term effectiveness on weight maintenance (25, 179). Further studies on 
the influence of less “aggressive” programs following (e.g. a motivational approach 
towards the improvement of lifestyle habits) would be important. 
Regarding sedentary behaviors, such as screen time, parents should define the period of 
duration and its content, while outdoor playing should be encouraged, if safeness is 
granted (5). 
Once again, each obese individual is a particular case and should be addressed in that 
way. The child should be challenged and motivated to increase physical activity gradually 
and to achieve realistic goals. Unpleasant situations should be avoided. 
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10.3.1. Biochemical outputs of physical exercise 
An adequate performance of physical exercise presents several beneficial effects. For 
instance, there is an improvement of the lipid profile, with the reduction of TG and the 
increase of HDLc. A key factor underlying this improvement seems to be the increase in 
insulin sensitivity that follows the increased physical fitness. In fact, the improvement of 
the hepatic insulin sensitivity is associated with changes in the lipoproteins produced by 
this organ, towards the production of less atherogenic lipoproteins (181, 182, 223, 224). 
Nevertheless, there are still some contradictory results (55). Diet, on the other hand, 
although presenting a significant role in the reduction of TC and LDLc, seems to have 
limited impact on HDLc and insulin sensitivity, being the increase in physical exercise the 
main pathway to achieve those changes (217).  
The increase in regular physical activity is also associated with an improvement of the 
inflammatory status, with the reduction of inflammation markers, such as IL-6, CRP,  leptin 
and TNF-α (55, 225-227) and the increase in anti-inflammatory adiponectin (228, 229). 
Moreover, the exercise-related improvement in the IR is likely to be associated with the 
reduction in pro-inflammatory mediators and the increase in anti-inflammatory mediators, 
such as adiponectin, namely the HMW adiponectin (230, 231). However, there are still 
some controversy regarding changes in inflammatory mediator levels with physical 
exercise and weight loss, particularly on which markers vary and in the extent of the 
modification. The results obtained with adiponectin multimers are particularly confusing 
(42, 232, 233) 
The variation in the training protocol used in an intervention program can lead to different 
results. Although both aerobic training (AT) alone, and aerobic combined with resistance 
training (ART) improved adiposity measures, as BMI, BMI z-score, visceral fat and 
subcutaneous fat, and were effective in reverting MS in obese individuals, the 
improvement achieved with ART, namely in adiposity markers (with exception of 
subcutaneous adipose tissue (SAT)), TC, glucose and adiponectin levels was higher than 
with AT (234). 
Cardiorespiratory fitness (CRF) is inversely associated with CVD risk markers and total 
mortality (235) and one of the main determinants of the physical activity levels in children 
and adolescents (222). In fact, a lower CRF is related to increased sedentary behaviors 
and weight gain (236). Although CRF has a considerable genetic background, it increases 
with exercise (222). The use of training protocols aiming to increase CRF, as well as the 
Genetic contribution and follow up study based on the reduction of the body mass index 
70 
 
use of CRF as an outcome of exercise programs, might be a good strategy to control the 
effectiveness of interventional programs.   
Some studies suggest that improvements in IR, lipid profile (e.g. HDLc) and inflammatory 
status (e.g. adiponectin) are only present in the case of a substantial improvement in BMI 
(e.g. a reduction of BMI z-score > 0.5) (226, 227, 237). Besides the weight reduction that 
might accompany the increase in physical exercise, a key factor to explain the metabolic 
changes that occur, are the changes in the body composition, particularly the reduction in 
central adiposity, known to be associated with worsening of the risks factors for CVD (4, 
39, 44). Thus, some of the conflicting results regarding the effects of physical exercise 
and diet on metabolic parameters might be related to the effective changes in body 
composition. More than considering only changes on weight or BMI to evaluate the 
success of an interventional program, the analysis of markers of adiposity distribution, 
such as WC, WC/H, skin folds and DEXA, would, probably, be a better option 
Study the impact of small reductions of adiposity on CVD risk markers would be important. 
Smaller improvements might be a more realistic target, which could be more easily 
achieved and sustained, avoiding the loss of motivation in longer, stricter programs.  
 
10.4. Pharmacological strategies 
Pharmacological strategies to improve weight loss in pediatric obese patients have been 
proposed. Nevertheless, these strategies must be always an adjuvant to lifestyle changes, 
including diet and increased physical exercise. The weight loss obtained by the use of 
drugs are, usually, small but significant (25, 213, 238).  
The use of an adjuvant pharmacologic therapy should be considered carefully and in 
specific cases, when the relation risk/benefit is favorable. Patients that could be 
considered for pharmacological therapy include obese individuals that do not respond to 
behavioral treatments or present comorbidities, and overweight children presenting 
comorbidities. Overweight or obese children with a strong family history of T2DM or CVD 
should also be considered, even when comorbidities are still not present (25, 213, 238).  
In Portugal the only drug approved for the treatment of obesity is Orlistat, however it is not 
recommended for children and adolescents (239-241). 
Inflammation and atherogenic risk in obese children and adolescents  
71 
 
The drugs used have specific actions and can be included in the following groups: drugs 
reducing energy intake (anorexigenics), drugs that interfere with dietary nutrients and 
drugs interfering with the metabolism (25, 238). Table 12 resumes some of the drugs that 
have been studied and/or used in pediatric obese patients.  
Other drugs have been used in adults with interesting results regarding weight reduction, 
however the information about their applicability in pediatrics is limited or absent. This list 
of drugs enclose bupropion (anti-depressive), lorcaserin (selective 5-HT2C receptor 
agonist), tesofensine (monoamine re-uptake inhibitor), pramlintide (amylin analogue), 
exenatide and liraglutide (GLP-1 analogs); other drugs, as acarbose 
(pseudotetrasaccharide), have still limited support, even in adults (238). Rimonabant (CB1 
cannabinoid receptor inhibitor), an apparently promising drug, was withdraw due to the 
association to the increased risk of suicide idealization and attempt (5).  
Another therapeutic option for the treatment of obesity, available in Portugal, is a medical 
device called XL-S Medical®. The functional component of this device is Litramine, a 
complex of soluble organic and vegetal fibers that jellify in the stomach, capturing the fats 
and lipids present in the meal, diminishing their absorption, with effects similar to orlistat 
(although the mechanism of action is different). It is not recommended for individuals 
under the age of 18 years or with a BMI lower than 18.5 kg/m2 (241, 242).  
Obesity is a multiorgan pathology, and weight control is mediated by a large number of 
mechanisms in the organism. In this way, the use of therapies combining different drugs, 
acting by different mechanism, to treat or prevent weight gain, such as the combination of 
peripheral and central acting drugs, can enhance the success of the pharmacologic 
therapy (213, 238). Some of the combinations used in adults are phentermine and 
topiramate (approved by FDA for the treatment of obesity in adults, in 2012), bupropion 
and naltrexone (recommended for approval by FDA Metabolic Drugs Committee), amylin 
and leptin analogues, and pramlintide and phentermine or sibutramine (238).  None of 
these combinations are available in Portugal (239-241).  
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Table 12. Pharmacological options for obesity treatment 
Drug Mechanism of action Side effects 
Centrally acting anorexigenic 
Phentermine1 and  
diethylpropion1 (238-241) 
Anorexogenic effects by increasing adrenergic tone, decreasing energy intake 
and increasing resting energy expenditure 
Euphoria, palpitations, hypertension, cardiac arrhythmias, 
dizziness, blurred vision and abuse potential. 
Fluoxetine, chlorphentermine1, 
fenfluramine2  and 
dexfenfluramine2 (238-241) 
Reduce appetite by increasing serotonergic release or inhibiting re-uptake 
Cardiac valvulopathies, increased risk of primary pulmonary 
hypertension, headache, abdominal pain, drowsiness, insomnia, dry 
mouth, increased activity and irritability 
Methylphenidate and 
dextroamphetamine1 (238-241) 
Anorexogenic effect by inhibiting dopamine reuptake  
Agitation, insomnia, tachycardia, hypertension, hyperhidrosis and 
abuse potential 
Sibutramine2 (25, 179, 213, 214, 
238-241) 
Inhibits serotonin, norepinephrine and dopamine reuptake, presenting an 
anorexogenic effect and increasing energy expenditure 
Cardiovascular events (myocardial infarction and stroke), 
hypertension, increased heart rate, headache, dry mouth, 
anxiousness, insomnia, depression, constipation and cholelithiasis 
Leptin1,3 (25, 179, 238-241) 
Transmit information to hypothalamic centers of the adipocyte lipid reserves 
and of nutrients and energy of meals – satiation effect 
Increased inflammation 
Topiramate (25, 213, 238-241) Anorexogenic effects by GABA-ergic stimulation 
Psychomotor disturbances, difficulties with concentration, 
sedation, reduction of learning skills, paresthesias and taste 
impairment. 
Drugs affecting dietary nutrients 
Orlistat4 (25, 179, 213, 214, 238-
241) 
Inhibit gastrointestinal and pancreatic lipases, reducing the absorption of 
ingested dietary fats 
Intestinal gases, oily stools, oily spotting, oily evacuation, 
abdominal pain, fecal urgency, diarrhea and gallstones. Lipid 
soluble vitamins deficiency. 
Drugs affecting the metabolism 
Metformin (25, 179, 213, 214, 238-
241) 
Modulation of insulin action. Inhibit intestinal glucose absorption, reduces 
hepatic glucose production and increases peripheral insulin sensitivity by 
improving glucose uptake and utilization 
Diarrhea, nausea, vomiting and flatulence. Vitamin B12 and folic 
acid deficiency 
Octreotide5 (213, 238-241) 
Modulation of insulin action. Octreotide inhibits the release of the growth 
hormone, thyrotropin and corticotropin from the hypophysis; and of insulin 
and glucagon from the pancreas and ghrelin from the stomach. 
Transient elevation of blood glucose, diarrhea, abdominal pain, 
discomfort, flatulence influenza-like symptoms, constipation, 
headache, fatigue, dizziness, nausea, anemia, hypertension, and 
gallstones 
Growth hormone6 (213, 238-241) 
Modulation of lipolysis. Inhibits LpL, increases hormone-sensitive lipase 
levels and stimulates lipolysis in adipocyte, stimulates protein synthesis and 
increased fat-free mass 
Increased risk of tumor, potential adrenal insufficiency, insulin 
resistance, increased risk of sleep apnea and increased cardiac 
diameter 
Ephedrine combined with 
caffeine1 (238-241) 
Modulation of energy expenditure. Ephedrine increases catecholaminergic 
tone while caffeine acts by inhibiting phosphodiesterases. Ephedrine presents 
a thermogenic effect that is enhanced with the administration of caffeine 
Cardiac effects, nausea, insomnia, tremor, dizziness and 
palpitations 
1, not commercially available in Portugal. 2, withdraw from Portuguese market. 3, Used only to treat syndromic obesity related to lack of leptin production. 4, only 
pharmacological option approved in Portugal. 5, Used only for the treatment of patients with hypothalamic obesity. 6, used only to treat syndromic obesity characterized 
by reduced synthesis of growth hormone – e.g. Prader Willi Syndrome.  
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The use of pharmacologic treatment should always be considered with caution, 
particularly in pediatric patients, and faced as adjuvant of lifestyle modification strategies. 
Nevertheless, it should not be a taboo and, when a positive risk benefit balance is 
considered, the use of drugs can be a helpful tool. Portuguese and European regulatory 
agencies have adopted a particularly restrictive position towards possible pharmacological 
options, particularly when compared to the USA’s FDA. As a direct consequence, off-label 
use is a growing reality in obese treatment. More flexible legislation and clearer guidelines 
would probably guarantee the safety and efficacy of obesity treatments. When considering 
the pros and cons of pharmacological options it is important to consider not only the 
comorbidities presented by the patient, but also the risk for future obese-related 
complications. Thus, the balance between the benefits and risks of controlling adiposity, 
especially in young ages, is very important, as obesity is a chronic condition that tracks 
into adulthood. Moreover, the drugs to treat obesity, both in adults and in children, have to 
demonstrate long-term safety and efficacy, particularly when treatment is started in 
pediatric ages (213, 238).  
 
10.5. Surgical treatment and other options 
Surgical treatment in obese children and adolescents is controversial and the last 
therapeutic option, used only when the traditional approaches failed. It might be 
considered in case of extreme obesity (BMI > 40kg/m2) with associated comorbidities 
(hypertension, dyslipidemia, IR, NAFLD…), and in case of BMI > 35 kg/m2 with associated 
serious comorbidities (T2DM, sleep apnea, endocraneal hypertension or serious NAFLD) 
(5, 25, 179). Moreover, as adolescents are still in development, bariatric surgery should 
be carefully considered. The recommendations for bariatric surgery include: 
 A minimum Tanner stage of 4 or 5.  Less mature individuals could be 
considered if severe comorbidities are present;  
 Have reached at least 95 % of growth potential, especially if malabsorptive 
surgery is considered;  
 Psychological maturity and capacity to understand the limitations that will follow 
the procedure: 
o Dietary and activity changes;  
 Family and social support;  
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 Exclusion of genetic or syndromic obesity (5, 214, 215);  
 Failure of lifestyle intervention, with a duration of at least 6 months (5).  
Bariatric surgery is also contraindicated in adolescents with history of alcohol or drug 
abuse in the last year, pregnancy or planning to get pregnant in the next 2 years, and in 
patients who did not correctly followed previous lifestyle treatment (215). 
The most relevant bariatric techniques in pediatric obesity are gastric bypass, gastric 
banding and gastric balloon. 
The gastric bypass in Y of Roux, due to its malabsorptive and restrictive nature, is one of 
the most used surgical options in obesity. In fact, it is the most used technique in the USA. 
This surgery consists of a reduction of stomach size and a reduction of intestinal 
absorptive capacity via the creation of a gastrojejunal anastomosis (5, 214). The gastric 
bypass allows the loss of 50-60% of the body weight, as well as improvements in several 
metabolic parameters, such as TG, TC and IR (5, 25, 179, 214). Side effects involve 
nutritional deficiencies, due to malabsorption. Patients submitted to this surgery need to 
be followed by a multidisciplinary team, including doctors, psychologists and nutritionists 
before and after surgery (25, 179, 214). 
The gastric banding is a less invasive surgical technique, when compared to gastric 
bypass. This option has increasing acceptance nowadays, due to its reversibility and 
lower number of side effects. The gastric banding is, in fact, the most used bariatric 
surgery in Europe for the treatment of obese adolescents, presenting a considerable 
success. It consists in the laparoscopic placing of a silicon ring around the proximal part of 
the stomach that will limit food ingestion. This ring can be regulated by introducing saline 
in a subcutaneous reservatory. However, the weight reductions are more limited than with 
gastric bypass, reaching around 20-30%. The side effects, as malabsorption, are less 
frequent and have less impact in the development of the adolescents than gastric bypass 
(25, 214, 215).  
The endoscopic implantation of a gastric balloon is the lowest invasive option, when 
compared to the other two. Similarly to the gastric banding this is a reversible technique 
with lower number of side effects.  Achieved weight reductions are comparable to those 
obtained with the gastric banding (20-30% of weight reduction) (5, 25, 214, 215).  
The temporary nature of the gastric balloon, and the reversibility of gastric banding, come 
with the common problem of weight rebound, once the balloon or the banding are 
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removed. A multidisciplinary team with psychologists and dietitians, beside pediatricians, 
need to follow the patient, before and during the whole process, and particular attention 
after the removal of the restrictive device is needed (215). 
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11. Aims 
Obesity is a disease characterized by a state of low grade inflammation, and increased 
visceral adiposity. The WAT, an active endocrine organ, secrets several molecules 
collectively known as adipokines. These adipokines are mainly involved in primary 
inflammatory processes and, therefore, in inflammatory diseases. While most of the 
inflammatory markers are increased in obese individuals, adiponectin, an important anti-
atherogenic, anti-diabetic and anti-inflammatory molecule, is reduced.   
Inflammatory mediators have been studied as potential markers of CVD. In fact, increased 
inflammation has been linked to an increase in other CVD risk markers, such as IR, 
dyslipidemia, obesity and hypertension. These known markers for CVD risk are also often 
present in obesity.  
In pediatric obesity an increased inflammatory process with systemic changes are already 
present. This is particularly important in Portugal, as our country presents a high 
prevalence of obesity and overweight in young ages. Considering the high prevalence of 
CV events in Portugal, we found as important to better understand the biology of children 
and adolescent’s obesity, the relation between obesity and the classical and new CV risk 
markers, as well as the clinical value of lifestyle intervention in improving the risk profile. 
To achieve these aims, we designed a work involving a Portuguese obese pediatric 
population that consisted of three parts:  
 A transversal analysis: with the objective of improving the knowledge about the risk 
profile and the values of classical and new CV risk factors, as well as their inter-
relation, in young obese patients (Papers I to V); 
 A longitudinal analysis: intending to evaluate the influence of an improvement in the 
BMI on CV risk markers. Two approaches to achieve weight loss were: 
o Lifestyle motivational program (Paper VI) 
o Interventional program (Paper VII) 
 Analysis of the criteria used to classify obesity in Portugal (Paper VIII) 
 
  
Genetic contribution and follow up study based on the reduction of the body mass index 
78 
 
  
Inflammation and atherogenic risk in obese children and adolescents  
79 
 
12. Methods 
 
12.1. Subjects 
Children and adolescents participated in the cohort study, after informed and written 
consent of their parents. Two recruitment strategies were used. Part of the population was 
identified from medical records, at two outpatient clinics of pediatric obesity in Porto, and 
invited to participate. A second group of children was involved in a school-based physical 
exercise (PE) promotion program, carried out in 5 primary and 2 middle and high public 
schools from Porto suburban setting.  
The longitudinal study consisted of either a lifestyle modification motivational program in 
the hospitals, taking advantage of routine obesity appointments with the paediatricians; or 
a physical exercise program of 8 months that took place in the aforementioned schools.  
Only children and adolescents who completed the evaluation protocols, pre and post-
program participation, and who were not participating in any other formal sports or 
physical exercise program were included in the longitudinal approaches. Individuals who 
did not complete the entire programs, were included only in the cohort study. 
 
12.2. Exclusion criteria and ethical approval 
Smokers, subjects under regular medication or with diabetes mellitus, endocrinologic 
disorders, hereditary, inflammatory or infectious diseases were excluded from the study.  
The protocol used for all participants was approved by the Committees on Ethics of the 
University Hospital S. João and of the Children’s Hospital Maria Pia, Central Hospital of 
Porto. The Regional Education Board approved the study protocol, and students, parents 
and school responsibles agreed to participate. The project, its benefits and risks were 
explained to the volunteers.  
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12.3. Procedures and assays 
 
12.3.1. Anthropometric, nutritional and clinical evaluation 
Height, weight and waist circumference were measured. Obesity was defined by a BMI z-
score higher than +1.65 for age and gender, according to 2000 Centre for Disease Control 
and Prevention (CDC) growth charts (27). Children’s BMI z-score was also classified 
according to the WHO criterion (6). Body composition was evaluated by dual-energy X-ray 
absorptiometry (DEXA). 
The development of puberty was clinically assessed on the basis of Tanner stages.  
 
12.3.2. Lifestyle modification motivational program 
All obese individuals involved in the lifestyle modification program were motivated to 
change their lifestyle habits (conventional weight loss programs based on dietary 
counseling and encouragement to exercise). Clinical and biochemical data were obtained 
at the beginning, as well as at the conclusion of the one year follow-up. 
 
12.3.3. Physical activity promotion program  
The participants were involved in a physical exercise program over a period of 8 months, 
from October to May. Besides regular classes of PE at school 3 times a week, participants 
were enrolled in an extra-activity PE program twice a week, resulting in a total of 5 hours 
per week of moderate to vigorous PE, matching the international recommendations. The 
PE proposed by the program aimed to increase moderate-vigorous PE intensities. All the 
activities were performed in indoor schools´ sports facilities, under the supervision of 
Physical Education teachers, after school time. The evaluation methods and procedures 
were approved by the Scientific Board of the Faculty of Sports of the University of Oporto. 
Clinical and biochemical data were obtained at the beginning and at the end of the 
exercise program. 
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12.4. Laboratory analysis 
 
12.4.1. Blood sampling 
Blood samples were obtained on a fasting basis and processed within 2h of collection. 
Blood was obtained by venipuncture in ethylenediaminetetraacetic acid (EDTA) containing 
tubes. Plasma and buffy coat aliquots were made and immediately stored at – 80ºC until 
assayed. 
 
12.4.2. Biochemical determinations 
The determination of circulating levels of glucose, insulin, TG, TC, HDLc, LDLc, apo A1, 
apo B, apo E, Lp(a), bilirubin and CRP were performed by using routine automated 
technology.  
LDLc and VLDLc concentrations were calculated using Friedwald formulas (243): LDLc = 
TC – HDLc – (TG/5); VLDLc = TG/5. Homeostasis model assessment – insulin resistance 
(HOMAIR) was used to detect the degree of insulin resistance, by using the following 
formula (244): insulin resistance (HOMAIR) = (fasting insulin (μU/mL) × fasting glucose 
(mmol/L)/22.5).  
Plasma concentration of adiponectin and adiponectin multimers were evaluated by using 
standard commercial enzyme-linked immunoassay (ELISA). 
 
12.4.3. Hematological data 
Total leukocyte count, red blood cell count, hematocrit, hemoglobin concentration and 
hematimetric indices (mean cell volume, mean cell hemoglobin and mean cell hemoglobin 
concentration) were measured by using an automatic blood cell counter. 
Blood cell morphology and leukocyte differential count were evaluated in Wright stained 
blood films. 
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12.4.4. DNA analysis 
Genomic DNA was extracted from white blood cells (buffy-coat) by proteinase K/salt 
precipitation method (25, 26). Genotyping was performed by polymerase chain reaction 
(PCR) followed by electrophoresis in polyacrylamide gel in a Tris/Borate/EDTA buffer. 
In the specific case of Apo E E2/E3/E4 polymorphism we used a PCR - Restriction  
Fragment Length Polymorphism (PCR-RFLP) analysis, as described by Hixson and 
Vernier (245). The restriction enzyme used, before electrophoretic analysis, was HhaI. 
 
12.5. Statistical analysis 
The distributions of continuous variables were analysed using Kolmogorov-Smirnov tests 
to assess significant departures from normality. Normally distributed variables are 
presented as mean±SD. Variables non-normally distributed are presented as median 
(interquartile range) and were log transformed, when necessary for further analyses. 
Comparisons between two groups were performed using Student’s unpaired t-test or 
Mann Whitney U-test. Multiple comparisons between groups were performed by one-way 
ANOVA supplemented with Tukey’s HSD post hoc test. Adjustment of statistical 
differences for confounding factors was performed using ANCOVA. The association 
between categorical variables was analyzed using chi-squared test and Fisher exact test. 
The strength of the association between the variables was estimated by Pearson or 
Spearman correlation coefficient. Multiple regression analysis was performed to evaluate 
the contribution of different variables to a specific output using stepwise selection, with an 
entry criterion of p <0.05.  
Statistical analysis was performed using the Statistical Package for Social Sciences 
(SPSS) (IBM, Armonk, NY, USA). Statistical significance was accepted at p less than 
0.05. 
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13. Specific objectives 
 
13.1. Paper I 
Hypoadiponectinemia and obesity are risk factors for the development of CVD (84, 246). 
Low levels of adiponectin were already observed in obese children and have been 
associated with increased CVD risk later in life, but some results are still controversial 
(84, 246). 
To clarify this association, suggesting a central role of adiponectin, we reviewed in 
pediatric patients:  
 How adiponectin is affected by gender and physiological changes occurring at 
young ages;  
 The association between circulating adiponectin levels and MS features in 
obese children and adolescents; 
 How adiponectin levels vary following different types of interventional programs 
in obese pediatric patients. 
The results of the review are presented in Paper I. 
 
13.2. Paper II 
Atherosclerosis is a chronic disease that begins early in life.  Apolipoprotein E has an 
important role in the atherosclerotic process, by facilitating cholesterol efflux from foam 
cells and increasing the hepatic uptake of remnant lipoproteins, through the LDL receptor 
and the LDL-receptor related protein (186, 187). Apo E gene polymorphism originates 
three possible isoforms (E2, E3 and E4), which have been related to changes in lipid 
profile. The individuals with the E4 allele present higher TC levels than the E3 and E2 
allele carriers (187).  
Adiponectin, by improving hepatic insulin sensitivity, is associated with a better lipid profile 
(increased HDL and reduced TG) and presents positive effects on the vasculature, by 
preventing foam cell formation and smooth cell proliferation. 
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We evaluated the interaction between obesity, apo E polymorphism and adiponectin 
levels, as well as the impact of apo E polymorphism and adiponectin levels on the lipid 
profile of the obese children and adolescents.  
The results of this study are presented in Paper II. 
 
13.3. Paper III 
Lp(a) results from the combination of LDL with a plasminogen like protein, (apo (a)). 
Increased levels of circulating Lp(a) are associated with CV risk (191). The plasmatic 
levels of Lp(a) are, mainly, genetically determined. A apo (a) PNR polymorphism 
(TTTTA)n has been reported to be associated with Lp(a) levels (193). The number of 
repeats vary from 5 to 12, and the smaller number of repeats are associated with 
increased Lp(a) circulating levels.  
The aim of this study was to access the levels of Lp(a) in obese pediatric patients, and to 
evaluate the influence of the PNR polymorphism on Lp(a) circulating levels.  
Results are presented in Paper III. 
 
13.4. Paper IV 
Bilirubin, the final product of haem catabolism, is a water insoluble molecule that 
circulates in plasma bound to albumin. To be excreted, bilirubin needs to be glucuronised 
by a microsomal enzyme, the uridine diphosphate glucuronosyltransferase 1A1 
(UGT1A1).  A common polymorphism in the UGT1A1 gene (UGT1A1*28), known to affect 
bilirubin levels, is a TA duplication polymorphism in the TATA box region of the gene 
promoter. The 6 and 7 repeats genotypes are the most relevant. The homozygous 
individuals carrying the A(TA)7TAA allele present higher levels of unconjugated bilirubin 
(170, 201). Although the toxicity of high levels of unconjugated bilirubin has been reported 
in some conditions, namely in newborns, a moderate bilirubinemia has been associated 
with beneficial effects, due to its anti-oxidant and anti-inflammatory capacities (171, 199). 
In fact, serum bilirubin levels have been inversely associated with MS and inflammation, 
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both in adults and in children. Obesity, particularly abdominal obesity, has been related to 
a decrease in bilirubin circulating levels (168, 171). 
The objectives of this study were to evaluate the influence of UGT1A1*28 polymorphism, 
hematological, biochemical and anthropometric variables on total bilirubin plasmatic 
levels, in Portuguese obese children and adolescents.  
Data is presented in Paper IV. 
 
13.5. Paper V 
Obesity is associated with increased inflammation and reactive leukocytosis (172, 173), 
however, little is known about the contribution of the different circulating leukocytes to the 
inflammatory process in obese individuals. It has been reported that increases in BMI and 
WC are accompanied by an increase in neutrophils and a decrease in lymphocytes (173).  
We evaluated circulating leukocytes (total and differential leukocyte count) in young obese 
patients, and studied the relation between the changes in the leukogram and those in 
anthropometric variables and inflammatory status, to clarify the role of leukocytes.  
Results are presented in Paper V. 
 
13.6. Paper VI 
Obesity, including pediatric obesity, is associated with metabolic risk changes, such as 
dyslipidemia, IR and a pro-inflammatory state (5, 28, 37). Weight loss, conversely, lead to 
an improvement on those markers (181, 182, 223, 224), however different weight 
reduction interventional programs reported different outcomes, probably due to different 
design protocols, population studied and goals (218, 219).  
Participants in this study were only asked and recommended to improve lifestyle habits. 
We evaluated the impact of a non-interventional approach in children and adolescents, on 
weight loss, lipid profile, glucose metabolism and inflammatory markers (CRP and 
adiponectin).  
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Data is presented in paper VI. 
 
13.7. Paper VII 
As already referred, adiponectin is an insulin-sensitizer, anti-inflammatory, anti-oxidant 
and anti-atherogenic adipokine that is reduced in obesity. Adiponectin circulates in three 
forms, HMW, MMW and LMW adiponectin (153). The HMW form seems to be the most 
protective, with positive effects on IR and lipid profile, while little is known about the 
biological functions of the other multimers. The reduction of total adiponectin in obese 
individuals has been associated, mainly, with the reduction of the HMW oligomer, what 
might contribute to the risk changes present in obesity (84, 246).  
Weight loss, through diet and exercise, is said to improve total and HMW adiponectin, in 
children and adolescents (84, 246). Nevertheless, it seems that it is necessary a 
significant reduction in adiposity, with a change in body composition, towards a reduction 
of central adiposity, to achieve those results (42, 51, 148). 
We studied the circulating levels of total adiponectin and multimers, as well as their 
association with CV risk markers (lipid profile, IR, inflammation) in an obese pediatric 
cohort. We also analyzed how a regular physical exercise program influences those 
variables.  
Results are presented in Paper VII. 
 
13.8. Paper VIII 
As referred in the Introduction section, the most used criteria for the determination of the 
BMI z-score in pediatric patients are those from CDC and WHO. We used the CDC 
criterion as it was the recommended criterion when this study was started. Currently, the 
recommended criterion is the WHO’s criterion.   
Obesity is part of the cluster of risk factors for CVD, known as the MS. The classification 
of children according to their nutritional status is important. Therefore, we studied the 
impact of this change in the identification of children at risk for CVD and MS. 
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In this way, we evaluated and compared, in a Portuguese obese pediatric population, the 
relation between the BMI z-score, calculated by both criteria, with MS ad with its features. 
Data is presented in Paper VIII. 
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14. Results 
The results of this work are presented in the form of articles/papers, published or under 
consideration for publication. 
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14.1. Paper I 
Nascimento H, Quintanilha A, Santos-Silva A, Belo L. “Adiponectin relation with 
inflammation and metabolic syndrome features in pediatric obese patients - impact of 
interventional studies”. Submitted. 
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Abstract 
Pediatric obesity is a major health problem nowadays and has grown worldwide, 
accompanying the trend in general obesity. Obesity in childhood is usually associated with 
increased risk of type 2 diabetes, metabolic syndrome (MS) and cardiovascular diseases 
in adulthood. Nevertheless, changes in features of metabolic syndrome are already 
present in young ages and tend to increase with augmenting adiposity. 
Children increased body weight is associated with reduced adiponectin, an adipokine 
associated with beneficial effects, particularly regarding MS components (dyslipidemia, 
high blood pressure and insulin resistance), inflammation and oxidative stress, all 
common findings in obese children. 
With the objective to tackle obesity many interventional studies have been done and 
different results were obtained.  This variability probably come from the different studies 
designs and strategies used, including age and pubertal stage of the studied subjects, 
exercise practice, diet counseling,  group or individual therapy… 
Although the general positive effect on weight loss, inflammatory markers and MS of the 
different interventional studies, changes in adiponectin levels are more inconstant. In fact, 
improvements in adiponectin might only occur with great weight loss or intensive physical 
exercise, particularly in pediatric individuals experiencing puberty.  
 
Keywords: Pediatric Obesity, Adiponectin, Metabolic Syndrome, Inflammation, 
Interventional Studies 
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1. Introduction 
The increase in obesity worldwide at pediatric ages has been accompanied by the 
appearance of diseases that were considered exclusive of adults, namely type 2 diabetes 
mellitus (T2DM), dyslipidemia and hypertension.  These pathologies are commonly 
accompanied by central obesity, representing a metabolic derangement usually referred 
as the metabolic syndrome (MS), a cluster of factors that are associated with increased 
risk of cardiovascular disease (CVD) (15, 19). 
Obesity is closely associated with both hypoadiponectinemia and MS. Also, low levels of 
circulating adiponectin are a potential predictor of MS development and, therefore, 
adiponectin has been studied as a possible link between obesity and MS. Furthermore, 
growing evidence support a relation between obesity in childhood and low levels of 
adiponectin and increased CVD risk factors in adulthood (20, 21). 
The objectives of this review are:  
1. To describe physiological and external factors affecting adiponectin; 
2. To present up-to-date information on the relation between adiponectin and 
features of MS in childhood and adolescence;  
3. To analyze the impact of interventional studies in adiponectin levels. 
 
2. Influence of age and gender on adiponectin levels 
Gender, age and puberty play a role on the regulation of adiponectin levels.  
The results of different studies on the concentration of adiponectin in pre-pubertal (PP) 
children vary widely (Table 1). Nevertheless, some studies unveil alterations, even in such 
young ages.  
 
Table 1. Reported studies assessing the relation between total adiponectin levels 
and different features associated with metabolic syndrome in pre-pubertal children 
Population MS Adiposity IR Dislip BP 
215 British-born of European (138; 3y; 49f) and South Asian 
(77; 3y; 27f) origins. UK. (24) 
 (-)  (-)#  
34 ob (9.4±0.4y; 11f). 20 lean cts. Spain. (18)  (-)* (-) (-)  
56 ob (6-18y; 29f). 29 lean cts. Mexico. (17)  (-)*    
159 boys (9y). China. (11)  (-)* NS NS (-) 
70 ob (8.92±1.80y; 22f).  61 lean cts. Spain. (25)  NS (-)   
305 (5-13 y; 161f). Italy. (2)  NS    
30 ob (7.8±1.3y). 35 lean cts. Poland. (26)  NS    
61 ow and ob (7–9y 34f) 22 lean ct. Portugal. (5) NS NS  NS NS 
*, correlation with total and central adiposity; #, positive correlation with HDL. BP, Blood Pressure; Dislip, 
Dislipidemia; IR, Insulin Resistance; MS, metabolic syndrome; (-), negative association; NS, not significant. 
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A study in Polish children found that T, HMW and MMW adiponectin were decreased in 
PP OB children, when compared to control (CT), suggesting that adiponectin multimers 
distribution might already be altered at young ages (26). Another study in PP children 
showed that HMW adiponectin was lower in OB girls when compared to their lean 
counterparts, while no difference was observed for boys (2). 
The difference in adiponectin levels according to gender is well established in adults. 
Women have higher adiponectin concentrations than men (29, 30), showing that sexual 
hormones might play an important role. Before puberty no differences were found 
between genders (31, 32), strengthening the hormonal influence in adiponectin levels 
(Figure 1). In accordance, Martos-Moreno found no difference in total and HMW 
adiponectin levels between PP boys and girls (25). Interestingly, in this study, PP OB 
children presented with increased total adiponectin levels, in spite of the decreased level 
of HMW isoform, when compared to CT. This finding might be related to weight gain at 
this age, accompanied by adipocyte hyperplasia, rather than hypertrophy, leading to an 
increase in adiponectin synthesis (25). In a 4 years longitudinal study in PP children (4 to 
8 years) no difference in adiponectin levels was also observed between girls and boys, 
although it was already visible a trend toward a reduction in adiponectin with age, despite 
the increasing metabolic control during the studied period, as shown by gradually 
improving insulin sensitivity and the lipid profile (33).  
Several studies have shown an increase in adiponectin levels with age in adults (43); 
however adiponectin levels are usually presented as negatively correlated with age at 
young ages (6, 29). Longitudinal studies showed that adiponectin was reduced thought-
out the study period (20, 33). In agreement, adiponectin decreases with puberty for both 
genders and stabilizes afterwards; these changes through puberty have been associated 
to a rise in IR (32, 35). This effect is more marked in boys (35), presenting the post-
pubertal girls higher adiponectin plasmatic concentrations than post-pubertal boys (32). In 
contrast, a study in Chilean children found no difference between genders, before and 
after puberty (6), in contrast with others reports (7, 17). 
Sexual hormones are the most probable cause of adiponectin changes during puberty. 
The influence of sexual hormones involves peroxisome proliferator activator receptor  
(PPAR ). PPAR  regulates adiponectin expression in vitro (44), and drugs, such as 
thiazolidinediones, that activate PPAR , are known to increase adiponectin 
concentrations (45). Animal studies showed that estrogens activate more efficiently PPAR 
 than androgens, what could explain part of the sex related differences in adiponectin 
values (30).  
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In a study involving obese adolescents, total adiponectin concentration and adiponectin-
to-leptin ratio increased following a 6 months lifestyle intervention program. This increase 
was higher in the individuals taking a daily dose of metformin (1500 mg), a known PPAR γ 
stimulator (46). This result is in agreement with another study in obese and insulin 
resistant children and adolescents (47).  
On the other hand, children with Kawasaki disease have lower values of total and HMW 
adiponectin, despite the increased PPAR  gene expression in peripheral leucocytes. This 
fact can be due to an unbalance in the inflammatory pathways in the chronic inflammatory 
state present in these patients. Similar mechanisms can be present in OB individuals (48). 
It is important to emphasize that different pathways can influence adiponectin levels. 
Figure 1 presents the reports concerning the differences in total adiponectin according to 
gender, separated by the pubertal status of the studied population. The lack of differences 
between boys and girls before puberty is almost consensual, while it is ambiguous in more 
mature subjects. The different findings in mixed populations, including PP and pubertal 
individuals, are probably due to the influence of the pubertal status in the final result, 
diluting putative differences.  
 
 
Figure 1. Number of reported studies comparing adiponectin levels between 
genders separated by the pubertal status of the population 
Included articles: (2, 5-7, 10, 12-18, 20, 23, 24, 28, 33, 35-42, 49) . NS, no significant difference 
between male and females in adiponectin concentration; P, post-pubertal inidviduals; PP, pre-pubertal 
individuals. 
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The impact of puberty itself on adiponectin levels is also not very clear, with almost half of 
the reviewed studies finding no difference between pre and post-pubertal individuals, 
while the other half found a decrease in adiponectin with puberty (5-7, 13, 23, 35, 38, 49, 
50).  
Another aspect that should be considered, particularly in PP children, is that IR is not the 
only factor related to adiponectin. Murphy and colleagues, in a 3 years longitudinal study, 
found that adiponectin decreased with age and adiposity in PP children, despite the better 
metabolic control, as suggested by the increased insulin sensitivity and HDLc throughout 
the study (33). Metcalf also described that, despite the decrease in adiponectin in the 
group with increased physical activity (PA), IR did not differ in PP lean children with 
different levels of PA (51).  Thus, in PP individuals adiponectin relation with IR and 
adiposity is not as clear as in older individuals. 
The controversial results are probably influenced by the different study designs, 
populations, the use of statistical adjustment or even to other factors that influence 
adiponectin, e.g. adiposity and IR. 
 
3. Adiposity and Metabolic Syndrome in obese children and adolescents 
Animal and human studies showed that adiponectin levels decrease as the body weight 
rises. This is, somehow, a reversible mechanism, as levels of adiponectin increase after 
weight loss (52). 
Some contradiction exists in literature regarding adiponectin levels in young obese 
patients. Total adiponectin levels are generally accepted to be lower in OB chidren and 
adolescents when compared with control (CT) and overweight (OW) subjects (22, 35). 
However, Medina-Bravo found no differences in adiponectin concentration between OB 
and lean pubertal children, while pre-pubertal (PP) OB children presented decreased 
levels, when compared to their lean counterparts (17) (Table 1). Roth, on the other hand, 
found that adiponectin was increased in OB children, although HMW adiponectin was 
decreased (3) (Table 2). 
The MS is a cluster of factors that are associated with increased risk of CVD, such as 
dyslipidemia, hypertension, central obesity and IR (15, 19). These risk factors are already 
altered in early ages in OB individuals, and changes in adiponectin levels may underlie 
such risk. Adiponectin appears to be associated with several features of MS. Shaibi found 
adiponectin to be  negatively related to waist-circumference (WC), triglycerides 
concentration (TG), 2h-glucose tolerance and to systolic blood pressure (SBP), and 
positively related to high density lipoprotein cholesterol (HDLc) concentration in OW Latin 
children (53).  Similarly, a studies in Japanese adolescents showed that adiponectin levels 
decreased with increasing number of CV risk factors (15).  
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Adiponectin has been proposed as a marker of MS. Calcaterra found adiponectin to be 
lower in OB, when compared to CT, and even lower in OB adolescents presenting MS 
(13). In fact, in a pediatric study comparing OB children and adolescents with and without 
MS, only adiponectin differed between those groups, while leptin and TNF-α presented no 
difference (54).  
Mexican children in the lower tertiles of adiponectin levels presented an increased 
prevalence of MS and worsening of MS markers. This association was not exclusive of 
obese individuals, and was present both in OB and eutrophic individuals (36). Adiponectin 
was also found as an independent predictor of MS in an Italian pediatric cohort (49).  
An association between adiponectin levels and the probability of developing MS in the 
future has been raised. Lower levels of adiponectin, together with increased levels of 
adipocyte fatty acid binding protein (A-FABP), predicted the development of MS in Korean 
boys, in a 3 year prospective study (11). Similarly, lower levels of adiponectin in 16 years 
old females were related with the development of MS at the age of 23 years (55). Another 
study also showed adiponectin as a predictor of MS, in OW children with family history of 
type 2 diabetes (T2DM), even when adjusted for age, gender, Tanner stage, body mass 
index (BMI), visceral fat and insulin resistance (IR) (53). Nevertheless, a meta-analysis 
found no association between total adiponectin and coronary heart disease and stroke in 
adult individuals without clinically manifest vascular disease (56). 
T2DM is commonly present in individuals with MS. In T2DM OB adolescents, adiponectin 
levels were found to be lower than in normal individuals, and even lower than in OB 
individuals without T2DM. In patients with T2DM, IR, a central feature of MS, appeared to 
be a main determinant of adiponectin concentrations, more than BMI itself (19).  
Regarding adiponectin multimers, Araki stated that HMW adiponectin is a better metabolic 
marker than total adiponectin, and that HMW is negatively associated with MS (37). 
Besides the amount of weight excess, in obesity it is important to consider also body fat 
distribution. Increased abdominal obesity was associated with lower levels of adiponectin 
(15, 22, 57). A study in healthy adult women showed that abdominal visceral adipose 
tissue (VAT), rather than abdominal subcutaneous adipose tissue (SAT), is inversely 
correlated with adiponectin levels (58). Also, a relation between high adiponectin and low 
waist-to-hip ratio, an indirect measure of central fat distribution, was described (59). 
However, adiponectin messenger ribonucleic acid (mRNA) was found to be more 
expressed in SAT than in VAT in adult humans (60).  
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Table 2. Reported studies assessing high (HMW), medium (MMW) and low (LMW) molecular weight adiponectin levels in obese 
children and adolescents. Association with some features of the metabolic syndrome 
Population 
Obese 
(vs. control) 
MS Adiposity IR Dyslip BP 
38 f (mean 16y) with AN.  13 lean cts. 
Israel. (8) 
+ (HMW%)      
44 ob (9.97y (5.2–13.9), 16f). Ct: 28 
(10.4y; 15.9–14.9; 13f). Japan. (61) 
  (-) (HMW)    
14 ob with PWS (11.35y (7.13–14.61); 
9f). 14 cts. USA. (62) 
  (-) (HMW) (-) (HMW)   
59 ob (10.3±0.3y; 21f). 28 lean ct. (37) 
(-) (HMW, HMW%) (-) (HMW, HMW%) (-)* (HMW,HMW%) (-) (HMW, HMW%) 
(-) (HMW vs TG) 
NS (HMW vs 
HDLc) 
NS (HMW%) 
 
(-) (MMW) 
(+) (MMW%) 
NS (MMW,)     
(+) (LMW, LMW%) NS (LMW)     
70 ob (12.9±3.3y; 40f). 55 lean cts. 
Austria. (1) 
(-) (HMW, HMW %)  (-) (HMW) (-) (HMW) (-) (HMW)  
(+) (LMW%)     
(+) (LMW vs 
DBP) 
71 ob (12.9±3.3y; 44f). 75 lean cts. 
Austria. (4) 
(-) (HMW, HMW%)      
(+) (LMW%)  (+)* (LMW%)  
(+) (LMW% vs 
HDLtg) 
(+) (LMW% vs 
SBP) 
70 pp ob (8.92±1.80y; 22f).  61 lean cts. 
18 months follow up. Spain. (25) 
(-)º (HMW)  (-)º (HMW) (-)º (HMW)   
30 pp ob (7.8±1.3y). 35 lean cts. 
Lifestyle intervention program (3-
months). Poland. (26) 
 
(-)º (HMW, HMW%)  NSº (HMW)    
NSº (MMW)  NSº (MMW)    
(+)º (LMW%) 
NSº (LMW) 
 NSº (LMW)    
305 pp subjects (5-13 y; 161f; Tanner 
stage 1). 105 lean (46f); 60 ow (28f) and 
140 ob (70f). Italy. (2) 
NSº (HMW boys) 
(-)º (HMW girls) 
 (-)º* (HMW) (-)º (HMW) (-)º (HMW vs TG)  
(-), negative association; (+), positive association; *, correlation with total and central adiposity; º, pre-pubertal individuals. AN, nervous anorexia; ct, controls; f, female; BP, 
Blood Pressure; Dyslip, Dyslipidemia; IR, Insulin Resistance; MS, metabolic syndrome; NS, not significant; ob, obese; ow, overweight; y, year 
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The association between VAT accumulation and lower adiponectin levels was also found 
in children (63). Actually, adiponectin was negatively associated to visceral-to-
subcutaneous fat ratio (while TNFα was positively associated), and significantly predicted 
that ratio (42). The association between hypoadiponectinemia and increased VAT seems 
to appear early in life, as Medina-Bravo found it to be particularly strong in PP children 
(17). Central fat distribution is also associated with a worse metabolic control. In fact, 
accompanying the increased abdominal obesity and reduced adiponectin, adolescents 
also presented increased TG levels and decreased levels of HDLc (15). 
Inappropriate/pathological eating habits do not seem to interfere in the relation between 
adiponectin and adiposity.  In a group of Ballet dancers presenting decreased fat mass, 
due to an energy intake inappropriate to the  exercise intensity, adiponectin was found to 
be increased (50). Furthermore, in extremely malnourished anorexic female adolescents 
total adiponectin and HMW adiponectin were increased (8). Likewise, adiponectin did not 
differ between OB adolescents who had binge eating or nervous bulimia, and those who 
had not such disturbances (64).  
The importance of ethnicity should also be considered, as some studies suggest that 
adiponectin levels might differ between ethnicities. Actually, in a study involving Indian 
teenagers, adiponectin did not correlate with any marker of MS (14). Furthermore, 
adiponectin levels were not related to family history of diabetes or levels of physical 
activity. These findings are somehow in agreement with results in Indian adult populations 
(14), but greatly different from the results found in Hispanic children, to whom adiponectin 
was a predictor of MS (53). 
The negative relation of adiponectin with MS appears to be accepted, especially in 
pubertal subjects. In figure 2 is shown that the proportion of reports corroborating these 
associations is higher than those who do not. However, these relations are not so clear in 
PP individual (table1). Nevertheless, it is important to highlight that the diagnosis of MS in 
young children (under 10 years) is not recommended by the International Diabetes 
Federation. Reasons include the lack of age and gender adjusted cut-offs for MS 
components and the ambiguous causality evidence in such young ages relating MS and 
increased risk of CVD later in life (65).  
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Figure 2. Number of reported studies in mixed (pre and post-pubertal) pediatric 
populations assessing the association between total adiponectin levels with 
metabolic syndrome and with its common features  
Included articles: (1-3, 5-7, 10-18, 22-27, 29, 35-37, 39, 42, 49, 53-55, 61, 63, 64, 66-70).BP, Blood 
Pressure; Dislip, Dilipidemia; IR, Insulin Resistance; MS, metabolic syndrome; Neg, negative 
association; NS, not significant. 
 
 
4. Adipokines and other inflammatory mediators 
Different mediators are known to influence adiponectin levels such as other adipokines, 
hormones (e.g. insulin, insulin-like growth factor 1 (IGF-1), growth hormone (GH)), or 
other type of molecules, produced within the adipose tissue or in other different organs 
and tissues. 
Obesity in pediatric ages, as in adults, has been considered a low grade inflammation 
state, which is usually accompanied by a rise in pro-inflammatory mediators, and a 
decrease in anti-inflammatory molecules, especially adiponectin. In accordance, many 
studies have shown that adiponectin is, in pediatrics, negatively associated with pro-
inflammatory mediators, such as interleukin (IL) IL-1β, IL-6, and IL-8 and TNF–α (3). In a 
large cross-sectional study, Zhang found that adiponectin was reduced in OB children and 
adolescents, together with increased levels of pro-inflammatory leptin, resistin and 
complement C3; a particular worse risk profile for the “mixed” type of obesity was 
observed, when compared to obesity with central and peripheral adipose tissue 
distribution types (23). 
Inflammatory status appear to vary within obesity grades, as severely OB children and 
adolescents, when compared with individuals presenting a moderate type of obesity, have 
increased MS features and inflammatory markers, including reduced adiponectin and 
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increased C-reactive protein (CRP), leptin, IL-6 and resistin (68). However, other studies 
did not find differences in adiponectin levels when comparing different degrees of obesity, 
although a positive correlation between BMI and CRP was present (29). 
TNF-α is a particularly important mediator, especially regarding IR. Adiponectin reduces 
TNF-α secretion by macrophages, marking its anti-inflammatory action (52). On the other 
hand, TNF-α, and well as IL-6 and CRP, reduce adiponectin mRNA expression, which 
may explain, at least in part, the relations of these cytokines to IR (52, 71).  Actually, TNF-
α is known to inhibit insulin signaling (72), while adiponectin is an insulin sensitivity agent.  
Roth found that TNF-α was negatively correlated to adiponectin levels in children (3). In 
agreement, in an OB and OW adolescent population with IR, one-month supplementation 
with n3 fatty acids led to the increase in adiponectin, accompanied by a reduction of TNF-
α and leptin, and an improvement in IR (73).  
The relation between adiponectin and TNF-α in PP children are less clear. A study in PP 
children did not find any correlation between adiponectin and TNF-α, in both OB and CT 
(18). Also, in a Romanian OB population, adiponectin did not correlate with TNF-α (7). 
Moreover, in OB and OW adolescents, presenting a decrease in TNF-α, IL-10 and IL-8 
after weight and fat loss, following a physical exercise program, no changes in adiponectin 
were present (74). 
Leptin, a product of the Ob gene, is one of the adipokines more closely associated to 
adiposity. Leptin is known to correlate inversely with adiponectin and positively with BMI. 
Actually, children whose BMI increased the most in a 3 years longitudinal study, also 
presented lower values of adiponectin and increased levels of leptin (20). Likewise, 
adiponectin levels were negatively associated with leptin in female adolescents (8). In OB 
Romanian children a worse adipokine profile was observed, when compared to lean CT, 
with increased IL-6, leptin and resistin and decreased adiponectin concentration. In this 
study, adiponectin was only correlated, negatively, with leptin. Nevertheless, this relation 
with leptin disappeared when corrected for WC and BMI z-score. Actually, WC has been 
proposed as the good predictor of adiponectin levels, highlighting the influence of 
adiposity distribution in adipokines (7).  
In contrast, Papoutsakis did not find any correlation between adiponectin and leptin, 
despite the association of both with IR and adiposity (leptin with an increase, and 
adiponectin with a decrease, of those variables) (27). Similar results were found in either 
post-puberty (69) and PP (5) OW and OB children. Other studies also did not find any 
association between total adiponectin and leptin. Nonetheless, HMW adiponectin 
correlated negatively with leptin, while LMW and LMW % adiponectin correlated positively 
with leptin (1, 4). 
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CRP is a classic marker of inflammation and a risk marker for CVD in adults. It is usually 
increased and associated to the low grade inflammatory state present in childhood obesity 
(66). The correlation between adiponectin and CRP is not clear in pediatric OB 
individuals, although there are strong evidence that both are related to obesity and IR (29, 
66).  
A study in OW and OB PP Portuguese children found a negative correlation between 
adiponectin and CRP (5). In Chilean children, however, adiponectin was only negatively 
correlated to CRP in post-pubertal children, with no association in PP individuals (6). 
Moreover, in another Portuguese study, involving PP and pubertal individuals, no 
correlation was observed (29, 66). In agreement, a study in obese children and 
adolescents showed that, lower adiponectin levels was correlated with increased IR, 
dyslipidemia, adiposity, PAI-I, fibrinogen and uric acid, however, no correlation was found 
between adiponectin and CRP or IL-18 (49). Mangge also did not find any association 
between either CRP and total adiponectin, or between CRP and HMW and LMW 
adiponectin (1, 4). 
IL-6, a pro-inflammatory mediator, is usually increased in obesity. In lean individuals IL-6 
controls energy intake but, in obese individuals, a state of resistance to IL-6 actions 
appears to develop. IL-6 stimulates CRP secretion in the liver. The IL-6 synthetized by the 
abdominal VAT has a particular importance in this mechanism, working through the portal 
system (3). In a similar way to what is described for adults, adiponectin was found 
negatively associated with IL-6 in children (3). However, there are still contradictory 
results (7). 
Resistin influence in IR has been studied in animal models, showing a positive association 
between them. In human studies, especially in children, the results are not conclusive. No 
association between adiponectin and resistin in children (1, 7), or in PP obese patients, 
were found (2). Also, no link between resistin and HMW and LMW adiponectin was 
reported (1).  
Part of the anti-inflammatory effect of adiponectin is linked to IL-10, an anti-inflammatory 
and anti-atherogenic interleukin, as adiponectin induces the synthesis of IL-10 by 
macrophages. Considering that in obesity there is a reduction in adiponectin and an 
increase in the infiltration of macrophages in the adipose tissue, it would be expected that 
the hypoadiponectinemia would diminish circulating IL-10. However, it has been reported 
an increase in serum IL-10 in obese adults, probably as a mechanism to reduce the 
increased inflammation in those individuals. Another explanation is that a state of 
resistance to IL-10 actions may develop in OB individuals, as occurs for resistance to IL-6, 
leptin and insulin) (13, 75). Contrarily to adults (75), no correlation was observed between 
adiponectin and IL-10, in OB children with or without MS (13).  
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5. Other factors affecting adiponectin 
Exogenous factors, as diet and drugs, can also interfere with adiponectin concentrations. 
It has been negatively correlated with dietary fat intake in OB adolescent; an increase in 
adiponectin has been found following an intervention program to reduce that 
macronutrient intake (12). An increased fat intake seems to deregulate the microbiological 
intestinal system, increasing the passage of endotoxin from intestinal lumen into the blood 
stream. This increase in circulating endotoxin would lead to activation of the inflammatory 
mechanisms. In agreement with this, adiponectin levels are inversely related with 
circulating endotoxin levels in OB adolescents. (12). 
Growth hormone (GH), is relevant due to its global influence on metabolism, particularly 
during childhood and adolescence. Growth hormone diminishes adiponectin secretion by 
adipocytes and increases visceral fat deposition, a fat depot associated to 
hypoadiponectinemia. In agreement, in diseases presenting lower values, or a reduced 
activity, of GH, like Prader Willi (PWS) and Laron syndromes, respectively, adiponectin is, 
in fact, increased. Besides, the increased adiponectin, and probably because of it (at least 
in part), these patients also present a reduction in IR, conferring these changes a 
“protection” for CVD complications, when compared to BMI matched individuals (62, 76). 
Insulin-like Growth Factor 1 (IGF-1) has been reported to decrease adiponectin 
expression in the adipose tissue (77). As adiponectin presents an insulin sensitizer action, 
this effect of IGF-1 could represent a negative feedback inhibition.  However, there are still 
conflicting data in children (76).  
 
6. Adiponectin isoforms in pediatric obese patients 
Adiponectin is important as a mediator of other inflammatory factors and as an anti-
atherogenic, anti-dyslipidemic and insulin sensitizer factor. Adiponectin has a particular 
difference to most of the other mediators: each one of its 3 circulating isoforms appears to 
be linked with different, sometimes opposite, actions in the organism (1, 4). Thus, studies 
should focus also on its multimers, instead of looking only to total adiponectin 
concentration.  
Total and HMW adiponectin concentration were reported to be lower in OB children and 
adolescents, when compared to lean CT (1, 26). Besides, the reduced multimer absolute 
concentration, the relative percentages of the isoforms were also altered: HMW% 
adiponectin was decreased, while LMW% adiponectin was increased.  Furthermore 
LMW% adiponectin, a multimer that has not been much studied, was positively correlated 
with adiposity, particularly with SAT. Moreover, LMW % adiponectin was also positively 
correlated with HOMA, leptin, oxLDL, and liver transaminases. Nevertheless, no 
correlation was found with CRP (4). These deleterious associations of LMW adiponectin 
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are opposite to those reported for HMW adiponectin. Actually, HMW adiponectin multimer 
is usually linked to an improvement in IR and lipid profile in children (1), and it has been 
negatively associated with MS (37). The negative association of HMW adiponectin with IR 
and adiposity appear to be present even in PP individuals (25). In another study, in PP 
children, HMW adiponectin was negatively associated with BMI z-score, IR, TG, leptin, 
and sICAM, however, after adjustment for age and sex, only BMI z-score and TG kept 
their association with HMW adiponectin (2). In this same study, there was no correlation 
between HMW adiponectin and pro-inflammatory mediators, such as resistin, IL-8 and IL-
18 (2). This lack of correlation with inflammatory mediators suggests that the influence of 
adiponectin multimers on metabolism are more linked with IR and with lipid profile. 
As already referred, in children with PWS HMW adiponectin present a higher 
concentration, as compared with age and BMI matched controls, and present a negative 
association with IR. In fact, the high circulating HMW adiponectin in PWS probably 
underlies the protection against dyslipidemia and IR, despite the severe obesity observed 
in those patients (62).  
The figure 3 resumes the reviewed association between total, HMW and LMW adiponectin 
with inflammatory mediators, hormones, and other factors. 
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Figure 3. Studies reporting associations between inflammatory markers and total, 
high molecular weight (HMW), and low molecular weight (LMW) adiponectin 
Underlined are the inflammatory factors that appear in both columns (ambiguous results). º, pre-pubertal; *, 
post-pubertal; Ac, acid; A-FABP, adipocyte fat acid binding protein; CRP, C-reactive protein; IL, interleukin; 
INF, interferon; MCP, monocyte chimeo attractant protein; NEFA, non-esterified fatty acid. 
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7. Lipid profile 
The effect of adiponectin on lipid metabolism has been studied by many research groups. 
Adiponectin is known to lower the synthesis of free fatty acids and to stimulate β-oxidation 
(78). Furthermore, HMW adiponectin seems to lower apo B and apo E release from the 
liver, decreasing, in this way, the release of TG rich lipoproteins [(e.g. very low density 
lipoprotein (VLDL)] and increasing high density lipoprotein cholesterol (HDLc) levels (79).  
The positive link between adiponectin and an improved lipid profile has been confirmed by 
many studies (Figure 2). The most consensual effects for adiponectin are a positive 
association with HDLc and a negative correlation with TG (6, 15, 27, 66). These 
associations are present even in PP ages (18, 24). A recent study from our group, 
involving obese children and adolescents, also showed that adiponectin may modulate the 
effect of less favourable apo E genotype on blood lipids, namely on total cholesterol/HDLc 
and apo B/apo A1 ratios. Higher levels of adiponectin were associated with an 
improvement in those atherogenic ratios (29). Furthermore, adiponectin in obese 16 years 
old girls were positively correlated with HDLc both at baseline and after 7 years of a 
follow-up study, raising the possibility of a long term modulation of the metabolism. On the 
other hand, in the same work, no correlation was found between adiponectin and TG or 
LDL (55). Snehalatha also found a positive association between adiponectin and HDLc, in 
boys (14). Conversely, other studies did not found any association between adiponectin 
and the lipid profile, neither in OW and OB Portuguese children (5), nor in PP Chinese 
children (11).   
Regarding adiponectin multimers, HMW has been linked with improvements in the lipid 
profile (1), even in PP individuals (2). LMW, oppositely, seems to have a deleterious 
impact, presenting a positive association with TG (4). 
In the longitudinal studies reviewed, no association between changes in lipid profile and 
variations in adiponectin levels were reported. 
 
8. Blood Vessels and Blood Pressure 
The positive effects of adiponectin in the vasculature appear to be independent from its 
relation to IR (30). Adiponectin improves vessels status and reduces atherogenesis by 
inducing nitrous oxide production by endothelial cell, which induces vasodilatation and 
reduces platelet aggregation. It also reduces vascular smooth muscle cells proliferation 
(80, 81) and prevents macrophage activation and, therefore, the development of foam 
cells (82). Through these effects it prevents the development of atherosclerosis while still 
in early stages. An inverse correlation between the levels of adiponectin and the internal 
media thickness (IMT) of carotid arteries (cIMT) (83, 84), and a positive association 
between adiponectin and brachial artery distensibility (30), has been observed in pediatric 
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cohorts. On the other hand, Arnaiz did not find any correlation between adiponectin with 
cIMT or flux mediated vessel distensibility in Chilean children (including OB, OW and CT) 
(6).  
The development of oxidative stress is a predictive risk factor for CVD events (e.g. 
coronary artery disease, myocardial infarction) (85). Adiponectin presents anti-oxidant 
activity reducing the production of reactive oxygen species (ROS) that are deleterious to 
endothelial cells (86). Increased markers of oxidative stress in OB children have been 
described. These markers are usually increased in the presence of features of MS and 
lower values of adiponectin (87). OB children also present lower anti-oxidant  
defenses(88), leading to increasing HDL and LDL oxidation (89). Increased oxLDL is 
linked to the formation of foam cells, a key step in atherosclerosis initiation.  The PON1, 
an anti-oxidant enzyme, usually presents a reduced enzymatic activity alongside with 
lower adiponectin values in OB. In fact, adiponectin concentration directly and positively 
correlates with PON1 arylesterase activity in OB children, and was found to be its main 
determinant (89).  
Decreased levels of adiponectin are also related to other oxidative stress markers as 
adipocyte fatty acid binding protein (A-FABP) and lipocalin-2 (90). A negative association 
between adiponectin and A-FABP was also found in children (11). Moreover, higher 
concentrations of A-FABP and lower levels of adiponectin were described as predictors of 
MS development in a 3 year longitudinal study (11). 
Opposite effects of HMW and LMW adiponectin multimers in oxidative stress have been 
reported. In Japanese OB children, HMW adiponectin was the only adiponectin multimer 
that was negatively associated with isoprostane, an oxidative stress marker, which is 
increased in OB individuals (61). LMW% adiponectin, on contrary, was positively 
associated with increased oxidative stress (as measured by oxLDL), cIMT, SBP and 
oxLDL (1). 
Conflicting results exist in literature regarding the association of adiponectin levels with 
blood pressure (BP) (Figure 2). Some studies point to a negative association between 
adiponectin and both SBP and diastolic blood pressure (DBP) (6, 7, 36), or with SBP 
alone (22, 49, 53), having these relations been observed even in PP children (11). 
Conversely, other works describe no associations between adiponectin and BP (5, 14, 
27). 
Regarding adiponectin multimers, LMW was associated with increased SBP and DBP in 
Austrian children (1, 4) (Table 1). 
On the subject of longitudinal studies, no associations were found between fluctuations of 
adiponectin and changes in BP. Although Choi found in PP children, a positive relation 
between baseline adiponectin and BP changes during a three years follow-up, the 
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differences were lost when adjusted to Tanner stage (11) (Table 1). Morrison also did not 
find any association between adiponectin concentration at 16 years and the values of BP 
7 years later (55). 
 
9. Insulin Resistance 
IR is known as the unifying factor of MS, underlying and linking all the other features 
(dyslipidemia, obesity and hypertension). IR is also closely associated with inflammation.  
Apart from PP individuals (Table 1), the relation between adiponectin, obesity and IR 
appears to be clear (Figure 2). Total adiponectin is negatively correlated with IR, and 
increases following a lifestyle intervention, leading to a decrease in IR (70).  
Some studied showed that total adiponectin, and HMW in particular, have a closer relation 
with IR markers (as HOMA) than with BMI or body fat, which was particularly noticeable in 
OB children (1), especially in PP subjects (3). On contrary, a positive association between 
LMW % adiponectin and HOMA was reported (1) (Table 2). In fact, a study by Martos-
Moreno did not find any correlation between total and HMW adiponectin with adiposity 
markers in OB PP children, although a negative association was already present between 
total adiponectin and HOMA (25). 
Nevertheless, the association of adiponectin with IR might not be present from birth. 
Indeed insulin levels increase until one year of age, while a reduction in adiponectin 
occurs being present no association with HOMA (91). Actually, the inverse association 
between total and HMW adiponectin with IR seems to appear only after 2 to 6 years of 
age (18, 92). In accordance, a study in Portuguese children showed that adiponectin 
levels did not differ between PP OW and CT, despite the increased dyslipidemia and IR in 
OW subjects  (5).  Another study from our group found similar results in OB and CT PP 
individuals (H Nascimento et al - unpublished data). An Italian PP cohort study, also did 
not find any association between HMW adiponectin and IR, after adjustment for age and 
BMI, despite the increased IR present in the OB individuals, and that lean girls presented 
increased levels of HMW adiponectin when compared to OW and OB girls (2).  
HMW adiponectin has been proposed to be more closely related to IR than total 
adiponectin. Children and adults with PWS (genetic syndrome characterized by severe 
obesity and cognitive deficiency) are known to present decreased insulin and HOMA, 
when compared to age and BMI matched OB CT. These findings might be due to the 
increase in total and HMW % adiponectin observed in these individuals (62). A study of 
girls with Laron syndrome (a syndrome characterized by dwarfisms and severe obesity) 
showed similar observations. A common feature to both of these syndromes is the lower 
concentration of GH (in PDW), or its absence, or loss of action (in Laron syndrome). The 
diminished level or activity of GH in these two syndromes might explain their paradoxical 
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hyperadiponectinemia, increased insulin sensitivity and lower percentage of visceral fat, 
when compared to OB matched CT (76).  
Adiponectin and leptin are closely related, and oppositely associated to adiposity and IR. 
In obese individuals an increased inflammatory cluster profile was present associating 
increased leptin and leukocyte activation with IR, on the other hand, lean individuals 
presented a profile characterized by increased adiponectin, lower leukocyte activation and 
increased insulin sensitivity (93).  Adiponectin-to-leptin ratio has appeared as a relevant 
marker of IR presenting a strong negative association with HOMA and insulin. In fact, it 
might be a better marker than HOMA to predict IR, as was shown in OB adolescent 
cohorts (9, 94). In opposition, a cross-sectional study in Chinese children found that leptin 
was the best predictor of IR (grouped both by Tanner stage and weight), while adiponectin 
only predicted IR in OB and OW boys and OW girls, and had no influence when regarding 
lean individuals (35).  
Adiponectin levels in childhood and adolescence can also be used as a marker of risk for 
developing MS or CVD later in life. High adiponectin levels in girls at the age of 16 were a 
negative predictor of HOMA and insulin levels at 23 years. This relation was particularly 
notable regarding OB girls that had paradoxically high adiponectin (higher than the 
median for lean CT of the same age) (55).  
There is some debate regarding if decreased adiponectin is a cause or a consequence of 
IR. Indeed, lower values of adiponectin might be the cause, not the consequence, of IR, at 
least in some ethnic groups, as in South Asians (sub continental India), who showed 
reduced adiponectin levels in infants, despite the normal levels of insulin or lipid profile 
(24). Lower adiponectin values are also present in both adult (52) and adolescent black 
individuals (55), despite the better lipid profile. Associated with the lower adiponectin 
levels, black adolescents also presented an increased IR (55). It must be highlighted, 
once again, that the link between adiponectin and other metabolic parameters should 
always be considered regarding the population background. 
 
10. Interventional studies and adiponectin levels  
Longitudinal studies are crucial as they allow us to obtain causal associations, in this case 
between adiponectin and other factors. Table 3 presents a revision of interventional 
studies involving physical exercise and/or nutritional counseling programs.   
Improvements in adiponectin levels may be obtained by energy restriction and exercise, 
and, the combination of both approaches appears to have a greater impact, as was 
observed in OB adolescent boys (9). The magnitude of the weight loss does not seems to 
be a confounding factor as, in this study, the group practicing only exercise had no 
significant weight loss, but the adiponectin levels increased even so. Thus, changes in 
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body composition might be the real factor behind adiponectin improvement, being weight 
loss and exercise two complementary ways to achieve these changes (9). This is in 
agreement with a lifestyle interventional study in children, in which adiponectin variation 
was negatively associated with changes in total percentage of fat and this change was 
present even in the absence of an effective weight loss (70). Lazzer and colleagues, 
likewise, found that a weight reduction program for OB adolescents, involving physical 
exercise and diet restriction, lead to an increase in adiponectin together with an increase 
in lipid oxidation rates. The adiponectin levels were kept in the individuals that maintained 
weight after the program, and reduced in the others (41).  
Interestingly, in a study involving OB females, with and without eating disorders (binge 
eating and nervous bulimia), adiponectin did not differ between those two groups, before 
and after the exercise and diet intervention program. The presence of eating disorders 
does not seem to be a bias regarding the response of metabolism to interventional 
programs, as both groups presented an increase in adiponectin following the program but, 
in spite of that, only the group without eating disorders presented a negative correlation 
between adiponectin variation and the changes in total percentage of fat and HOMA 
(regardless of no correlation between adiponectin and HOMA, at baseline) (64). This 
increase in adiponectin, regardless of changes in body fat, highlights that other factors, as 
inflammatory mediators and exercise per se, must influence adiponectin changes. 
Some studies in pediatric ages support the fact that a considerable amount of adiposity 
must be lost before any improvement in adiponectin concentrations occurs (22). In fact, 
several studies showed that just a reduction of BMI z-score higher than 0.5 lead to 
changes in IR and adiponectin in children (3, 95, 96). In an interventional study, involving 
increased exercise and nutritional counseling (Obeldicks program), only children who 
reduced their BMI z-score in more than 0.5 presented increased total adiponectin and 
reduced HOMA (3). Strengthening the importance of weight loss magnitude, Lira found 
that OB adolescents following exercise and dietary intervention, who reduced more than 5 
% of their fat mass increased adiponectin. Besides the fat mass reduction, the increase in 
adiponectin might be influenced by the fact that all subjects in Lira’s study were already in 
the final stage of pubertal development and, therefore, no longer under the age and 
puberty associated reduction in adiponectin (12). 
A study by our group reported that reductions in BMI z-score, as small as 0.3, even 
without an interventional program, are already associated with an improvement in HOMA 
and with the maintenance of adiponectin levels, while a reduction of adiponectin was 
found in individuals who did not achieve that reduction value  (66).  
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Table 3. Interventional studies evaluating the effect on adiponectin levels, and the 
relation between changes in adiponectin levels and the variation of adiposity and IR 
Population Adiposity IR Effect 
ENCP. 26 severely ob (12–16y; 14f).  9m program. France. 
(41) 
(-)  (+) Program 
ENCP. 37 ob (10y (8-12); 24f). 16 lean ct. 1y program. 
Germany. (97) 
  
(+) Program 
(D-BMIzsc>0.5) 
ENCP. 21 ob boys (13.1±0.7y). 2m program (exercise and 
energy restriction, separately or combined). Tunisia. (9) 
(-) (-) 
(+) Program 
(more in energy 
restriction and 
exercise 
combined) 
ENCP. 50 ow and ob (12.0±0.9 y; 25f). 7d program.  Korea. 
(28) 
  (+) Program 
ENCP. 115 ob (10.7±0.29; 57f). 30 lean cts. 62 ob (11±0.5y; 
34f) participated in 1y program. Germany. (3) 
(-) (-) 
(+) Program 
(D-BMIzsc>0.5) 
ENCP. 30 ob (16.71±1.47y; 10f). 1y program of aerobic only 
(AT) or aerobic and endurance training combined (AET). 
Brazil. (98) 
  
(+) Program 
(AET) 
NS (AT) 
ENCP. 25 ow and ob (13–16 y; 12f; 18 ob). 13m program. 
Spain. (74) 
NS  NS Program 
ENCP. 80 ob (10.9±0.3; 42f). 40 lean ct. 1y program. 
Germany. (34) 
(-)  (+) Program 
ENCP. 18 ob (16.6±1.67y; 11f). 1y program. Brazil. (12, 42) (-)  (+) Program 
ENCP. 28 ob (15-19y, 21f) with (binge eating or bulimia 
nervous). 55 ob ct. 1y intervention. Brazil. (64) 
(-) (-) (+) Program 
ENCP. 402 ow and ob (13.9±2.3; 238f). 4-6w program. 
Germany. (69) 
(+) (BMIbs)  (+) Program 
MENCP. 104 ow or ob (10.7±3.2y; 53f). 55 lean ct. 1y lifestyle 
intervention (48 participated). (70) 
(-) (D-%fat mass) 
NS (D-weight) 
 (+) Program 
MENCP. 25 ob (10–16y; HOMA >3.0). 6m lifestyle 
intervention. Two groups (receiving, or not, a daily dose of 
1500mg of metformin). Canada. (46) 
(-)  (+) Program 
MENCP. 60 ob (11.0±2.4, 29f). 1y lifestyle intervention. 
Portugal. (66) 
(-)  (+) Program 
MENCP. 70 pp ob (8.92±1.80y; 22f).  61 lean cts. 18 ms follow 
up. Spain. (25) 
(-) (T, HMW)  (+) Program 
MENCP. 30 pp ob (7.8±1.3y). 35 lean ct. 3m lifestyle 
intervention. Poland. (26) 
 
  
(+) Program 
(T, HMW, 
HMW% and 
MMW) 
(-) Program 
(LMW%) 
NT. 38f (mean 16y) with AN.  13 lean cts. Israel. (8)   
(-) Program (T, 
HMW%) 
MENCP. 40 obese individuals (13.3±2.0y; 22f), 39 OB CT 
and 34 lean CT without lifestyle intervention.  3 m, 1 and 2 y 
follow-up. Netherlands. (22) 
  NS Program 
NCP. 61 pp ow and ob (7–9y 34f). 22 lean ct. 1y individual or 
group-based treatment. Portugal. (5) 
 NSº NS Program 
PI. 151 insulin resistant ob (13.±2.3y; 102f). Double blind 
placebo controlled study (metformin). No lifestyle 
intervention. UK. (47) 
  (+) Program 
ENCP, Exercise and Nutritional Counseling Program; MENCP, Motivation to Exercise and Nutritional Counseling 
Program; NCP, Nutritional Counseling Program; NT, Nutritional therapy; PI, Pharmacological Intervention. HMW, High 
Molecular Weight adiponectin;  LMW, Low Molecular Weight adiponectin. +, positive increase with intervention 
program; º; pre-pubertal individuals; AN, nervous anorexia; bs, baseline; ct, control; BMI, body mass index; f, female; 
HOMA, Homeostasis Model Assesment insulin resistance; IR, insulin resistance; ob, obese; overweight, ow; PP, pre-
puberty; T, total adiponectin; y,  year. 
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Regarding the influence of lifestyle interventions on multimeric distribution of adiponectin, 
a study in PP children found that total and HMW adiponectin were lower in OB children 
when compared to lean CT, with no differences for MMW and LMW adiponectin. The 
HMW % adiponectin was lower and LMW % adiponectin was higher in OB children, 
suggesting that adiponectin multimerization, that take place within the adipocyte, is 
probably turned towards the LMW form, with a decrease in the formation of MMW and 
HMW adiponectin (26). Although no correlation was found between adiponectin, or its 
multimeric forms, with BMI for the OB patients, the lifestyle intervention, induced an 
average reduction of 10 % in the BMI, increased total, HMW, MMW adiponectin, as well 
as HMW % adiponectin, while a reduction in LMW % adiponectin was observed (26). 
Controversial results are found not only in adolescents but also (and particularly) in 
children (Table 3). Adiponectin did not improve after a lifestyle intervention with nutritional 
counseling, but no exercise program, despite BMI z-score reduction and lipid profile 
improvement being achieved (however HOMA also did not improve)  (5). As well, Romeo 
and colleagues did not found adiponectin increase, even after BMI improvement and fat 
reduction, following a diet and exercise program (EVASYON) (74). It is possible that the 
improvement in total adiponectin, especially in children, requires a greater reduction of 
adiposity than in adults, as there is an age related trend towards adiponectin reduction 
(mainly in peri-pubertal period), or a shorter duration intervention with high intensity, 
leading do increase weight loss over a short period (66). Indeed, in an intensive 
intervention involving 7-day exercise and nutrition program, Lee and colleagues managed 
to significantly increase adiponectin, and decrease BMI, in a cohort of OB children (28). In 
another short term intervention (4-6weeks) adiponectin increased following BMI weight 
loss (69). 
Different types of training may have different impact in adiponectin (74, 98). A study by 
Mello on OB adolescents suggested that aerobic combined with endurance training (AET) 
increases adiponectin and improves IR, both in short (6 months) and long term (1 year), 
while aerobic training (AT) alone does not. Both AET and AT were accompanied by an 
improvement in some of the MS features (BMI, visceral fat, dyslipidemia) however, the 
global improvement was higher with AET.  It was hypothesized that the greater 
improvement in dyslipidemia observed in the AET group was caused by the increased 
adiponectin found in these individuals, but absent in the AT group (98). 
Ballet, for instance, is characterized by intense physical activity and increased lean mass. 
Adolescent female ballet dancers present increased adiponectin levels when compared to 
non-dancers lean CT, and an increase in adiponectin through puberty, which was not 
observed in the CT group. This increase in adiponectin was present despite an increase in 
BMI z-score and a trend towards a central distribution of fat mass (50). 
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In a non-intervention 3 years longitudinal study in PP lean children (5-8 years old) it was 
found that increased PA was linked to a decrease in adiponectin, despite no changes in 
IR, leptin and CRP were observed. The relation between adiponectin and IR varied 
among children with different PA patterns and a stronger negative association was found 
in the less active individuals. The authors postulated that in response to increased PA the 
adiponectin, an insulin sensitizer agent, might decrease due to the decrease in IR induced 
by exercise, by a kind of negative feedback inhibition (51).  
These changes in lean PP children might be also triggered in response to interventional 
programs in OB children, particularly in those programs involving exercise. As the OB 
children engage in a more regular PA, after an initial increase in adiponectin, as reported 
by Lee (28), the IR reduction could “signal” to reduced adiponectin synthesis. This 
increase of adiponectin in response to IR can be seen in T1DM children (38, 99). 
Regarding pharmacological intervention, metformin appear to increase adiponectin, 
particularly adiponectin-to-leptin ratio, in obese pediatric patients both after 3 and 6 
months of treatment, accompanying reduction in BMI z-score, without noticeable side 
effects. Still, long-term maintenance of metformin effect on adiponectin levels in children 
and adolescents is still unknown, particularly in children, an so its use should be 
considered carefully  (46, 47). 
In synthesis, the negative association between adiponectin, adiposity and IR appears to 
be well established.  Furthermore, the impact of the majority of the interventional studies 
on adiponectin levels is positive and pharmacologic strategies could be good adjuvants of 
the treatment. Nevertheless, there are factors that might influence that impact, such as the 
study design, population studied and the type and intensity of exercise practiced. The 
amount of lost adiposity, and the magnitude of the changes in body composition, appears 
to be a particular importance.  
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11. Conclusions and Final Remarks 
 
The relation between adiponectin and MS in children and adolescents has been studied 
for some time. 
Obesity, and particularly, abdominal obesity, a component of MS, is closely associated 
with lower adiponectin values in pediatric ages. Adiponectin acts as an insulin sensitizer, 
decreasing as the IR rises. Regarding the lipid profile, an increase in circulating 
adiponectin is particularly associated with increased HDLc and lower levels of TG, with 
limited effect on LDLc. Adiponectin also acts in the vasculature and prevents 
atherosclerosis through multiple mechanisms, as reduced foam cell formation, inhibition of 
the synthesis of inflammatory mediators by macrophages,... Adiponectin is also 
associated with smaller IMT of the arteries and increased vessel elasticity, in children. 
Likewise, increased adiponectin is linked to reduced, healthier, BP. 
Considering the different adiponectin multimers, HMW adiponectin appears to be, 
associated with a better metabolic control, mainly by improving IR, while the LMW 
multimer presents opposite effects. It is important to consider not only the absolute 
concentrations of these multimers, but also their relative percentage, as potential markers 
of CVD risk. 
Combining the specific effects of adiponectin and its association with the lipid profile, BP, 
IR and obesity, adiponectin was shown to predict the future development and help 
diagnosis MS in pediatric individuals.  
HMW adiponectin might be a better predictor of MS than total adiponectin.  An 
increase of total and HMW adiponectin seems to occur following interventional programs, 
particularly those programs involving exercise and diet interventions. Changes in body 
composition, with reduction of total and central body fat, appear to be the key to the 
therapeutic success, more than absolute changes in body weight. 
The positive effects of adiponectin on general metabolism are not so clear in PP 
individuals, particularly its relation with IR. No significant differences are usually observed 
between genders in PP individuals. The OB PP children present a trend towards lower 
adiponectin concentration than pubertal individuals. After puberty, and possibly through a 
mechanism involving sexual hormones, adiponectin lowers with age in both genders but 
more markedly in boys. 
The controversial of results obtained by different groups are, probably, related to the study 
design, subjects studied and population background. Different outcomes between different 
populations and ethnic groups might be, in fact, caused by genetic differences. Diet, as 
well, can be particularly specific from a certain population, influencing adiponectin levels.  
The study design of interventional studies is especially important, as many factors can 
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vary: the presence and type of the exercise (eg. aerobic, endurance, strength), the 
duration, the age of participants and pubertal status, diet control or counseling,…  
The complex cross-talk between adiponectin, obesity and IR makes hard to unveil which 
factors are causes, and which are consequences. The use of statistical strategies that 
allow adjustment for confounding factors is important; however longitudinal studies are the 
best option to find casual relations.  
Future studies should focus on longer longitudinal studies to clarify controversies 
regarding physiological changes and the role of adiponectin, as well as the stability of the 
obtained results. Particularly important is the inclusion in those studies of low age 
participants (controls and obese patients), as well as the measurement of adiponectin 
isoforms, considering that such information is scanty. 
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ARTICLE
Lipid Profile in Portuguese Obese Children
and Adolescents
Interaction of Apolipoprotein E Polymorphism With Adiponectin Levels
Henrique Nascimento, Licenciatura; Letı´cia Silva; Pedro Lourenc¸o; Radka Weinfurterova´, PharmD;
Elisabeth Castro, PhD; Carla Rego, MD; Helena Ferreira, MD; Anto´nio Guerra, MD, PhD;
Alexandre Quintanilha, MD; Alice Santos-Silva, PhD; Luı´s Belo, PhD
Objective: To evaluate how the lipid profile associates
with apolipoprotein (apo) E gene polymorphism, plasma
adiponectin level, and body mass index (BMI) z score in
Portuguese youth.
Design: Transversal cohort study.
Setting:HospitaldeSa˜oJoa˜oandHospitaldeCrianc¸asMaria
Pia, Porto, Portugal, between May 2006 and March 2007.
Participants: One hundred thirty-eight obese children
andadolescents(62boys;meanage,10.8years[range,4-16
years]). Participants were grouped according to (1) apo
E polymorphism: presence of the apo E alleles 2 or 4 in
E2 (n=11) and E4 (n=31) carriers, respectively, or as E3/
E3 (n=94) (carriers of E2/E4 [n=2] were excluded from
apo E analysis because they carry both alleles) and (2) BMI
z score: group 1, BMI z score less than 2 (n=31); group
2, BMI z score of 2 or more and less than 2.5 (n=65); and
group 3, BMI z score of 2.5 or more (n=42).
Main Outcome Measures: Lipid variable compari-
sons between apo E polymorphism and BMI z score
groups and influence of BMI z score and adiponectin level,
adjusted for apo E polymorphism, on total cholesterol
to high-density lipoprotein cholesterol and apo A-I to apo
B ratios.
Results: E4 carriers presented with a worse lipid pro-
file when compared with E2 and E3/E3 carriers. There
was also a clear risk of worsening for the group with the
highest BMI z score. Apolipoprotein E polymorphism,
BMI z score, and adiponectin level were significantly as-
sociated with total cholesterol to high-density lipopro-
tein cholesterol (standardized coefficient=0.283, 0.354,
and −0.292, respectively; P .001 for all) and apo A-I to
apo B (standardized  coefficient=−0.372, −0.284, and
0.327, respectively; P .001 for all) ratios.
Conclusion: Our data suggest a more atherogenic lipid
profile for some apo E genotypes and for increasing BMI
z score, whereas adiponectin level seems to play a pro-
tective role.
Arch Pediatr Adolesc Med. 2009;163(11):1030-1036
O BESITY IS INCREASING ALLover the world and is asignificant risk factor forcardiovascular disease(CVD). Cardiovascular
morbidity and mortality of obesity are as-
sociated with classic risk factors, namely
dyslipidemia, hypertension, and im-
paired glucose metabolism. These risk fac-
tors, known as the predictors of future
CVD, make part of what is known as the
metabolic syndrome.1
The dyslipidemia commonly ob-
served in obese patients may be due to al-
tered cholesterol metabolism. Obese pa-
tients present with elevated cholesterol
synthesis compared with normal-weight
individuals.2 The augmented cholesterol
synthesis is likely to be caused by higher
activity of the enzymes participating in
cholesterol synthesis and by the larger liv-
ers observed in obese individuals.3
The adipocyte is an important source
of cytokines, namely interleukin 6 and tu-
mor necrosis factor , that are signifi-
cantly higher in the plasma of obese pa-
tients.4 It is known that proinflammatory
cytokines (eg, interleukin 6 and tumor ne-
crosis factor ) may promote the devel-
opment of obesity-related features, namely
dyslipidemia, insulin resistance, and en-
dothelial dysfunction, all known risk fac-
tors for CVD. In contrast to other adipo-
cytokines, adiponectin, which is adipose
tissue specific, has been noted as an im-
portant antiatherogenic and antidiabetic
protein and as an anti-inflammatory pro-
tein.5 Also in contrast to other cytokines,
plasma concentrations of adiponectin are
decreased in obese subjects. Adiponectin
level seems to be inversely related to sys-
tolic blood pressure, waist circumfer-
ence, and triglyceride (TG) and 2-hour
glucose levels and positively related to
Author Affiliations are listed at
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high-density lipoprotein cholesterol (HDL-C) level.6 In
this way, hypoadiponectemia seems to work as an inde-
pendent biomarker of the metabolic syndrome.
Apolipoprotein (apo) E plays an important role in ath-
erosclerosis by modifying inflammatory responses, fa-
cilitating cholesterol efflux from foam cells, and regu-
lating hepatic uptake of remnant lipoproteins through
the low-density lipoprotein (LDL) receptor and LDL re-
ceptor–related protein.7 The E2/E3/E4 apo E polymor-
phism results from variations in exon 4 at codon posi-
tions 112 and 158. E2 has a T allele at both positions 112
and 158; E3 has T and C alleles at positions 112 and 158,
respectively; and E4 has C at both positions. These ge-
netic variances create apo E isoforms with the following
amino acid differences at positions 112 and 158, respec-
tively: E2: Cys and Cys; E3: Cys and Arg; and E4: Arg
and Arg. All combinations of the 2 isoforms are pos-
sible: E2/E2, E2/E3, E2/E4, E3/E3, E3/E4, and E4/E4.8,9
For the apo E polymorphism, subjects carrying the E2
and E4 alleles tend to have lower and higher cholesterol
levels, respectively, compared with E3/E3 individuals.8 Con-
tradictory results are found in the literature concerning the
effect of the apo E allele on TG levels. However, a meta-
analysis reported that TG levels were higher in E2 carriers
and E3/E4 subjects than in E3/E3 subjects.8 Similar re-
sults were found in obese adult and child populations.9-11
The frequencies of the apo E alleles did not seem to differ
between normal-weight and obese individuals.11
Although atherosclerosis is a chronic disease that be-
gins early in life, and obesity is an important risk factor for
the development of CVD, few studies have addressed CVD
markers in obese children and adolescents. Particularly, to
date, limited investigations have examined the associa-
tions between adiponectin level and the lipid profile in chil-
dren and adolescents. Also, to our knowledge, no study has
assessed the concomitant influence of adiponectin level and
apo E genetic polymorphism on the lipid profile in that
population. Because atherogenesis begins early in life, the
study of individual differences in the early onset and pro-
gression of potential initiating risk factors is important. This
is of particular concern in our country because a recent study
showed a very high prevalence of overweight/obesity
(31.5%) in Portuguese children when compared with other
European countries.12
The aim of our work was to evaluate how the lipid pro-
file is influenced by the apo E gene polymorphism, adi-
ponectin plasma levels, and body mass index (BMI) z score
in Portuguese obese children and adolescents. We hy-
pothesized that (1) apo E polymorphism and BMI z score
would be significantly and independently related to the
lipid profile and (2) the effect of the apo E polymor-
phism on the lipid profile could be influenced by plasma
levels of adiponectin.
METHODS
SUBJECTS
The protocol used for all participants was approved by the eth-
ics committees of Hospital de Sa˜o Joa˜o and Hospital de Crian-
c¸as Maria Pia, Porto, Portugal. Obese children and adoles-
cents, aged 4 to 16 years, were identified from medical records
at the departments of Pediatrics of Hospital de Sa˜o Joa˜o and
Hospital de Crianc¸as Maria Pia. All children who met the in-
clusion criteria were invited to participate. One hundred thirty-
eight obese children and adolescents (62 boys and 76 girls) par-
ticipated in the study after informed and written consent by
their parents. The study took place between May 2006 and March
2007.
Obesity was defined as a BMI greater than the 95th percen-
tile for age and sex (calculated as weight in kilograms divided
by height in meters squared), according to 2000 Center for Dis-
ease Control and Prevention growth charts. Because BMI is not
normally distributed, we calculated BMI z score using a calcu-
lator based on the 2000 Center for Disease Control and Pre-
vention growth charts. Because we also wanted to study the value
of obesity as defined by BMI z score, we divided the obese popu-
lation into 3 groups: group 1, less than the percentile 97.5, cor-
responding to a BMI z score less than 2; group 2, between the
percentiles 97.5 and 99.5, corresponding to a BMI z score of 2
or more and less than 2.5; and group 3, more than the percen-
tile 99.5 (10% of our obese population), corresponding to a BMI
z score of 2.5 or more.
Clinical data regarding the sample population were col-
lected; the development of puberty was clinically assessed in
the hospitals, on the basis of Tanner stages, by the pediatri-
cians of our team. The physical examination included the mea-
surement of height, weight, circumferences of waist and hip,
Tanner stage assessment, and the presence of skin lesions re-
lated to obesity and its comorbidity. The participants were in-
vited to come to the research centers after an overnight fast,
and after clinical examination, blood was collected for labora-
tory analysis. Smokers and subjects with diabetes mellitus, en-
docrine disorders, hereditary diseases, or inflammatory or in-
fectious diseases or who were undergoing any therapy that could
interfere with our results were excluded from the study.
PROCEDURES AND ASSAYS
Blood Samples
Blood samples were obtained on a fasting basis and processed
within 2 hours of collection. Blood was obtained by venipunc-
ture in EDTA-containing tubes and in test tubes without an-
ticoagulant. Aliquots of plasma, buffy coat, and serum were made
and immediately stored at −80°C until assayed.
DNA Analysis
Genomic DNA was extracted from white blood cells (buffy coat)
by the proteinase K/salt precipitation method.13,14 Apolipopro-
tein E genotyping was performed by polymerase chain reac-
tion (PCR)–restriction fragment length polymorphism using
the method of Hixson and Vernier,15 with some modifica-
tions. A 244–base pair (bp) fragment located in exon 4 of the
apo E gene was amplified using oligonucleotide primers that
flank positions 112 and 158 in the referred exon (F4: 5-
ACAGAATTCGCCCCGGCCTGGTACAC-3 and F6: 5-
TAAGCTTGGCACGGCTGTC-CAAGGA-3). The PCR reac-
tion was carried out in a thermal cycler (HYBAID TouchDown;
Thermo Hybaid, Franklin, Massachusetts) using 1 µL of DNA
in a volume of 20 µL containing 1 PCR buffer (HotStarTaq
polymerase buffer, with a final concentration of 2.0mM mag-
nesium chloride; Qiagen, Valencia, California), 1µM of each
primer, 10% (volume to volume ratio) dimethyl sulfoxide,
0.2mM deoxyribonucleotide triphosphate, and 0.5 U of
HotStarTaq DNA Polymerase (Qiagen). The PCR conditions
were 95°C for 15 minutes followed by 31 cycles at 95°C for 45
seconds, 60°C for 1 minute, and 72°C for 2 minutes and, fi-
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nally, at 72°C for 8 minutes. The PCR products (20 µL) were
digested with 10 U of HhaI in the recommended buffer (REact
2; Gibco BRL, Carlsbad, California) for 3 hours at 37°C. Each
reaction mixture was loaded onto an 8% polyacrylamide gel in
TRIS/borate/EDTA and electrophoresed. The gel was stained
with ethidium bromide and DNA fragments were visualized by
UV illumination. The sizes of the HhaI fragments were esti-
mated by comparison with known size markers (10-bp DNA
ladder; Invitrogen Life Technologies, Carlsbad). HhaI cuts
codons for arginine residues at positions 112 and 158. If both
restriction cutting sites were present in both alleles (E4/E4),
the length of the fragments were 72, 19, 48, and 35 bp; if the
restriction cutting site at position 158 was present in both alleles
(E3/E3), the size of the fragments were 91, 48, and 35 bp; if
both restriction cutting sites were absent in both alleles (E2/
E2), the fragment sizes were 91 and 83 bp. The gel patterns
obtained for the E2/E3, E2/E4, and E3/E4 genotypes were com-
binations of the homozygous fragments.15
Serum Analysis
Serum lipid, lipoprotein, and apo analyses were performed in
an auto-analyzer (Cobas Mira S; Roche, Nutley, NJ) using com-
mercially available kits. Serum total cholesterol (TC) and TG
concentrations were determined by enzymatic colorimetric tests
(CHOD-PAP and GPO-PAP methods, respectively; Roche).
High-density lipoprotein cholesterol and LDL cholesterol
(LDL-C) levels were measured using enzymatic colorimetric
tests after selective separation of high-density lipoprotein and
LDL fractions (Direct HDL Cholesterol and Direct LDL Cho-
lesterol; Roche). Apolipoprotein A-I and apo B levels in serum
were evaluated by immunoturbidimetric assays (uni-kit apo A-I–
and B–specific antiserums; Roche).
Plasma Analysis
Plasma concentration of adiponectin was evaluated by using a
standard commercial enzyme-linked immunoassay (Adiponec-
tin; R&D Systems, Minneapolis, Minnesota). Intra-assay and
interassay coefficients of variation were lower than 5% and 7%,
respectively.
STATISTICAL ANALYSIS
Statistical analysis was performed using SPSS software (ver-
sion 16.0 for Windows; SPSS, Chicago, Illinois). Kolmogorov-
Smirnov analysis was used to test if the results were normally
distributed. The results normally distributed are presented as
mean (SD) and those not normally distributed are presented
as median (interquartile range).
Male and female patients were compared using an
unpaired t test or Mann-Whitney U test. The distribution of
boys and girls with respect to genotypes and other categori-
cal variables was analyzed using the 2 test and Fisher exact
test.
Multiple comparisons between groups were performed by
1-way analysis of variance supplemented with the Tukey Hon-
estly Significant Difference post hoc test, after log transforma-
tion of the variables (when necessary). Adjustment of statisti-
cal differences for confounding factors was performed using
analysis of covariance. The strength of the association be-
tween the substances was estimated by Pearson correlation co-
efficient, after log transformation of the variables (when nec-
essary). To evaluate the contribution of the different variables
to adiponectin levels, we performed multiple regression analy-
sis, using stepwise selection, with an entry criteria of P .05.
To evaluate the influence of BMI z score and adiponectin level,
adjusted for apo E polymorphism (allele carriers), on both TC:
HDL-C and apo A-I:apo B ratios, we performed multiple re-
gression analysis using the 3 variables in the models. Signifi-
cance was accepted at P .05.
RESULTS
The clinical characteristics of the obese children and ado-
lescents (n=138) are presented in Table1. The mean age
and BMI z score were 10.8 years and 2.30, respectively.
Concerning the comparison between boys and girls
(data not shown), no major differences were observed
in both clinical and laboratory data, except for waist cir-
cumference (mean, boys, 95.4 cm and girls, 90.9 cm;
P .05) and waist to hip ratio (mean, boys, 0.955 and
girls, 0.930; P .005), which were higher in boys, and
adiponectin levels (mean, boys, 6.92 mg/L and girls, 8.35
mg/L; P .05), which were lower for boys. No statisti-
cally significant differences were found in the distribu-
tion of subjects with respect to apo E genotype between
boys and girls.
Apolipoprotein E polymorphism was associated with
different lipid and lipoprotein status (Table2). To evalu-
ate the association of lipid and lipoprotein values with
Table 1. Clinical Characteristics, Genotype, and
Biochemical Data in 138 Obese Children and Adolescents
No. (%)
Clinical characteristic
Age, y, mean (SD) 10.8 (3.0)
Tanner stage of puberty 2 69 (50)
Waist, cm, mean (SD) 92.9 (13.4)
Hip, cm, mean (SD) 98.8 (13.9)
Waist to hip ratio, mean (SD) 0.941 (0.051)
BMI, mean (SD) 29.69 (5.34)
BMI z score, mean (SD) 2.30 (0.45)
BMI z score 2 31 (22.5)
BMI z score 2 and 2.5 65 (47.1)
BMI z score 2.5 42 (30.4)
Genotype
E2/E2 0
E2/E3 11 (8.0)
E2/E4 2 (1.4)
E3/E3 94 (68.1)
E3/E4 28 (20.3)
E4/E4 3 (2.2)
Biochemical data, median (IQR)
TG level, mg/dL 77.0 (53.0-109.8)
TC level, mg/dL 161.0 (143.0-181.2)
HDL-C level, mg/dL 42.0 (35.8-48.0)
LDL-C level, mg/dL 104.0 (89.0-122.5)
apo A-I level, mg/dL 118.0 (108.4-128.6)
apo B level, mg/dL 79.0 (68.0-93.3)
TC:HDL-C ratio 3.89 (3.29-4.59)
apo A-I:apo B ratio 1.50 (1.24-1.75)
Adiponectin level, mg/L 7.92 (5.19-10.99)
Abbreviations: apo, apolipoprotein; BMI, body mass index
(calculated as weight in kilograms divided by height in meters squared);
HDL-C, high-density lipoprotein cholesterol; IQR, interquartile range;
LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol;
TG, triglycerides.
SI conversion factors: To convert apo A-I and apo B to grams per liter,
multiply by 0.01; HDL-C, LDL-C, and TC to millimoles per liter, multiply by
0.0259; TG to millimoles per liter, multiply by 0.0113.
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the apo E polymorphism, we divided subjects in 3 groups:
E2 carriers (E2/E2 and E2/E3), E3/E3 individuals, and
E4 carriers (E3/E4 and E4/E4). The 2 E2/E4 subjects were
not included in analysis involving the apo E polymor-
phism because they presented with both alleles, and the
group was too small for an adequate statistical analysis.
They were, however, included in the other analyses. The
results obtained in E2 carriers and E4 carriers were mainly
due to the contribution of E2/E3 and E3/E4 genotypes,
respectively. E4 carriers presented with significantly higher
values of TC, LDL-C, and apo B compared with E2 car-
riers and E3/E3 individuals (Table 2). E4 carriers also pre-
sented with the highest TG level, although it was not sta-
tistically significant, and the lowest values for HDL-C and
apo A-I and, consequently, with significantly higher TC:
HDL-C and lower apo A-I:apo B ratios when compared
with the other 2 groups (P .05 for both). No differ-
ences in adiponectin levels were found between the dif-
ferent apo E genotypes. No statistical significance was lost
after adjustment for BMI and age.
We further analyzed our results in terms of BMI z score
(Table3) by dividing participants into 3 groups (group 1:
zscore2,n=31;group2:zscore2and2.5,n=65;group
3: z score2.5, n=42). A clear trend for worsening of the
lipid profile was found from group 1 to group 3. Group 3
presented with the lowest apo A-I value and apo A-I:apo B
ratioandthehighestTC:HDL-Cratio(P.05 forall). Inad-
dition, group 3 presented with significantly higher values
forTC,LDL-C,andapoBwhencomparedwithgroup1.On
the other hand, group 1 had a significantly higher value of
HDL-C when compared with the other 2 groups.
When all participants were considered, no statistically
significant correlations were observed between the age of
the participants and the lipid values, except for apo A-I level,
which was inversely correlated with age (r=−0.200;P=.02).
The age of the participants was strongly positively corre-
lated with BMI (r=0.528; P .001).
Adiponectin levels correlated inversely and signifi-
cantly with age (r=−0.288; P=.001), BMI (r=−0.305;
P .001), waist to hip ratio (r=−0.238; P=.005), TG level
(r=−0.392; P .001), and TC:HDL-C ratio (r=−0.265;
P= .002) and correlated positively and significantly
with HDL-C level (r=0.267; P=.002). In the multiple re-
gression analysis, TG level, age, and waist to hip ratio
were the only variables that remained statistically asso-
ciated with adiponectin values (log adiponectin
value=5.683−0.354 log TG value−0.023 age−0.947 waist
to hip ratio; standardized coefficients=−0.310, −0.261,
and −0.186; P .001, P=.001, and P=.02, respectively).
Because apo E polymorphism, BMI z score, and adi-
ponectin levels were significantly associated with changes
in the TC:HDL-C and apo A-I:apo B ratios (important
“atherogenic” ratios), we evaluated the combined effect
of apo E genotype with both other factors on such ra-
tios. We observed that the effect of apo E polymorphism
on TC:HDL-C and apo A-I:apo B ratios seems to be in-
fluenced by BMI z score (Figure1) and adiponectin val-
ues (Figure 2). Indeed, by using multiple regression
analysis, and when adjusted for apo E genotype, both BMI
z score and adiponectin level remained significantly
associated with TC:HDL-C ratio (log TC:HDL-C ra-
tio=0.245	0.063 apo E polymorphism	0.094 BMI z
Table 2. Lipid, Lipoprotein, and Adiponectin Levels
According to apo E Polymorphism Distribution in Obese
Children and Adolescents
Mean (SD)
E2
Carriersa
(n=11)
E3/E3
Carriers
(n=94)
E4
Carriersa
(n=31)
Log TG level,
mg/dL
1.826 (0.248) 1.888 (0.221) 1.911 (0.248)
Log TC level,
mg/dL
2.168 (0.076) 2.205 (0.073) 2.255 (0.109)b
Log HDL-C level,
mg/dL
1.622 (0.094) 1.616 (0.094) 1.601 (0.112)
Log LDL-C level,
mg/dL
1.947 (0.109) 2.006 (0.102) 2.086 (0.132)b
apo A-I level,
mg/dL
129.4 (18.9) 118.9 (17.9) 115.0 (17.9)
apo B level,
mg/dL
71.7 (16.9) 80.2 (16.0) 92.8 (28.9)b
Log TC:HDL-C
ratio
0.546 (0.117) 0.589 (0.107) 0.653 (0.142)b
apo A-I:apo B
ratio
1.917 (0.594)b 1.534 (0.368) 1.324 (0.368)b
Log adiponectin
level, mg/L
0.776 (0.234) 0.885 (0.269) 0.881 (0.242)
Abbreviations: See Table 1.
SI conversion factors: See Table 1.
aE2 carriers had either the E2/E2 or E2/E3 genotype. E4 carriers had either
the E3/E4 or E4/E4 genotype. The E2/E4 subjects were not included in the
analysis.
bP .05 vs other 2 groups.
Table 3. Lipid, Lipoprotein, and Adiponectin Levels
According to BMI z Score Distribution in Obese Children
and Adolescents
Mean (SD)
Group 1
(BMI z Score
2)
(n=31)
Group 2
(BMI z Score
2 and2.5)
(n=65)
Group 3
(BMI z Score
2.5)
(n=42)
Log TG level,
mg/dL
1.832 (0.235) 1.889 (0.227) 1.946 (0.213)
Log TC level,
mg/dL
2.186 (0.065) 2.212 (0.078) 2.234 (0.104)a
Log HDL-C level,
mg/dL
1.668 (0.096)b 1.612 (0.090) 1.575 (0.092)
Log LDL-C level,
mg/dL
1.979 (0.090) 2.014 (0.104) 2.055 (0.138)a
apo A-I level,
mg/dL
123.4 (22.4) 121.3 (17.0) 112.0 (14.2)b
apo B level,
mg/dL
75.0 (14.9) 81.3 (17.5) 89.1 (25.8)a
Log TC:HDL-C
ratio
0.517 (0.079)b 0.599 (0.109) 0.658 (0.126)b
apo A-I:apo B
ratio
1.694 (0.397) 1.566 (0.432) 1.325 (0.318)b
Log adiponectin
level, mg/L
0.903 (0.243) 0.877 (0.256) 0.849 (0.279)
Abbreviations: See Table 1.
SI conversion factors: See Table 1.
aP .05 vs group 1.
bP .05 vs other 2 groups.
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score−6.77 E-6 adiponectin; standardized  coeffi-
cients: 0.283, 0.354, and −0.292, respectively; P .001
for all) and apo A-I:apo B ratio (log apo A-I:apo B
ratio=2.787−0.286 apo E polymorphism−0.262 BMI z
score	2.62 E-5 adiponectin value; standardized  co-
efficients: −0.372, −0.284, and 0.327, respectively;P .001
for all). For a better visualization of the results (graphi-
cally), obese participants were divided on the basis of their
BMI z score (Figure 1) and having an adiponectin level
lower than or higher than or equal to 7.92 mg/L (cutoff
corresponds to the median value for the entire group)
(Figure 2).
COMMENT
Obesity is associated with dyslipidemia, and both adipo-
nectin level and apo E polymorphism are known to influ-
ence lipid values. However, as far as we know, this is the
first study assessing the concomitant influence of the apo
E polymorphism and adiponectin level on the lipid pro-
file in obese children and adolescents. This is also the first
study, to our knowledge, assessing adiponectin levels in
Portuguese obese children and adolescents.
The adiponectin values that we describe in this ar-
ticle are comparable with those found in other popula-
tions.16,17 Adiponectin levels were reported to be lower
in boys than in girls, and the difference seems to be more
striking at postpubertal states.16,17 Moreover, adiponec-
tin levels were inversely related to age and were signifi-
cantly lower in pubertal compared with prepubertal obese
children.17 In our study, we also observed statistically sig-
nificant differences between boys and girls, with boys pre-
senting with lower adiponectin values. The 2 groups (boys
and girls) were matched for age, BMI z score, and pu-
berty stage, and therefore, the analysis of adiponectin level
was not affected by these possible confounding factors.
A significant inverse correlation between adiponectin lev-
els and age was also observed for both sexes.
Adiponectin levels were lower in nonlean individu-
als compared with lean individuals18 and it was re-
ported that mean adiponectin values decreased for ev-
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Figure 1. Effect of apolipoprotein (apo) E polymorphism on total cholesterol
(TC) to high-density lipoprotein cholesterol (HDL-C) (A) and apo A-I:apo B
(B) ratios, according to body mass index (BMI) z score. Results are
presented as mean (95% confidence interval [CI]). The influence of BMI
z score, adjusted for apo E polymorphism (allele carriers), on both the
TC:HDL-C and apo A-I:apo B ratios was highly significant (P .001) by
multiple regression analysis.
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Figure 2. Effect of apolipoprotein (apo) E polymorphism on total cholesterol
(TC) to high-density lipoprotein cholesterol (HDL-C) (A) and apo A-I:apo B (B)
ratios, according to adiponectin level. For a better visualization of the results,
we used a cutoff for adiponectin level of 7.92 mg/L, which corresponds to the
median value for the entire group. Results are presented as mean (95%
confidence interval [CI]). The influence of adiponectin level, adjusted for apo E
polymorphism (allele carriers), on both the TC:HDL-C and apo A-I:apo B ratios
was highly significant (P .001) by multiple regression analysis.
(REPRINTED) ARCH PEDIATR ADOLESC MED/ VOL 163 (NO. 11), NOV 2009 WWW.ARCHPEDIATRICS.COM
1034
©2009 American Medical Association. All rights reserved.
 at University of Washington - Seattle, on November 12, 2009 www.archpediatrics.comDownloaded from 
ery unit increase in BMI z score.16 However, in obese
subjects, adiponectin plasma concentrations were not
correlated with BMI standard deviation score.17 In the
present study, group 3 individuals, defined as obese chil-
dren and adolescents having the highest BMI z scores
(2.5), presented with the lowest adiponectin values com-
pared with the other 2 groups, but it was not statisti-
cally significant (Table 3). We also found that adiponec-
tin levels correlated inversely with BMI and waist to hip
ratio but not with BMI z score.
It was previously reported that adiponectin level is posi-
tively correlated with HDL-C level and negatively cor-
related with TG level in both lean and nonlean adoles-
cents18 and that these relationships strengthened with
increasing adiposity. In the present study, we con-
firmed these relations and also that adiponectin levels cor-
related inversely and significantly with the TC:HDL-C
ratio. As previously mentioned, adiponectin level was also
inversely related to age, BMI, and waist to hip ratio. In
the multiple regression analysis, TG level, waist to hip
ratio, and age were the only variables that remained sta-
tistically associated with adiponectin values.
Regarding the apo E polymorphism, the distribution
of subjects with respect to genotype was similar to that
found in a previous work involving Portuguese obese chil-
dren11 and pregnant women.19 Thus, and although a con-
trol group (nonobese children) was not evaluated in the
present study, the frequency of the apo E genotypes is
unlikely to be altered in obese children.
The association of the apo E polymorphism with
changes in lipid and lipoprotein profiles is highly ex-
plored in adults, but not in children, particularly Portu-
guese children. In our studied population, significant al-
lele effects of apo E genetic variability on plasma
lipoprotein and apoprotein levels were observed. The re-
sults observed in carriers of E2 and E4 alleles were mainly
due to the contribution of E2/E3 and E3/E4 subjects, re-
spectively. E4 carriers presented with the highest LDL-C
level, compared with those with the E3/E3 genotype and
E2 carriers, in agreement with previous reports in obese
children11 and adults.9 E4 carriers also presented with the
highest TG levels and lower HDL-C and apo A-I levels,
although this was not statistically significant. A previ-
ous study in pregnant women found no differences in the
HDL-C levels between women with different apo E geno-
types.10 However, a meta-analysis reported HDL-C lev-
els to be lower in E3/E4 than in E3/E3 nonpregnant sub-
jects.8 Furthermore, in the current study, E4 carriers
presented with significantly higher TC and apo B levels
(P .05 for both groups); therefore, the TC:HDL-C ra-
tio was significantly higher and apo A-I:apo B ratio sig-
nificantly lower in this group when compared with the
other 2. All these results remained statistically signifi-
cant after adjustment for confounding factors such as age,
sex, Tanner stage, and BMI z score.
A major finding of this study, achieved by perform-
ing multiple regression analysis, was that the effect of
apo E polymorphism on the TC:HDL-C and apo A-I:
apo B ratios seemed to be influenced by BMI z score
(Figure 1) and adiponectin level (Figure 2). Individuals
presenting with lower adiponectin levels or a higher
BMI z score presented with higher TC:HDL-C and
lower apo A-I:apo B ratios than those with higher adi-
ponectin levels or lower BMI z scores, irrespective of
their apo E polymorphism–carrying nature (Figure 1
and Figure 2). These atherogenic ratios therefore seem
to worsen with lower adiponectin levels and higher BMI
z scores, modulating early in life the effect of apo E
genotype on lipids (ie, in children and adolescents). An
article by Wardaningsih et al20 reported worsening of
the lipid profile for E3/E3 children with lower adipo-
nectin levels, especially in boys.
These relations between adiponectin level, apo E poly-
morphism, BMI z score, and lipid profile that we pre-
sented in Figure 1 and Figure 2 may be because adipo-
nectin reduces hepatic release of apo E from hepatocytes
and because the hepatic secretion of apo B is also re-
duced by adiponectin, possibly by a genetic mechanism
involving the hepatic nuclear factor 4-.21
Considering that the relationships between adiponec-
tin, HDL-C, and TG levels are strengthened with increas-
ing adiposity, heavier adolescents seem to have a greater
benefit from high levels of adiponectin than their leaner
counterparts.18 Furthermore, a recent study performed
in obese children demonstrated an increase in adiponec-
tin levels due to a significant weight loss over a 1-year
period.17 This may be of particular importance in obese
individuals with certain “risk” apo E genotypes, as we
demonstrated that the influence of the apo E polymor-
phism on lipids is influenced by BMI z score and adipo-
nectin levels. Atherosclerosis is a multifactorial disease,
involving the interplay of genetic and environmental fac-
tors. The improvement of the latter factors, through a
healthier lifestyle, seems therefore to be particularly wor-
thy in those obese individuals with a less favorable ge-
netic background.
In conclusion, the lipid profile in obese children and
adolescents worsens with increasing adiposity (increas-
ing BMI z score) and the effect of the apo E polymor-
phism on the TC:HDL-C and apo A-I:apo B ratios is modu-
lated by BMI z score and adiponectin levels. This may
be of particular relevance because obese individuals, par-
ticularly those with risk apo E genotypes, may benefit
from a closer clinical follow-up. Moreover, the imple-
mentation of lifestyle modifications (mainly by practic-
ing regular physical activity and eating a healthy diet)
should be highly encouraged in such obese children and
adolescents.
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Even when freshly washed and relieved of all
obvious confections, children tend to be
sticky.
—Fran Lebowitz
(REPRINTED) ARCH PEDIATR ADOLESC MED/ VOL 163 (NO. 11), NOV 2009 WWW.ARCHPEDIATRICS.COM
1036
©2009 American Medical Association. All rights reserved.
 at University of Washington - Seattle, on November 12, 2009 www.archpediatrics.comDownloaded from 
 
Inflammation and atherogenic risk in obese children and adolescents  
95 
 
14.3. Paper III 
Nascimento H, Silva L, Lourenço P, Vieira E, Dos Santos R, Rego C, Ferreira H, 
Quintanilha A, Santos-Silva A, Belo L. "Lipoprotein (a) levels in obese children and 
adolescents: contribution of pentanucleotide repeat (TTTTA)n polymorphism in 
apoliporprotein (a) gene". Archives of Pediatrics & Adolescent Medicine. 2009; 163:393-
394. 
  
Genetic contribution and follow up study based on the reduction of the body mass index 
96 
 
  
THE PEDIATRIC FORUM
Lipoprotein(a) Levels in Obese
Portuguese Children and Adolescents:
Contribution of the Pentanucleotide
Repeat (TTTTA)n Polymorphism
in the Apolipoprotein(a) Gene
L ipoprotein(a) (Lp[a]) levels are known to bemainly genetically determined. A pentanucleo-tide repeat polymorphism, (TTTTA)n, 1.4 kilo-
bases upstream from the gene reading frame has been stud-
ied as a possible influence in Lp(a) levels.1 To date, repeat
sequences ranging from 5 to 12 have been found, with
the 8-repeat sequence the most common. Alleles con-
taining more repeats are usually associated with lower
Lp(a) levels. The influence of the pentanucleotide re-
peat on Lp(a) seems to be independent from other poly-
morphisms.1,2 To our knowledge, this is the first study
to assess the influence of this polymorphism in an obese
pediatric population.
In this study, we hypothesized that the pentanucleo-
tide repeat polymorphism influenced the Lp(a) levels in
obese Portuguese children and adolescents and that the
alleles with more repeats would correspond to lower Lp(a)
values. To achieve this, the population was divided ac-
cording to 2 criteria: individuals with Lp(a) concentra-
tions (1) higher/equal to or lower than 19.2 mg/dL (to
convert to micromoles per liter, multiply by 0.0357), the
physiological cutoff that corresponds to the median of
our population, or (2) higher/equal to or lower than 30
mg/dL, the traditional cutoff of an atherothrombotic se-
rum Lp(a) concentration.
Methods.The study protocols were approved by the eth-
ics committees of the University Hospital S. Joa˜o and the
Children’s Hospital Maria Pia, Porto, Portugal. Obese chil-
dren and adolescents aged 4 to 16 years were identified
from medical records held in the hospitals’ pediatrics de-
partments. One hundred forty-seven obese children and
adolescents (66 boys and 81 girls) participated in the study
after informed written consent was obtained from their
parents.
Obesity was defined as a body mass index greater than
the 95th percentile for age and sex, according to 2000
Centers for Disease Control and Prevention growth charts.
Because body mass index is not normally distributed, we
used body mass index z scores. The sample’s character-
istics are presented in the Table.
Genomic DNA was extracted from a buffy coat by the
proteinase K/salt precipitation method.3,4 Apolipopro-
tein(a) genotyping was performed by polymerase chain
reaction followed by electrophoresis in a polyacryl-
amide gel as described by Trommsdorff et al.2 The num-
ber of pentanucleotide repeat repeats was confirmed by
automated sequencing for homozygous 8/8, 9/9, and 10/10
repeats and for heterozygous 6/8, 7/8, 8/9, 8/10, 8/11, and
9/10 repeats. Serum Lp(a) was quantified by an immu-
noturbidimetric method in an autoanalyzer. Clinical data
were compared between groups using an unpaired t test
or a Mann-Whitney U test. The distribution of groups
with respect to alleles and other categorical variables was
analyzed using the 2 test and the Fisher exact test. Sig-
nificance was set at P .05.
Results. Groups were similar with respect to age, sex,
and obesity scores (Table). The apolipoprotein(a) allele
Table. Clinical Characteristics and Apo(a) Polymorphism Allelic Distribution According to Lp(a) Levels in Obese Portuguese Children
Characteristic
Total
(N = 147)
Physiological Cutoff Traditional Cutoff
Mean (SD)
P
Value
Mean (SD)
P
Value
Lp(a)  30 mg/dL
(n = 92)
Lp(a)  30
mg/dL
(n = 55)
Lp(a)  19.2
mg/dL
(n = 73)
Lp(a)  19.2
mg/dL
(n = 74)
Age, y 10.9 (2.9) 10.9 (2.9) 11.0 (2.9) .85 10.9 (2.9) 11.0 (2.9) .67
Male sex, No. (%) 66 (44.9) 39 (42.4) 27 (49.1) .49 30 (41.1) 36 (48.6) .41
BMI 29.8 (5.4) 29.6 (5.2) 30.3 (5.9) .53 29.4 (5.1) 30.3 (5.7) .43
Waist to hip ratio 0.941 (0.050) 0.938 (0.051) 0.946 (0.048) .38 0.937 (0.051) 0.945 (0.048) .28
BMI z score 2.30 (0.44) 2.30 (0.48) 2.33 (0.38) .68 2.29 (0.48) 2.32 (0.41) .52
Lp(a), median (IQR), mg/dL 19.2 (7.26-42.8) 10.00 (4.18-17.78) 52.0 (39.0-82.0) .001 7.82 (2.47-10.70) 42.3 (28.08-67.50) .001
No. of Apo(a) alleles, No. (%)
6 1 (0.3) 1 (0.5) 0
.001
1 (0.7) 0
.007
7 2 (0.7) 0 2 (1.8) 0 2 (1.4)
8 209 (71.1) 121 (65.8) 88 (80.0) 93 (63.7) 116 (78.4)
9 39 (13.3) 34 (18.5) 5 (4.5) 28 (19.2) 11 (7.4)
10 39 (13.3) 25 (13.6) 14 (12.7) 22 (15.1) 17 (11.5)
11 4 (1.4) 3 (1.6) 1 (0.9) 2 (1.4) 2 (1.4)
Abbreviations: Apo(a), apolipoprotein(a); BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); IQR, interquartile range;
Lp(a), lipoprotein(a).
SI conversion factor: To convert Lp(a) to micromoles per liter, multiply by 0.0357.
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with (TTTTA) 8-repeat sequences was most prevalent
(71.1%). The allele frequencies that we found are simi-
lar to those previously reported in a smaller pediatric
population.5
The genotypic distribution between groups was some-
what different (data not shown) and reached statistical
significance (P=.03 and P=.02 for the traditional and
physiological cutoffs, respectively). Evaluation of the al-
lelic distribution (Table) provided more pronounced sta-
tistically significant differences between groups, using both
the traditional (P=.001) and the physiological (P=.007)
cut-off values. In general, alleles with a lower number of
repetitions are more frequent in the groups with higher
Lp(a) concentrations.
Comment. Our results show a contribution of the pen-
tanucleotide repeat polymorphism on serum Lp(a) con-
centrations in an obese pediatric Portuguese popula-
tion, with alleles with more repeats corresponding to lower
Lp(a) values. However, the statistical significance when
analyzing the genotypes (which actually determines an
individual phenotype) was not very strong, suggesting
that other polymorphisms are likely to affect Lp(a) con-
centrations. Actually, few studies examining genetic as-
sociations have found that a single polymorphism ac-
counts for substantial variation of a measure or outcome.
A greater contribution of other polymorphisms to Lp(a)
has been observed in white adults.1,2 Additional studies
are needed, especially in obese nonwhite populations.
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Antipsychotic Agents and Cardiometabolic
Morbidity in Youth
T he October issue of Archives included what weconsider a landmark article by McIntyre and Jer-rell.1 As clinicians involved in the evaluation of
mentally ill youth, many of whom present for care tak-
ing multiple psychoactive medications for dubious in-
dications, we are alarmed by the authors’ finding that an-
tipsychotic agents in particular are associated with serious
cardiometabolic morbidity in children and adolescents,
as they are in adults.2,3 Their findings are all the more
impressive given the relatively high medical morbidity
in the untreated control group, with whom the subjects
taking antipsychotic agents were compared. In light of
the aggressive off-label marketing of antipsychotic drugs
to physicians involved in both state-managed and pri-
vate health care programs for youth, it is particularly im-
portant that both mental health specialists and primary
care physicians be aware of these data.
However, we would like to make a critical comment.
Specifically, we believe that caution should be exerted
in interpreting their conclusion that “Incident cardio-
vascular events were more likely with the use of conven-
tional . . . antipsychotics” compared with second-
generation antipsychotics (SGAs). Although this is
technically an accurate statement regarding the data as
presented, this conclusion inevitably leads to the pro-
jective assumption that SGAs may be comparatively less
risky than conventional antipsychotic drugs. We note that
this putative distinction was immediately seized upon as
a key talking point in a recent online continuing medi-
cal education activity with sponsorship from manufac-
turers of SGAs.4
In fact, less than 5% of the treated patients in the large
South Carolina Medicaid database evaluated in the au-
thors’ study included patients taking conventional anti-
psychotic drugs. Therefore, even though there was a
higher percentage of incident cardiovascular events among
the small number of conventional antipsychotic users and
a higher odds ratios of developing incident cardiovascu-
lar events, in absolute terms, conventional antipsy-
chotic agents would have been associated with a small
number of these events. The data from this study over-
whelmingly reflect the adverse cardiometabolic conse-
quences of SGAs, in particular higher rates of obesity and
type 2 diabetes mellitus, among a pediatric population
with very high rates of behavioral diagnoses, such as con-
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Abstract 
Objectives: Bilirubin has potential antioxidant and anti-inflammatory properties. The 
UGT1A1*28 polymorphism (TA repeats in the promoter region) is a major determinant of 
bilirubin levels and recent evidence suggest that raised adiposity may also be a 
contributing factor. We aimed to study the interaction between UGT1A1 polymorphism, 
hematological and anthropometric variables with total bilirubin levels in young individuals. 
Methods: 350 obese (mean age of 11.6 years; 52% females) and 79 controls (mean 
age of 10.5 years; 59% females) were included. Total bilirubin and C-reactive protein 
(CRP) plasma levels, hemogram, anthropometric data and UGT1A1 polymorphism were 
determined. In a subgroup of 74 obese and 40 controls body composition was analyzed 
by dual-energy X-ray absorptiometry.   
Results: The UGT1A1 genotype frequencies were 49.9%, 42.7% and 7.5% for 6/6, 6/7 
and 7/7 genotypes, respectively. Patients with 7/7 genotype presented the highest total 
bilirubin levels, followed by 6/7 and 6/6 genotypes. Compared to controls, obese patients 
presented higher erythrocyte count, hematocrit, hemoglobin and CRP levels, but no 
differences in bilirubin or in UGT1A1 genotype distribution. Body fat percentage was 
inversely correlated with bilirubin in obese patients but not in controls. This inverse 
association was observed either in 6/7 or 6/6 genotype obese patients. UGT1A1 
polymorphism and body fat percentage were the main factors affecting bilirubin levels 
within obese patients (linear regression analysis).  
Conclusion: In obese children and adolescents, body fat composition and UGT1A1 
polymorphism are independent determinants of total bilirubin levels. Raised inflammation 
and oxidative stress in obese patients may trigger the consumption of bilirubin. 
 
Keywords: UGT1A1*28 polymorphism, body fat, bilirubin, inflammation, pediatric obesity 
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1. Introduction 
Bilirubin is the ultimate product of the haem group catabolism and serves as a diagnostic 
marker of liver and blood disorders.(1) Bilirubin is a water-insoluble compound that 
circulates bounded to albumin and requires glucuronidation by a microsomal enzyme, the 
uridine diphosphate glucuronosyltransferase (UGT) 1A1, to be excreted. The UGT1A1 
gene locus has been mapped to chromosome 2q37(2) and one of the most common 
genetic variants that affects the glucuronidation of bilirubin is a TA duplication 
polymorphism in the TATA box region of the gene promoter. Homozygous individuals 
carrying the A(TA)7TAA allele have higher levels of unconjugated bilirubin (UCB), caused 
by a reduction of 30% in the UGT1A1 transcription.(3) The estimated frequency of this 
allele is 0.35 in Caucasians, leading to a homozygous genotype in about 10% of the 
population, but the frequency is highly variable in different ethnicities.(4,5) Homozygosis 
for the TA duplication was considered as the main cause of Gilbert syndrome in 
Caucasian population(3,4), and justify some of the inter-individual variations in bilirubin 
levels.(6) 
Under certain conditions bilirubin can be toxic.(7) High plasma concentrations are 
associated with deleterious effects in new-borns, increasing the risk of neurological 
dysfunction(7,8), as a result of its toxic effect on neuronal tissue. However, recent 
investigation has recognized that UCB exerts anti-oxidant and anti-inflammatory activities, 
and that mild hyperbilirubinaemia might have positive health effects. UCB inhibits lipid 
peroxidation(9) and suppresses inflammation in activated neonatal neutrophils(10), and 
population studies documented that individuals with higher circulating UCB have a 
reduced incidence of cardiovascular problems(11-13) and of carcinoma in general.(14) 
Furthermore, subjects with Gilbert syndrome seem to present low levels of oxidative 
stress associated with hyperbilirubinemia.(15) 
Obesity, a low-grade inflammatory disease(16), is increasing all over the world and is a 
significant risk factor for cardiovascular diseases (CVD). This is of particular concern in 
our country, considering the very high prevalence of overweight/obesity (31.5%) in 
Portuguese children when compared to other European countries.(17) In obesity, 
cardiovascular morbidity and mortality are associated with classic risk factors, namely 
dyslipidemia, hypertension and impaired glucose metabolism. These risk factors, known 
as predictive of CVD, are characteristic of the metabolic syndrome (MS).(18) Moreover, 
serum bilirubin levels are inversely associated with the MS and systemic inflammation in 
adults(19-21), as well as in children and adolescents.(22) In particular, abdominal obesity 
per se seems to be associated with low serum bilirubin levels.(21-23) Furthermore, a 
recent study hypothesized that circulating bilirubin levels might be already altered in 
overweight asymptomatic middle-aged individuals before full development of the MS.(24) 
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The aim of our work was to evaluate how total bilirubin (TB) levels are influenced by 
UGT1A1*28 polymorphism, haematological, biochemical and anthropometric variables in 
Portuguese obese children and adolescents.  
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2. Material and methods 
 
2.1. Subjects 
Obese children and adolescents, aged 4-18 years, were identified from medical records, 
at the outpatient clinics of pediatric obesity in two hospitals in Porto - Portugal. A group of 
children from 5 primary and 2 middle and high public schools from Oporto suburban 
setting, were also recruited to this study, providing a control group and enlarging the 
obese group.  
The study protocol was approved by the Committees on Ethics of the two hospitals, by the 
Review Committee of the Scientific Board of the Faculty of Sport of the University of Porto 
as well as by the Foundation of Science and Technology. 
A total of 350 obese children and adolescents and 79 controls participated in the study 
after informed and written consent of their parents. Smokers, subjects with diabetes 
mellitus, endocrine disorders, hereditary diseases, inflammatory or infectious diseases or 
under any therapy that could interfere with our results were excluded from the study. 
 
2.2. Procedures and assays 
 
2.2.1 Anthropometric characterization and clinical evaluation 
All participants were subjected to clinical examination. Height and weight were 
measured. Obesity was defined as body mass index (BMI) z-score greater than +1.65 for 
age and gender, according to 2000 Centre for Disease Control and Prevention (CDC) 
growth charts. Body composition was evaluated by dual-energy X-ray absorptiometry 
(DEXA) in a subgroup of participants (74 obese and 40 controls).  
 
2.2.2. Blood samples 
Blood was collected by venipuncture in EDTA containing tubes, after overnight fasting 
(10-12h) and processed within 2h of collection. Aliquots of buffy-coat and plasma were 
made, and immediately stored at -80oC until assayed. 
 
2.2.3. Haematological data 
Red blood cell (RBC) count, haematocrit (Ht), haemoglobin (Hb) concentration and 
haematimetric indices [mean cell volume (MCV), mean cell Hb (MCH) and mean cell Hb 
concentration (MCHC)] were measured by using an automatic blood cell counter (ABX 
Micros 60-OT).  
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2.2.4. DNA analysis 
Genomic DNA was extracted from buffy-coat) by proteinase K/salt precipitation 
method.(25,26) Genotyping TA duplication in the TATA box of the UGT1A1 promoter was 
performed by polymerase chain reaction (PCR) (forward: 5´-
TAACTTGGTGTATCGATTGGTTTTTG-3´; reverse: 5´-ACAGCCATGGCGCCTTTGCT-
3´). PCR was followed by electrophoresis in 15% polyacrylamide gel in a 
Tris/Borate/EDTA buffer. The gel was stained with silver nitrate, photographed and 
samples were classified. 
 
2.2.5. Plasma analysis 
The plasma levels of C-reactive protein (CRP) were determined by immunoturbidimetry 
[CRP (latex) High-Sensitivity, Roche Diagnostics] and quantification of TB was performed 
by a colorimetric test (diazotized sulfanilic acid reaction, Roche Diagnostics). 
The determination of circulating levels of glucose and insulin was performed by using 
routine automated technology (ABX Diagnostics). Homeostasis model assessment of 
insulin resistance (HOMAIR) was calculated.(27) 
 
2.3. Statistical analysis 
The distributions of continuous variables were analysed using Kolmogorov-Smirnov tests. 
Normally distributed variables are presented as mean ± SD and those non-normally 
distributed are presented as median (interquartile range). Comparisons between two 
groups were performed using Student’s unpaired t-test or Mann-Whitney U test. 
Adjustment for confounding factors was performed using ANCOVA. The association 
between categorical variables was analysed using chi-squared (2) test and Fisher’s exact 
test. 
The strength of the association between the variables was estimated by Pearson 
correlation coefficient, after log transformation of the variables (whenever necessary). To 
evaluate the contribution of the different variables to TB levels, multiple regression 
analysis was performed, using stepwise selection, with an entry criteria of P <0.05.  
Statistical analysis was performed using the Statistical Package for Social Sciences 
(SPSS), version 20.0 (IBM, Armonk, NY, USA). Statistical significance was accepted at p 
less than 0.05. 
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3. Results 
The anthropometric data, UGT1A1 genotypes and haematological parameters of the 
obese children and adolescents (n=350) and controls (n=79), according to gender, are 
presented in Table 1.  
 
Table 1. Anthropometric data, UGT1A1*28 polymorphism, haematological and 
biochemical parameters of the participants in the study 
p p p † p ††
Number of participants 47 32 182 168
Age (years) 10.5 ± 4.0 10.7 ± 3.6 0.830 11.6 ± 2.9 11.7 ± 2.9 0.559 0.083 0.113
Height (cm) 139.7 ± 17.9 143.8 ± 17.6 0.317 151.3 ± 13.2 155.4 ± 15.4 0.008 <0.001 <0.001
Weight (kg) 37.0 ± 14.6 39.7 ± 15.8 0.440 72.1 ± 22.5 76.2 ± 27.4 0.128 <0.001 <0.001
BMI (kg/m²) 18.1 ± 2.9 18.3 ± 2.9 0.691 30.7 ± 5.8 30.5 ± 6.4 0.762 <0.001 <0.001
BMI z-score 0.17 ± 0.65 0.24 ± 0.77 0.636 2.22 ± 0.34 2.30 ± 0.40 0.046 <0.001 <0.001
Body fat (%) 30.8
a
± 4.1 25.4
b
± 5.2 0.001 43.5
c
± 4.1 39.8
d
± 6.6 0.156 <0.001 <0.001
Trunk fat (%) 25.6
a
± 4.8 21.9
b
± 6.0 0.045 41.1
c
± 8.9 37.8
d
± 7.9 0.107 <0.001 <0.001
UGT1A1  genotype
6/6, n  (%) 21 (44.7%) 12 (37.5%) 0.298 92 (50.6%) 89 (53.0%) 0.433 0.455 0.085
6/7, n  (%) 21 (44.7%) 19 (59.4%) 79 (43.4%) 64 (38.1%)
7/7, n  (%) 5 (10.6%) 1 (3.1%) 11 (6.0%) 15 (8.9%)
RBC (x1012/L) 4.62 ± 0.29 4.77 ± 0.29 0.031 4.78 ± 0.32 5.03 ± 0.39 <0.001 0.003 <0.001
Hb (g/dL) 13.1 ± 0.9 13.6 ± 1.2 0.029 13.6 ± 0.8 14.2 ± 1.2 <0.001 0.001 0.017
Ht (L/L) 0.39 ± 0.03 0.40 ± 0.04 0.263 0.40 ± 0.02 0.42 ± 0.03 <0.001 0.033 0.003
MCV (fL) 84.9 ± 4.6 84.0 ± 6.1 0.486 84.2 ± 5.1 83.8 ± 4.7 0.454 0.432 0.846
MCH (pg) 28.4 ± 1.7 28.6 ± 2.0 0.684 28.5 ± 1.7 28.2 ± 1.6 0.185 0.909 0.239
MCHC (g/dL) 33.4 ± 1.2 34.0 ± 1.1 0.025 33.8 ± 1.0 33.7 ± 1.1 0.271 0.027 0.081
Total bilirubin (µmol/l) 8.89 (5.47-13.34) 7.52 (5.30-11.54) 0.463 8.89 (6.16-11.63) 9.23 (6.84-12.65) 0.232 0.919 0.079
Acute phase protein
CRP (mg/L) 0.26 (0.20-0.73) 0.36 (0.26-0.83) 0.121 1.83 (0.85-3.73) 1.64 (0.85-3.54) 0.527 <0.001 <0.001
Glucose metabolism
Glucose (mg/dl) 85.3 ± 9.3 87.0 ± 6.5 0.365 84.0 ± 8.9 85.8 ± 12.6 0.121 0.384 0.419
Insulin (µU/ml) 6.8 (5.0-9.9) 5.3 (4.1-8.5) 0.051 16.6 (11.7-23.2) 12.8 (9.1-20.0) 0.001 <0.001 <0.001
HOMAIR 1.41 (1.06-2.05) 1.14 (0.82-1.83) 0.130 3.39 (2.21-4.87) 2.75 (1.88-4.06) 0.006 <0.001 <0.001
Females Males
Obese patients (n =350)Controls (n =79)
Females Males
 
Values are given as mean ± SD or median (interquartile range), unless otherwise indicated.BMI, body mass 
index; RBC, red blood cells; Hb, haemoglobin; Ht, haematocrit; MCV, mean cell volume; MCH, mean cell 
haemoglobin; MCHC, mean cell haemoglobin concentration; CRP, C-reactive protein; HOMAIR, homeostasis 
model assessment insulin resistance.a, n=25; b, n=15; c, n=34; d, n=40. † Controls versus obese patients 
(females); †† Controls versus obese patients (males) 
 
Comparing males and females within the control group, body fat and trunk fat percentages 
were significantly lower for boys, whereas RBC count, Hb levels and MCHC values were 
significantly higher. Within obese patients, RBC count, Hb levels and Ht values were 
significantly higher for boys, whereas insulin levels and HOMAIR values were lower. No 
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statistical significant differences were found in the distribution of subjects with respect to 
UGT1A1 genotypes or in TB levels between boys and girls, within both groups.  
Compared to controls (independently of gender), obese patients presented significantly 
higher height, weight, BMI, BMI z-score, body fat and trunk fat percentages, erythrocyte 
count, Ht and HOMAIR values and Hb, insulin and CRP levels, but no significant 
differences in TB levels or in UGT1A1 genotype distribution.  
The UGT1A1 genotype frequencies in all studied individuals were 49.9%, 42.7% and 
7.5% for 6/6, 6/7 and 7/7 genotypes, respectively. UGT1A1*28 polymorphism was 
associated with different TB levels (Figure 1A); patients with 7/7 genotype presented the 
highest TB levels, followed by 6/7 and 6/6 genotypes (p<0.01 between all groups). No 
significant differences were observed between obese and control individuals, for the 
different UGT1A1 genotypes (Figure 1B). 
 
 
Figure 1. Total bilirubin levels in all participants according to the number of TA 
repeats in the promoter region of UGT1A1 gene (A) and also according to group 
(B), control and obese 
The boxes represent the interquartile range (IQR), with the upper and lower edges of the boxes representing 
the 75th and 25th percentiles, respectively. The central horizontal lines within the boxes represent median 
levels for each group. The vertical whiskers above and below the boxes represent the range of outlying data 
points up to 1.5 times the IQR. 
 
Within the control group (n=79), TB levels correlated positively and significantly with age 
(r=0.304, p=0.007), height (r=0.360, p=0.001), weight (r=0.390, p<0.001), BMI (r=0.370, 
p=0.001), Ht (r=0.247, p=0.028), MCV (r=0.292, p=0.009), and correlated negatively and 
significantly with MCHC (r=-0.258, p=0.022). Within the obese group (n=350), TB levels 
correlated positively and significantly with age (r=0.284, p<0.001), height (r=0.285, 
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p<0.001), weight (r=0.219, p<0.001), BMI (r=0.123, p=0.021), Hb (r=0.305, p<0.001), Ht 
(r=0.352, p<0.001), MCV (r=0.394, p<0.001), MCH (r=0.301, p<0.001) and correlated 
negatively and significantly with BMI z-score (r=-0.131, p=0.014), MCHC (r=-0.149, 
p=0.006) and CRP (r =-0.178, p=0.001). 
The characteristics of obese patients that evaluated their body composition by DEXA 
(n=74) are presented in Table 2. These obese patients were divided in two groups 
according on having a body fat lower or higher/equal than 42.5% (cut-off that corresponds 
to the median value for the obese group). The two groups of obese patients were matched 
for gender and UGT1A1 genotype distribution, but not for age. Patients presenting higher 
body fat had lower bilirubin and higher CRP levels (Table 2). These differences were 
similar to both sexes (Figure 2) and remained statistically significant after adjustment for 
age. No significant differences in HOMAIR values were found between the two groups.  
Associations between body and trunk fat were only accessed in participants that 
evaluated their body composition by DEXA (74 obese and 40 controls). Body fat and trunk 
fat percentages were negatively and significantly related with TB levels in obese patients 
(r =-0.287, p=0.013 and r=-0.245, p=0.038) but not within controls (r=0.012, p=0.941 and 
r=0.014, p=0.002).  
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Table 2. Anthropometric data, UGT1A1*28 polymorphism, haematological and 
biochemical parameters of obese patients according to body fat percentage (n=74) 
lower or higher/equal than 42.5% (median value for the obese group) 
p
Number of participants 37 37
Female, n  (%) 13 (35.1%) 21 (56.8%) 0.102
Age (years) 11.0 ± 3.0 9.5 ± 2.5 0.022
Height (cm) 149.2 ± 14.3 144.0 ± 14.2 0.126
Weight (kg) 59.8 ± 18.9 61.4 ± 23.9 0.749
BMI (kg/m²) 26.0 ± 4.0 28.4 ± 5.5 0.041
BMI z-score 1.98 ± 0.24 2.31 ± 0.26 <0.001
Body fat (%) 36.8 ± 4.3 46.1 ± 2.6 <0.001
Trunk fat (%) 34.5 ± 5.5 45.3 ± 3.4 <0.001
UGT1A1  genotype
6/6, n  (%) 21 (56.8%) 19 (51.4%) 0.359
6/7, n  (%) 14 (37.8%) 18 (48.6%)
7/7, n  (%) 2 (5.4%) 0 (0%)
RBC (x1012/L) 4.83 ± 0.38 4.91 ± 0.34 0.389
Hb (g/dL) 13.9 ± 1.0 13.6 ± 0.8 0.268
Ht (L/L) 0.41 ± 0.03 0.41 ± 0.02 0.798
MCV (fL) 85.4 ± 4.9 83.8 ± 4.6 0.156
MCH (pg) 28.7 ± 1.7 27.8 ± 1.5 0.017
MCHC (g/dL) 33.6 ± 0.8 33.2 ± 0.9 0.020
Total bilirubin (µmol/l) 11.29 (8.72-14.36) 8.89 (7.69-11.63) 0.013
Acute phase protein
CRP (mg/L) 1.31 (0.84-2.30) 2.00 (1.43-3.54) 0.017
Glucose metabolism
Glucose (mg/dl) 83.5 ± 7.6 81.0 ± 8.6 0.191
Insulin (µU/ml) 11.6 (8.9-14.6) 15.3 (7.5-22.9) 0.272
HOMAIR 2.25 (1.91-3.01) 3.15 (1.57-4.56) 0.361
Body fat ≤ 42.5% Body fat > 42.5%
Obese patients (n =74)
 
Values are given as mean ± SD or median (interquartile range), 
unless otherwise indicated. BMI, body mass index; RBC, red 
blood cells; Hb, haemoglobin; Ht, haematocrit; MCV, mean cell 
volume; MCH, mean cell haemoglobin; MCHC, mean cell 
haemoglobin concentration; CRP, C-reactive protein; HOMAIR, 
homeostasis model assessment insulin resistance. 
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Figure 2. Total bilirubin (A) and C-reactive protein (B) levels in obese participants 
according to gender and to body fat percentage (n=74), using the cut-off value of 
42.5 % (cut-off that corresponds to the median value for the obese group) 
The boxes represent the interquartile range (IQR), with the upper and lower edges of the boxes 
representing the 75th and 25th percentiles, respectively. The central horizontal lines within the boxes 
represent median levels for each group. The vertical whiskers above and below the boxes represent 
the range of outlying data points up to 1.5 times the IQR. 
 
 
By linear regression analysis, the UGT1A1*28 polymorphism and body weight were the 
only factors associated to bilirubin levels within controls (Ln TB= 1.143 +0.462 
UGT1A1*28 polymorphism +0.014 weight; standardised Beta: 0.598 and 0.490; p<0.001 
and p=0.001, respectively). Within obese patients, the UGT1A1 polymorphism and body 
fat percentage were the main determinant factors of bilirubin levels (Ln TB= 2.761 +0.251 
UGT1A1*28 polymorphism -0.020 body fat; standardised Beta: 0.348, -0.291; p=0.002 
and p=0.009, respectively). For a better visualization of the results (graphically), obese 
participants were divided on the basis of their UGT1A1 genotype and on having a body fat 
lower or higher/equal than 42.5% (cut-off that corresponds to the median value for the 
obese group; Figure 3). 
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Figure 3. Effect of body fat percentage on total bilirubin levels according to 
UGT1A1*28 polymorphism on obese patients 
 
For a better visualization of the results we used for body fat percentage a cut-off of 42.5% 
(cut-off that corresponds to the median value for the obese group). Results are presented 
as mean ± standard error of mean. The influence of body fat percentage, adjusted for 
UGT1A1 polymorphism, on total bilirubin levels, was highly significant (p = 0.009), by 
multiple regression analysis. 
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4. Discussion 
As far as we know, this is the first report assessing the concomitant influence of 
UGT1A1*28 polymorphism and adiposity markers on bilirubin levels in obese children and 
adolescents. We demonstrated that body fat percentage is a major determinant of TB 
levels independently of UGT1A1*28 polymorphism in obese children and adolescents. 
It is known that UGT1A1 polymorphisms are associated with bilirubin levels and our data 
is in agreement with previous reports in young patients and adults.(15,28-31) Patients and 
controls with 7/7 genotype presented the highest TB levels, followed by 6/7 and 6/6 
genotypes (Figure 1A and 1B).  
The frequency of 7/7 homozygotes (7.5% in the whole population) was lower than that 
observed in other works, namely in healthy Greek(29) and Slovenian(30) populations, with 
frequencies of 14.8% and 13.6%, respectively. However, the distribution of subjects with 
respect to UGT1A1 genotypes was similar to that found in previous studies involving 
Portuguese children with Hereditary spherocytosis, with a 7/7 frequency of 8.8%(28), as 
well as Portuguese healthy subjects, with frequencies observed in two studies of 6.3 and 
9.9%.(28,31) Thus, it seems reasonable to assume that the frequency of 7/7 homozygotes 
in the Portuguese population may be lower than that observed in other Caucasian 
populations.  
Other potential variables could influence TB levels. Within both controls and obese 
patients TB levels were positively and significantly correlated with age, height, weight, 
BMI, and Ht. However, BMI z-score, body fat and trunk fat percentages were negatively 
and significantly related with TB levels in obese patients, but not within controls. In 
multiple regression analysis, the UGT1A1*28 polymorphism and body weight were the 
only factors associated to bilirubin levels within controls, whereas the UGT1A1*28 
polymorphism and body fat percentage were the main determinant factors of bilirubin 
levels within obese patients.  
In the present study, the evaluation of body composition by DEXA was performed in a 
subgroup of participants. Despite the lower number of participants in this sub-analysis, the 
negative relation between bilirubin and body fat percentage was highly statistically 
significant and independent of the effect of UGT1A1*28 polymorphism. Furthermore, this 
negative relation is in agreement with a previous study involving 41 lean and obese adult 
men and women.(23)  
Bilirubin derives mainly from the haem present in Hb, released during breakdown of 
senescent erythrocytes.(1) Thus, in healthy conditions, it would be assumed that 
increases in Hb levels are generally associated with increases in TB. This explains our 
positive association between the age of the participants and TB, as in young individuals 
there is a physiological increase in Hb levels with age.  It is well known that Hb and Ht 
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increase substantially during childhood, whereas RBC count remains almost constant.(32) 
Differences according to gender become prominent in the second decade of life; with 
menstruation, these three variables tend to be lower in females.  The inclusion in our 
study of subjects with a range of age between 4 and 18 years old justifies the higher 
values of RBC and Hb observed in males within both controls and obese patients (Table 
1). The differences were particularly evident in obese patients, not only because of the 
large number of subjects included in this group but also due to the enhanced puberty 
development in obesity. Actually, the increasing prevalence of obesity in children 
worldwide is a major cause of precocious pubertal maturation, verified during the past 
decades.(33) 
Total and direct bilirubin levels were reported to be higher in normal weight adult males 
than in females(24,34,35), but similar within overweight patients.(24) In our study, we 
observed no statistical significant differences between boys and girls regarding TB levels, 
either in controls or in obese patients. Within these two groups, males and females were 
matched for age, weight, BMI and distribution of UGT1A1 genotypes (Table 1) and, 
therefore, the analysis of TB was not greatly affected by these factors.  
In the present manuscript, obese patients and controls were matched for age and 
distribution of UGT1A1 genotypes, allowing the comparison of groups. Independently of 
gender, obese patients presented higher RBC count, Hb levels and Ht values compared 
with controls (Table 1). The higher weight and BMI in obese patients trigger the 
stimulation of erythropoiesis in order to supply adequate oxygenation to increased body 
tissues. However, TB levels were similar between groups. This may be explained by the 
fact that obesity is associated with increased inflammation(16,36,37) and oxidative 
stress(38,39), and that bilirubin, presenting antioxidant and anti-inflammatory 
properties(9,10), may be somewhat consumed. In fact, oxidative stress increases with 
increasing BMI and age.(34) In line with this, we found that bilirubin levels are negatively 
correlated with body and trunk fat percentages and CRP levels within obese patients. 
Moreover, when obese patients were divided in two groups according to the median value 
of body fat presented by this group (42.5%), patients presenting higher body fat presented 
lower bilirubin and higher CRP levels (Table 2). The negative relation that we found 
between bilirubin and CRP levels is in line with the bilirubin's anti-inflammatory activity, as 
previously reported.(40-43)  
In obese patients, insulin resistance may also underlie the association between lower 
bilirubin levels and higher body fat percentages. Indeed, it seems that the activity of heme 
oxygenase-1, the rate-limiting enzyme of bilirubin production, is impaired in insulin 
resistant states.(44,45) Also, the up-regulation of heme oxygenase-1 in adipocyte by 
insulin was recently demonstrated.(46) In this work obese patients presented with higher 
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HOMAIR values compared to controls (Table 1). Obese patients with body fat percentages 
higher than 42.5% also presented with higher HOMAIR values, although without statistical 
significance. However, no significant correlation was obtained between HOMAIR and 
bilirubin. Thus, association between insulin resistance and bilirubin might not be so clear 
in paediatric populations. 
A previous work from our group demonstrated that BMI z-score is significantly and 
independently related to the lipid profile in obese children and adolescent.(47) However, in 
the present study BMI z-score was poorly related with TB levels in obese patients and it 
was not an independent predictor of bilirubin plasma concentration. This suggests that 
body fat percentage is a better indirect marker of oxidative stress, rather than BMI z-
score. Actually BMI z-score is calculated using the BMI of patients, adjusted to age and 
gender, but it may not necessarily express the degree of obesity. 
Individuals with a higher physical fitness index (which serves as an aerobic assessment) 
seem to present with higher bilirubin levels(24) and a study performed in overweight and 
obese adult patients demonstrated an increase in bilirubin levels due to short-term weight 
loss.(35) It seems that high doses of exercise training are necessary to significantly 
increase bilirubin levels in overweight and obese women.(48) The fact that bilirubin levels 
increase as a function of weight loss may be of particular importance in obese individuals 
with UGT1A1 genotypes associated to lower bilirubin levels, as we here demonstrated 
effects on TB by body fat composition in addition to the UGT1A1*28 polymorphism. It is 
important to keep in mind that atherosclerosis is a multifactorial disease that initiates early 
in life, involving the interplay of genetic and environmental factors. The lifestyle 
improvement is conditioned by environmental factors (such as nutritional behaviour and 
practice of physical activity) and may be particularly worthy in obese individuals with a 
less favourable genetic background.   
Despite the new data reported here, this work presented some limitations. Obesity was 
defined according to CDC although a novel criteria is now recommended for the 
Portuguese population, causing us to have probably underestimated the degree of 
obesity. Nevertheless, at the beginning of this study the criteria recommend by the 
Portuguese Ministry of Health was that of CDC. Also, the evaluation of body composition 
by DEXA was performed only in a subgroup of participants due to logistical constraints 
and equipment availability. Furthermore, we did not evaluate the association between 
bilirubin and the MS as a large proportion of our obese patients were under the age of 10, 
not allowing their classification according to the International Diabetes Federation (IDF) 
definition. 
In conclusion, body fat percentage is a major determinant of TB levels independently of 
UGT1A1*28 polymorphism in obese children and adolescents. This may have a particular 
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relevance, as obese individuals, particularly those with 6/6 UGT1A1 genotype and higher 
body fat mass, may benefit from a closer clinical follow-up, considering their increased risk 
for other comorbidities. Moreover, lifestyle modifications at low ages, when good habits 
can be created, should be highly encouraged in such obese children and adolescents. 
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Abstract: Objectives: to evaluate whether total and differential WBC counts are altered in young obese patients (aged 6-
12 years) and if a relationship exists between WBC counts and the severity of obesity as well as with CRP level.  
Materials and Methods: a group of 77 obese patients [32 males and 45 females] and 19 controls [7 males and 12 females] 
were studied. Total WBC count was performed by using an automatic blood cell counter. Blood cell morphology and 
WBC differential count were evaluated in Wright stained blood films. The plasma levels of CRP were evaluated by 
immunoturbidimetry. 
Results: obese participants presented with a statistically significant higher neutrophil percentage and CRP levels when 
compared to controls; the median CRP value was about 5 times higher than that observed in controls. Absolute neutrophil 
count and neutrophil/lymphocyte ratio were also higher in patients, though without statistical significance. The parameters 
that were statistically significant related with adiposity markers were neutrophil count and CRP levels. The neutrophil 
count was positively and statistically correlated with body mass index (BMI), BMI z-score, waist circumference and 
waist/height ratio, and also with CRP levels. In multiple regression analysis, the only variable that remained statistically 
associated with neutrophil count was CRP (neutrophil count = 2.612 + 0.439lnCRP; standardised coefficient/beta: 0.384, 
P=0.001). When performing multiple regression without CRP, the only variable that remained statistically associated with 
neutrophil count was BMI. 
Conclusions: our results demonstrated in obese patients aged 6-12 years, a significant change in the differential leukocyte 
count towards neutrophilia, together with a significant higher CRP concentration, and that absolute neutrophil count 
correlates with obesity markers and with CRP levels. Our data also indicate that neutrophil count, a current clinically used 
low-cost parameter, may be used as an obesity-related inflammatory marker in young obese patients.  
Keywords: Leukocytes, C-reactive protein, children obesity. 
1. INTRODUCTION 
 Obesity is increasing all over the world, particularly in 
industrialised countries, and is a significant risk factor for 
cardiovascular disease (CVD). This is of particular concern 
in our country, as demonstrated by the high prevalence of 
overweight/obesity (31.5%) in Portuguese children, 
compared to other European countries [1]. Furthermore, 
Portugal exhibits a high rate of CVD, particularly of 
cerebrovascular disease. 
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 Cardiovascular morbidity and mortality of obesity is 
associated with classic risk factors, namely dyslipidemia, 
hypertension and impaired glucose metabolism [2, 3]. 
Recently, it was shown that obesity may be regarded as a 
state of low-grade inflammation [3, 4] and atherosclerosis is 
accepted as an inflammatory process [5]. The adipocyte is an 
important source of cytokines, namely interleukin (IL)-6 and 
tumour necrosis factor (TNF)-alpha, and their levels are 
significantly higher in the plasma of obese patients [4, 6]. 
The rise in these cytokines, especially in IL-6, triggers an 
increased synthesis of C-reactive protein (CRP), one of the 
most sensitive makers of inflammation [7]. However, and 
although obesity is recognized as a possible cause for 
reactive leukocytosis [8], the contribution of leukocytes to 
the inflammatory process in obese patients is not fully 
understood.  
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 To date, limited investigations have examined the 
associations between white blood cell (WBC) count and 
obesity in children and adolescents. A National Health and 
Nutrition Examination Survey of the US population 
demonstrated that overweight is associated with higher WBC 
count in children [9]. Furthermore, a recent study performed 
in female obese adolescents showed that WBC count is 
positively related to body mass index (BMI), waist 
circumference, and total adipose tissue (TAT) and 
subcutaneous adipose tissue (SAT) areas [10]. After 
adjustment for metabolic risk factors, only neutrophil counts 
were positively related to BMI, waist circumference, and 
TAT; lymphocyte and basophil counts were negatively 
related to BMI and waist circumference [10]. This study was 
performed only in female adolescents (aged 10-19 years) and 
no control group was used.  
 It is still uncertain which WBC subfractions are more 
altered in obese children and adolescents, and how 
prematurely these changes occur in obesity. Thus, the aim of 
our work was to evaluate whether total and differential WBC 
counts are altered in young obese patients (aged 6-12 years) 
and if a relationship exists between WBC counts and the 
severity of obesity (according to BMI z-score, waist 
circumference and waist/height ratio) as well as with CRP 
level, a known sensitive marker of inflammation.  
2. MATERIAL AND METHODS 
2.1. Subjects 
 The protocol used for all participants was approved by 
the Committees on Ethics of the University Hospital S. João 
and of the Children’s Hospital Maria Pia, Porto. Obese 
patients, aged 6-12 years, were identified from medical 
records at the Departments of Pediatrics of Hospital Maria 
Pia and Hospital S. João, Porto. All children that reached 
inclusion criteria were invited to participate in the study. 
Seventy seven obese children participated in the study after 
informed and written consent of their parents. The study took 
place between May 2006 and March 2007. 
 Healthy control subjects, age and sex matched with obese 
patients, were recruited from the general population. 
 Obesity was defined as BMI greater than the 95th 
percentile for age and gender, according to 2000 Centre for 
Disease Control and Prevention (CDC) growth charts. 
Because BMI is not normally distributed, we used body-
mass index z-score (BMI z-sc); BMI z-sc values were 
achieved by using a calculator that has per basis the 2000 
CDC growth charts. 
 Clinical data regarding the sample population was 
collected. The physical examination included the 
measurement of height, weight, waist circumference, and the 
presence of skin lesions related with obesity and its co-
morbidities. 
 The participants were invited to the research centers after 
an overnight fast and, after clinical examination, blood was 
collected for laboratory analysis. 
 Smokers, subjects with diabetes mellitus, endocrine 
disorders, hereditary diseases, inflammatory or infectious 
diseases or under any therapy that could interfere with our 
results were excluded from the study. 
2.2. Procedures and Assays 
2.2.1. Blood Samples 
 Fasted blood samples were obtained and processed 
within 2h of collection. Blood was obtained by venipuncture 
in EDTA containing tubes. Plasma aliquots were made and 
immediately stored at  70oC until assayed. 
2.2.2. Laboratory Analysis 
 Total WBC count was performed by using an automatic 
blood cell counter (ABX Micros 60-OT). Blood cell 
morphology and WBC differential count were evaluated in 
Wright stained blood films. The plasma levels of CRP were 
evaluated by immunoturbidimetry [CRP (latex) High-
Sensitivity, Roche Diagnostics]. 
2.3. Statistical Analysis 
 Statistic analysis was performed using the Statistical 
Package for Social Sciences (SPSS, version 17.0) for 
Windows. Kolmogorov-Smirnov analysis was used to test if 
the results were normally distributed. The results normally 
distributed are presented as mean ± SD and those not-
normally distributed are presented as median (interquartile 
range).  
 Controls and obese patients were compared using 
Student’s unpaired t test or Mann-Whitney U test. The 
distribution of males and females with respect to categorical 
variables was analysed using chi-squared (2) test and 
Fisher’s exact test.  
 The strength of the association between the substances 
was estimated by Pearson correlation coefficient, after 
logarithmic transformation of the variables (when 
necessary). To evaluate the contribution of the different 
variables to neutrophil count, we performed multiple 
regression analysis, using stepwise selection, with an entry 
criteria of P <0.05. Significance was accepted at P less than 
0.05. 
3. RESULTS 
 The demographic and clinical characteristics of the obese 
participants (n=77) and controls (n=19) are presented in 
Table 1. The groups were matched for age and gender; as 
expected, BMI and BMI z-sc values were significantly 
higher in patients.  
 Obese participants presented with a statistically 
significant higher neutrophil percentage and CRP levels 
(Table 2). Absolute neutrophil count and neutrophil/l 
ymphocyte ratio were also higher in patients, though without 
statistical significance. 
 Concerning the comparison between boys and girls, no 
statistical significant differences were observed within both 
groups (data not shown). 
 The correlations between CRP levels and the absolute 
count for each type of leukocyte with adiposity markers are 
presented in Table 3. The only parameters that were 
statistically significant related with adiposity markers were 
neutrophil count and CRP levels. The neutrophil count was 
positively and statistically correlated with BMI, BMI z-sc, 
waist circumference and waist/height ratio, and also with 
CRP levels. In the multiple regression analysis, the only 
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Table 1. Characteristics of the Studied Subjects 
 Controls 
(n = 19) 
Obese patients 
(n = 77) 
P  
Age (years) 8.5 ± 1.6 9.1 ± 1.6 0.133 
Gender male (n) 7 (36.8%) 32 (41.6%) 0.708 
BMI (kg/m
2
) 16.27 ± 1.54 27.48 ± 3.73 <0.001 
BMI z-sc 0.005 ± 0.820 2.331 ± 0.317 <0.002 
Waist circumference (cm) - 86.9 ± 10.2 - 
Waist/Height ratio - 0.609 ± 0.054 - 
Values are given as mean ± SD, unless otherwise indicated.  
 
Table 2. Total and Differential Leukocyte Counts and CRP Levels in Controls and Obese Patients Aged 6-12 Years 
 Controls  
(n = 19)  
Obese patients  
(n = 77) 
P  
WBC (x 10
9
/l)  7.13 ± 1.94  7.37 ± 1.75  0.597  
Neutrophils (%) 47.61 ± 9.59  51.86 ± 7.91  0.048  
Eosinophils (%) 5.26 ± 5.02 3.65 ±2.20 0.186 
Basophils (%)  0.47 ± 0.34  0.53 ± 0.31  0.453 
Lymphocytes (%)  41.18 ± 9.49  38.39 ± 7.50  0.172  
Monocytes (%) 5.47 ± 1.64 5.57 ± 1.69 0.814 
Neutrophils (x 10
9
/l)  3.43 ± 1.31 3.87 ± 1.29 0.186 
Eosinophils (x 10
9
/l)  0.42 ± 0.48 0.26 ± 0.16 0.176 
Basophils (x 10
9
/l)  0.04 ± 0.03 0.04 ± 0.02 0.462 
Lymphocytes (x 10
9
/l)  2.85 ± 0.75 2.79 ± 0.71 0.739 
Monocytes (x 10
9
/l)  0.39 ± 0.13 0.40 ± 0.12 0.664 
Neutrophil/lymphocyte ratio  1.28 ± 0.53 1.44 ± 0.49 0.193 
CRP (mg/l)  0.32 (0.19-0.89)  1.73 (0.82-3.67)  <0.001  
Values are given as mean ± SD or median (interquartile range). 
 
Table 3. Correlations Between CRP Level and the Absolute Count for Each Type of Leukocytes with Adiposity Markers, in Obese 
Patients Aged 6-12 Years 
 Neutrophils (x10
9
/l) Lymphocytes (x10
9
/l) Monocytes (x10
9
/l) Eosiniphols (x10
9
.l) Basophils (x10
9
.l) Ln PCR 
BMI (kg/m
2
) 0.289* 0.046 0.076 0.089 0.058 0.261* 
BMI z-sc 0.249* 0.120 0.058 0.064 0.113 0.313** 
Waist 
circumference (cm) 
0.225* 0.089 0.101 0.019 -0.017 0.188 
Waist/height ratio 0.230* 0.178 0.099 0.175 0.097 0.317** 
Ln CRP 0.384** 0.075 0.295* 0.014 0.051 - 
*P<0.05; **P<0.01. 
variable that remained statistically associated with neutrophil 
count was CRP (neutrophil count = 2.612 + 0.439lnCRP; 
standardised coefficient/beta: 0.384, P=0.001); BMI was 
excluded from this model but its partial correlation almost 
reached statistical significance (0.212, P=0.067). When 
performing multiple regression without CRP, the only 
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variable that remained statistically associated with neutrophil 
count was BMI (neutrophil count = 1.117 + 0.100BMI; 
standardised coefficient/beta: 0.289, P=0.011). 
4. DISCUSSION 
 Leukocytosis is often associated with atherosclerotic 
disease and is accepted as a risk factor for CVD [11-13]. The 
association between leukocyte count and risk of 
atherosclerotic disease is plausible because leukocytes give a 
major contribution to the rheologic properties of blood, alter 
their own adhesive properties under stress and participate 
also in endothelial injury [11]. Moreover, the recruitment of 
monocytes and lymphocytes to the artery wall is 
characteristic of atherosclerosis [14].  
 Atherosclerosis is a chronic disease that begins early in 
life. Obesity is an important risk factor for the development 
of CVD, but, to date, limited investigations have examined 
the associations between WBC count and obesity in children 
and adolescents. 
 A study on subjects who were referred for further 
evaluation of leukocytosis by their family physicians 
demonstrated that obesity is the second most common cause 
of leukocytosis, being smoking the commonest cause [8]. 
Furthermore, in a previous large cross-sectional 
epidemiological study, performed in adults, an increased 
BMI was a statistically significant independent predictor of a 
higher peripheral blood leukocyte count [15]. Leptin, IL-1, 
IL-6 and TNF-, all produced by the human adipose tissue, 
have been implicated in this leukocyte rise [8, 14, 16, 17]. 
However, as far as we know, this is the first study assessing 
the association of leukocyte count with obesity and its 
associated inflammation, assessed by CRP levels, in obese 
patients and (lean) controls aged 6-12 years.  
 As leukocyte count changes with age and is influenced 
by gender [15], we matched controls and patients for gender 
and age. We chose participants aged 6-12 years, as in this 
age range it is not normally observable significant changes in 
leukocyte counts. In our study, we also did not find any 
significant correlation between total and differential 
leukocyte counts with age. 
 The median CRP value was about 5 times higher than 
that observed in controls, demonstrating an inflammatory 
process in such young obese patients (Table 2). The total 
leukocyte count did not show a statistically significant 
change in obesity, but a different ratio between the different 
leukocyte types was observed, as showed by the significantly 
higher value in the percentage of neutrophils with obesity. 
Even though no significant differences in absolute neutrophil 
count were observed, patients presented a trend to higher 
values. Moreover, absolute neutrophil count correlated not 
only with markers of obesity but also with CRP levels. This 
suggests that neutrophil count may be used as a marker of 
obesity severity, with its associated inflammatory state. The 
fact that CRP levels remained statistically associated with 
neutrophil count by multiple regression analysis may be 
explained by the fact that there are cytokines, produced and 
released by the adipocyte, namely IL-6 and IL-1, that are 
able to induce both an increase in CRP synthesis and 
neutrophilia via demargination of neutrophils from the 
marginal “pool”, acceleration of bone marrow neutrophil  
 
release or enhancement of bone marrow granulopoiesis [7, 
18, 19]. It is worthy to emphasise that in our study, when 
CRP was removed from the model, BMI was the only 
variable that remained statistically associated with neutrophil 
count. 
 The significant positive correlations that we found 
between neutrophil count and BMI and waist circumference 
values are in agreement with those obtained by Kim and 
Park [10] in female obese adolescents aged 10-19 years. 
However, we were unable to find any correlation with 
absolute lymphocyte count. Kim and Park [10] also found 
that WBC count is strongly related to subcutaneous rather 
than visceral adiposity.  
 There are a lot of beneficial effects on health resulting 
from moderated aerobic physical exercise, namely a 
reduction in obesity markers (e.g. BMI) and in risk of type 2 
diabetes, and an improvement in endothelial function and 
lipid profile, all risk factors for CVD [20-23]. Data from 
large study populations also suggest an inverse association 
between chronic physical activity and the level of some 
inflammatory markers (e.g. CRP and interleukin-6) [21, 24, 
25]. In obese adult subjects who lost weight significantly, 
leukocytosis and the acute-phase reactants seem to gradually 
return to normal [8]. However, few data exists in literature 
regarding young obese subjects. It was shown that 3 months 
of moderate lifestyle intervention in obese adolescents seems 
to attenuate the inflammatory state associated with obesity, 
as observed by a reduction in elevated circulating 
concentrations of CRP, fibrinogen and IL-6, non-traditional 
risk factors for CVD [16]. However, and despite the 
consistency of the results, the small sample size of this study 
(n = 8 in the intervention group) calls for attention in 
strengthening these results with further studies. Reinehr et al. 
[26], by evaluating 16 obese children who lost weight over a 
1-year period, found a significant decrease in CRP but no 
significant changes in TNF-alpha levels. If future research 
supports the idea that, at young ages, the protection provided 
by regular physical activity against obesity-mediated 
inflammation is relevant, this would encourage even more its 
practice. Moreover, at these young ages, this would also be a 
good opportunity to implement healthy lifestyles. 
 In conclusion, our results demonstrated a significant 
change in the differential leukocyte count towards 
neutrophilia, together with a significant higher CRP 
concentration, in obese patients aged 6-12 years, and that 
absolute neutrophil count correlates with obesity markers, 
especially BMI, and with CRP levels. Our data also indicate 
that neutrophil count, a current clinically used low-cost 
parameter, may be used as an obesity-related inflammatory 
marker in young obese patients. However, more studies are 
needed to confirm our findings, involving larger number of 
cases. Furthermore, young obese patients may deserve from 
physical activity programs. 
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Abstract: Objectives: Evaluate cardiovascular risk factors in Portuguese obese children and adolescents and the long-term 
effects of lifestyle modifications on such risk factors. 
Design: Transversal cohort study and longitudinal study.  
Setting: University Hospital S. João and Children’s Hospital Maria Pia, Porto.  
Patients/Participants: 148 obese children and adolescents [81 females (54.7%); mean age of 11.0 years] and 33 controls 
(sex and age matched) participated in a cross-sectional study. Sixty obese patients agreed to participate in an one year 
longitudinal study after medical and nutritionist appointments to improve lifestyle modification; a substantial body mass 
index (BMI) reduction was defined by a decrease in BMI z-score (BMI z-sc) of 0.3 or more over the studied period. 
Main Outcome measures: Lipid profile (triglycerides, cholesterol, HDLc, LDLc, lipoprotein (a), apolipoproteins A and B) 
and circulating levels of C-reactive protein (CRP), adiponectin, glucose, and insulin.  
Results: Compared with the lean children, obese patients demonstrated statistically significantly higher insulin resistance 
index [Homeostasis model assessment (HOMA)], and triglycerides, LDLc, apolipoprotein (apo) B, insulin and CRP 
concentrations, whereas their HDLc and apo A levels were significantly lower (cross-sectional study). In the longitudinal 
study (n=60), a substantial BMI reduction occurred in 17 (28.3%) obese patients which led to a significant reduction in 
triglycerides, cholesterol, LDLc, apo B, glucose and insulin levels and in HOMA. The !BMI values over the studied 
period correlated inversely and significantly with BMI (P<0.001) and HOMA (P=0.026) values observed at baseline. In 
multiple linear regression analysis, BMI at baseline remained associated to changes in BMI over the studied period 
(standardised Beta: -0.271, P=0.05). 
Conclusion: Our data demonstrates that small reductions in BMI-zc, imposed by lifestyle modifications in obese children 
and adolescents, improve the cardiovascular risk profile of such patients. Furthermore, patients with higher BMI and/or 
insulin resistance seem to experience a greater relative reduction in their BMI after lifestyle improvements. 
Keywords: Lipid profile, insulin resistance, inflammation, childhood obesity, lifestyle modifications. 
1. INTRODUCTION 
 Obesity is increasing all over the world both in developed 
and underdeveloped countries [1, 2] and is known to be  
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associated with inflammatory changes, insulin resistance and 
with a hyperlipidemic state [3]. The adipocyte is an 
important source of cytokines, namely plasminogen activator 
inhibitor type 1 (PAI)-1, leptin, interleukin (IL)-6 and tumor 
necrosis factor (TNF)-alpha, and their levels are significantly 
higher in the plasma of obese patients [4]. Moreover, some 
inflammatory markers, such as C-reactive protein (CRP), 
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show an independent positive association with body mass 
index (BMI) [5]. 
 Cardiovascular (CV) morbidity and mortality is 
associated with the classic risk factors, namely dyslipidemia, 
hypertension and impaired glucose metabolism. However, 
more recently, inflammatory mechanisms were recognized as 
playing a vital role in initiation, maintenance and 
progression of atherosclerotic vascular disease. 
Atherosclerosis is an inflammatory disease with the 
participation of leukocytes and several cytokines. Among 
several inflammatory markers that have been shown to 
predict CV events [namely IL-6, tumor necrosis factor-alpha 
and soluble intercellular adhesion molecule (ICAM)-1] CRP 
levels have emerged as the most powerful marker [6]. 
 Regular physical activity is known to reduce obesity-
related markers and risk of type 2 diabetes (physical activity 
is associated with improved insulin sensitivity) and to 
improve endothelial function, lipid profile (e.g., exercise 
decreases plasma triglycerides (TG) and increases high 
density lipoprotein (HDL), as well as several oxidative 
stress/inflammatory markers, all risk factors for CV disease 
(CVD) [7-10]. Diet restriction per se may reduce fat mass, 
total cholesterol (Chol) and low density lipoprotein 
cholesterol (LDLc) without apparent effect in HDL and 
limited effect on insulin resistance. The effect of both diet 
and physical exercise in obese individuals appear to be 
additive with greater impact in the improvement of lipid 
profile and insulin resistance [11]. However, few data exists 
in literature regarding the long-term effects of physical 
activity on young obese subjects. Moreover, in most studies, 
children obey to a restricted physical exercise program or a 
food intake program, but the effect of “natural” lifestyle 
modifications on CV risk factors has been poorly explored 
[12-14].  
 Higher cardiorespiratory fitness (CRF) has been 
associated to a decrease in CVD risk markers, CVD 
morbidity and mortality [15]. Besides physical activity, the 
initial CRF of an individual appears to be an independent 
predictor of weight variation. Individuals with lower CRF 
are more prone to gain weight when compared to those with 
higher CRF [16]. Actually, children with lower CRF usually 
present diminished levels of physical activity and increased 
time expended in sedentary behaviours. Despite the strong 
genetic influence, CRF status can be modulated through 
physical activity, which is a main determinant of CRF in 
pediatric populations [17]. 
 The physical activity performed by children and 
adolescents in southern European countries is lower than in 
countries from centre and northern Europe. This fact may 
explain the geographical differences in obese prevalence 
found in Europe [17]. In fact, recent studies showed a very 
high prevalence of overweight/obesity (about 30%) in 
Portuguese children when compared to other European 
countries [18, 19]. Thus, the study of obesity is of particular 
importance in our country.  
 The aim of this study was to evaluate the short-term 
effects of lifestyle modifications, through a decrease in body 
mass index z-score (BMI z-sc), on CV risk factors 
(circulating levels of C-reactive protein, glucose, insulin and 
lipid profile), in Portuguese obese children and adolescents. 
2. MATERIAL AND METHODS 
2.1. Subjects 
 The protocol used for all participants was approved by 
the Committees on Ethics of the University Hospital S. João 
and of the Children’s Hospital Maria Pia, Porto. Obese 
children and adolescents, aged 5-18 years, were identified 
from medical records, at the Departments of Pediatrics of the 
referred hospitals.  
 Obesity was defined as BMI greater than the 95
th 
percentile for age and gender, according to 2000 Centers for 
Disease Control and Prevention (CDC) growth charts. 
Because BMI is not normally distributed and not adjusted for 
sex and age we used BMI z-sc. 
 One hundred and forty eight (n=148) obese children and 
adolescents participated in the study after informed and 
written consent from their parents. Thirty three healthy 
control subjects, age and sex matched with obese patients, 
were recruited from the general population. The BMIs of the 
controls were lower than the 85
th
 percentile adjusted for sex 
and age. Obese patients were evaluated at the beginning of 
the study and compared with controls (cross-sectional study).  
 All obese individuals (n=148) were motivated to change 
their lifestyle habits (conventional weight loss programs 
based on dietary counseling and encouragement to exercise), 
but only sixty patients agreed to participate in a longitudinal 
study (one year of follow up). A substantial BMI reduction 
was defined by a decrease in BMI z-sc of 0.3 or more over 
the studied period. One year after the beginning of lifestyle 
modification intervention, obese children/adolescents were 
classified as: 1) those who have achieved a substantial BMI 
reduction or 2) those who have not achieved a substantial 
BMI reduction. In the longitudinal study, clinical and 
biochemical data were obtained at the beginning as well as at 
the conclusion, after one year of follow-up. 
 Criteria of exclusion were: smokers, subjects under 
regular medication or with diabetes mellitus, endocrinologic 
disorders, and hereditary, inflammatory or infectious 
diseases. 
2.2. Procedures and Assays 
2.2.1. Clinical Examination 
 The participants were invited to the research centers after 
an overnight fast and clinical data regarding the sample 
population was collected. The development of puberty was 
clinically assessed on the basis of Tanner stages. The 
physical examination included the measurement of height, 
weight and the observation of the presence of cutaneous 
markers related with obesity and its comorbidity. 
2.2.2. Blood Samples 
 Blood samples were obtained on a fasting basis and 
processed within 2h of collection. Blood was obtained by 
venipuncture in ethylenediaminetetraacetic acid (EDTA) 
containing tubes. Plasma aliquots were made and 
immediately stored at - 70
o
C until assayed. 
2.2.3. Laboratory Analysis 
 The determination of circulating levels of glucose, 
insulin, lipids, and lipoproteins was performed by using 
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routine automated technology (Glucose, Insulin, Cholesterol, 
Triglycerides, HDL Cholesterol Direct, LDL Cholesterol 
Direct, Apolipoprotein (apo) A1 and apo B, ABX 
Diagnostics). Lipoprotein (a) ((Lp(a)) plasma concentration 
was determinated by an immunoturbidimetric method. 
 Homeostasis model assessment (HOMA), used to detect 
the degree of insulin resistance [20], was calculated by using 
the following formula: resistance (HOMA) = (fasting insulin 
(µU/mL) " fasting glucose (mmol/L)/22.5).  
 Plasma levels of CRP were evaluated by 
immunoturbidimetry [CRP (latex) High-Sensitivity, Roche 
Diagnostics]. 
 Plasma concentration of adiponectin was evaluated by 
using a standard commercial enzyme-linked immunoassay 
(Adiponectin, R&D Systems). 
2.3. Statistical Analysis 
 Statistical analysis was performed using the Statistical 
Package for Social Sciences (SPSS, version 17.0) for 
Windows. Kolmogorov-Smirnov analysis was used to test if 
the results were normally distributed. Results with normal 
distribution were presented as mean ± standard deviation, 
whilst irregular distributions were presented as median 
(interquartile range).  
 To compare obese and control groups, Student’s unpaired 
t-test was used for parameters presenting a Gaussian 
distribution and the Mann-Whitney U-test in the case of a 
non-Gaussian distribution. To evaluate the differences 
occurring along the longitudinal study, we used the paired 
Student t test for parametric and Wilcoxon Signed Ranks 
Test for non-parametric variables. 
 Spearman’s rank correlation coefficient was used to 
evaluate relationships between sets of data.  
 To evaluate the contribution of the different variables to 
BMI reduction over the studied period, we performed 
multiple regression analysis, using stepwise selection with an 
entry criteria of P <0.05, after log transformation of the 
variables (when necessary). 
 Significance was accepted at P less than 0.05. 
3. RESULTS 
 The characteristics of the participants in the cross-
sectional study are presented in Table 1. Obese patients and 
controls were matched for age and gender. Compared with 
the lean children, obese patients demonstrated significantly 
higher insulin resistance index (HOMA), and TG, LDLc, apo 
B, insulin and CRP concentrations, whereas their HDLc and 
apo A levels were significantly lower (Table 2). The 
participants in the cross-sectional study had BMI which 
correlated positively and significantly to TG (r = 0.300, P < 
0.001), LDLc (r = 0.235, P = 0.001), insulin (r = 0.652, P < 
0.001), HOMA (r = 0.646, P < 0.001), and CRP (r = 0.451, 
P < 0.001) values, and negatively with HDLc (r = -0.462, P 
< 0.001). Adiponectin levels (n=153) correlated inversely 
and significantly with age (r = -0.299, P < 0.001), BMI (r = -
0.220, P = 0.006), TG (r = -0.390, P < 0.001) and total 
cholesterol/HDLc (Chol/HDLc) ratio (r = -0.270, P = 0.001), 
insulin (r = -0.211, P = 0.009) and HOMA (r = -0.223, P = 
0.006), and correlated positively and significantly with apo 
A (r = 0.214, P = 0.008) and HDLc (r = 0.270, P = 0.001).  
 Sixty obese patients participated in the longitudinal study 
and, after one year of follow up, 17 (28.3%) achieved a 
substantial BMI z-sc reduction (mean !BMI z-sc = -0.46 ± 
0.16), while 43 individuals did not reach the cut-off value 
(mean !BMI z-sc = 0.01 ± 0.26) (Table 3). At baseline (T1), 
no significant differences were observed in age, sex, BMI, 
BMI z-sc, and in any markers of the metabolic syndrome or 
inflammatory markers between obese children who 
presented with and without substantial BMI z-sc reduction, 
at the end of the study (T2). 
 A substantial decrease in BMI z-sc in 17 children led to a 
significant reduction in TG, cholesterol, LDLc, apo B, 
glucose, insulin levels and in HOMA (Table 4). In the 43 
children without change of BMI z-sc, a reduction in 
adiponectin and in glucose values occurred as well as a 
significantly increase in Lp(a) values (Table 4). 
 The !BMI values over the studied period (longitudinal 
study, n=60) correlated inversely and significantly with BMI 
at baseline (r = -0.487, P<0.001, Fig. 1A), and HOMA at 
baseline (r = -0.291, P=0.026, Fig. 1B). In multiple linear 
regression analysis, BMI values at baseline remained 
associated to changes in BMI over the studied period 
(standardised Beta: -0.271, P=0.05). 
4. DISCUSSION 
 The present study was able to demonstrate in young 
obese patients that small reductions in BMI z-sc are 
associated with significant improvements in lipid profile and 
in insulin resistance index.  
Table 1. Characteristics of the Participants in the Cross-Sectional Study 
 Controls (n=33) Obese (n=148) p 
Age (years) 10.2 ± 3.6 11.0 ± 3.0 0.173 
Sex (female) 20 (60,6%) 81 (54,7%) 0.852 
Weight (kg) 34.7 ± 12.8 69.0 ± 22.8 <0.001 
BMI (kg/m#) 17.4 ± 2.2 29.8 ± 5.4 <0.001 
BMI z-score 0.09 ± 0.68 2.30 ± 0.44 <0.001 
BMI, body mass index. 
Values are given as mean ± SD, unless otherwise indicated. 
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Table 2. Biochemical Data of the Participants in the Cross-Sectional Study 
  Controls (n=33) Obese (n=148) p 
Lipid profile 
TG (mmol/l) 0.72 (0.57-0.85) 0.86 (0.60-1.25) 0.017 
Chol (mmol/l) 4.29 (3.82-4.81) 4.11 (3.68-4.60) 0.241 
HDLc (mmol/l) 1.25 (1.12-1.33) 1.09 (0.92-1.24) <0.001 
LDLc (mmol/l) 2.31 (1.85-2.65) 2.63 (2.20-3.10) 0.001 
Lpa (mg/dl) 28.6 (18.1-50.3) 25.8 (10.6-46.5) 0.194 
Apo A (mg/dl) 132.5 ± 9.7 118.5 ± 18.2 <0.001 
Apo B (mg/dl) 73.8 ± 15.8 81.3 ± 20.3 0.042 
Chol/HDLc 3.53 (3.12-3.91) 3.86 (3.26-4.56) 0.017 
Apo A/Apo B 1.89 ± 0.50 1.53 ± 0.41 <0.001 
Glucose metabolism 
Glucose (mmol/l) 4.90 (4.68-5.17) 5.00 (4.80-5.20) 0.174 
Insulin (mmol/l) 5.28 (4.11-6.82) 12.95 (8.92-18.88) <0.001 
HOMA 1.14 (0.84-1.47) 2.90 (1.94-4.24) <0.001 
Inflammatoy markers 
Adiponectin (mg/l) 7.83 (5.15-10.01)* 7.99 (5.19-11.12)** 0.884 
CRP (mg/l) 0.25 (0.18-0.68) 1.64 (0.80-3.66)  <0.001 
*, n=14; **, n=139 ; Values are given as mean ± SD or median (interquartile range). 
TG, triglycerides; Chol, cholesterol; HDLc, High Density Lipoprotein cholesterol; LDLc, Low Density Lipoprotein cholesterol; Lp(a), lipoprotein (a); apo, apolipoprotein; HOMA, 
Homeostasis Model Assessment (insulin resistance index); CRP, C-reactive protein. 
 
Table 3. Characteristics of the Participants in the Longitudinal Study (One Year of Follow-Up) 
! BMI z-sc < 0,3 (n=43)  ! BMI z-sc " 0,3 (n=17)  
 T1 T2 p T1 T2 p 
Age (years) 11.5 ± 2.21 12.6 ± 2.2 <0.001 11.5 ± 3.0 12.6 ± 3.0 <0.001 
Weight (kg) 70.2 ± 19.1 78.0 ± 18.0 <0.001 69.9 ± 16.7 67.5 ± 13.4 0.191 
Waist/Hip 0.928 ± 0.054 0.920 ± 0.065 0.347 0.912 ± 0.028 0.905 ± 0.059 0.630 
Waist/Height 0.609 ± 0.059 0.616 ± 0.058 0.354 0.628 ± 0.045 0.569 ± 0.057 <0.001 
BMI (kg/m#) 29.2 ± 4.8 30.6 ± 4.8 0.005 30.2 ± 4.0 27.1 ± 3.1 <0.001 
BMI z-score 2.14 ± 0.36 2.15 ± 0.32 0.845 2.36 ± 0.68 1.90 ± 0.65 <0.001 
BMI, body mass index Values are given as mean ± SD. 
 In a first analysis (cross-sectional study) we compared 
obese patients with a lean control group. As some of the 
studied CV risk factors change with age and are influenced 
by gender, we matched controls and patients for gender and 
age. The results obtained confirm obesity as an inflammatory 
disease. Indeed, the median CRP value observed in obese 
children and adolescents was about 6 times higher than that 
observed in controls, demonstrating an inflammatory process 
in such young patients (Table 2). We also observed that 
obese patients presented with an altered lipid profile and 
raised markers of insulin resistance when compared with 
controls (Table 2). 
 There are few studies assessing the long-term changes of 
lifestyle modifications in obese children and adolescents, 
particularly on CV risk factors. In the present longitudinal 
study, obese patients (children and adolescents) were asked 
to improve their lifestyle habits (conventional weight loss 
programs based on dietary counselling and encouragement to 
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Table 4. Biochemical Data of the Participants in the Longitudinal Study (One Year of Follow-Up) 
! BMI z-sc < 0,3 (n=43) ! BMI z-sc " 0,3 (n=17) 
 T1 T2 p T1 T2 p 
Lipid profile 
TG (mmol/l) 0.77 (0.50-1.02) 0.65 (0.51-0.95) 0.795 0.87 (0.64-1.30) 0.63 (0.50-0.90) 0.003 
Chol (mmol/l) 3.93 (3.50-4.68) 4.10 (3.51-4.50) 0.929 4.24 (3.80-4.70) 4.00 (3.58-4.24) 0.009 
HDLc (mmol/l) 1.14 (0.98-1.32) 1.13 (0.93-1.31) 0.960 1.13 (0.98-1.26) 1.17 (0.92-1.32) 0.819 
LDLc (mmol/l) 2.59 (2.20-3.00) 2.47 (2.21-2.90) 0.534 2.69 (2.30-3.24) 2.42 (2.06-2.69) 0.007 
Lpa (mg/dl) 19.0 (10.0-43.0) 28.0 (12.6-48.6) 0.011 22.0 (14.0-49.1) 30.60 (8.29-51.55) 0.403 
Apo A (mg/dl) 118.5 ± 18.5 114.1 ± 18.0 0.052 118.3 ± 22.4 109.8 ± 17.4 0.060 
Apo B (mg/dl)  75.9 ± 16.0 73.8 ± 17.2  0.498 79.8 ± 14.7 72.9 ± 14.1 0.013 
Chol/HDLc 3.68 (3.17-4.16) 3.60 (3.10-4.50) 0.808 3.91 (3.34-4.24) 3.50 (3.05-4.20) 0.416 
Apo A/Apo B  1.62 ± 0.40  1.60 ± 0.33 0.780 1.54 ± 0.44 1.55 ± 0.37  0.803 
Glucose metabolism 
Glucose (mmol/l) 5.00 (4.83-5.22) 4.80 (4.50-5.10) 0.014 5.00 (4.64 - 5.28) 4.57 (4.04-4.98) 0.002 
Insulin (mmol/l) 12.70 (9.50-15.70) 11.40 (9.54-16.60) 0.395 14.40 (11.60 - 17.80) 10.90 (7.6-14.38) 0.015 
HOMA 2.80 (2.14-3.56) 2.33 (1.82-3.31) 0.255 3.01 (2.41 - 4.24) 1.98 (1.51-2.89) 0.007 
Inflammatoy markers 
Adiponectin (mg/l) 8.58 (5.56-11.66) 6.04 (4.74-9.13) 0.004 9.28 (7.37 - 15.02) 10.17 (6.63-14.22) 0.675 
CRP (mg/l) 1.61 (0.82-4.62) 1.67 (0.78-4.12) 0.402 0.94 (0.43 - 2.02) 1.07 (0.54-2.38) 0.213 
 
     
Fig. (1). Associations between change in body mass index (BMI) over the studied period (one year of follow-up) and BMI and insulin 
resistance index (Homeostasis model assessment; HOMA) values presented by participants at baseline. Spearman’s rank correlation 
coefficient values are shown. 
exercise) and an objective measure (BMI z-sc reduction) was 
used to observe which children achieved the objective after 
one year of follow-up. We observed that 17 patients (28.3%) 
presented a significant reduction in BMI z-sc (0.3 or more 
(!BMI $ -0.3)) over the studied period and that changes in 
BMI over the studied period were independently associated 
with BMI values presented at baseline. It seems that patients 
with higher BMI experience a greater relative reduction in 
their BMI (Fig. 1). Also, the correlation between HOMA in 
the beginning of the study and relative BMI reduction points 
to a predisposition for children who are more insulin 
resistant to lose more weight. These associations can be 
related to a change in body physiology towards weight loss.  
 In our longitudinal study, children did not obey to a 
restricted physical exercise program or a food intake 
programme. Also, it was not controlled the initial CRF of our 
population. Thus, it is impossible to know the possible 
impact of CRF in BMI z-sc reduction. It is true that the lack 
of standardisation on plans on intervention may mitigate the 
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interpretation of the results that we observed. On the other 
hand, the counseling to improve lifestyle habits may be a 
“more natural” approach, and is useful in clinical practice, as 
participants can directly observe the real benefits of 
changing their lifestyle habits. Furthermore, the reduction in 
BMI-zc that we observed is likely to express a real change in 
lifestyle habits. 
 It was shown that 3 months of moderate lifestyle 
intervention (45 min of physical activity 3 times per week) in 
obese adolescents seems to attenuate the inflammatory state 
associated with obesity, as observed by a reduction in 
elevated circulating concentrations of CRP, fibrinogen and 
IL-6, non-traditional risk factors for CVD [12, 14]. Reinehr 
et al., by evaluating 16 [14] and 10 [13] obese children who 
lost weight over a 1-year period, found a significant decrease 
in CRP but no significant changes in TNF-alpha levels. In 
the studies performed by Reinehr et al., obese children 
participated in a 1-year obesity intervention program and the 
cut-off value used for BMI z-sc reduction was 0.5. As we 
used a smaller cut-off value (0.3), this may explain why we 
did not observe significant changes in CRP levels. Indeed, 
CRP shows a positive association with BMI, and our cut-off 
value may be insufficient to observe clear improvements in 
CRP. Even thus, it is important to emphasize that in our 
study, involving a larger number of participants, 64.3% of 
the patients that reduced their BMI z-sc presented a decrease 
in circulating CRP levels, in contrast with the group without 
change of BMI z-sc (47.6%). Furthermore, we were able to 
demonstrate that smaller reductions in BMI z-sc are 
associated with significant improvements in lipid profile and 
in insulin resistance index HOMA. Previous studies 
suggested that the improvement of insulin sensitivity and CV 
risk factors in obese children only occurs if BMI z-sc 
decreases by at least 0.5 over a 1-year period [21], but our 
data suggests that such improvements may be observable 
with smaller reductions in BMI-zc. Again, our results are 
probably explained by the fact that the reductions that we 
observed in BMI z-sc are likely to express a continuous daily 
motivation in changing lifestyle habits. Nevertheless, 
although there was no change in HDLc, the lower values of 
HOMA together with the reduction in TG seen in the group 
that reached the cut-off values leads to the probable 
influence of concomitant changes in diet and in the levels of 
physical exercise in this group to be linked with the 
improvement seen in the global CV risk profile. 
 The improvement in insulin sensitivity with BMI z-sc 
reduction observed in our study is of particular importance, 
as insulin resistance represents a major underlying 
abnormality driving CVD [22]. It is important to emphasize 
that insulin resistance associates with increased TG and that 
one of the most striking findings in the longitudinal analysis 
of the present study was the reduction in TG levels. 
Although hypercholesterolemia is a major risk factor for the 
initiation and progression of atherosclerosis [23], 
hypertriglyceridemia and elevated levels of triglyceride 
(TG)-rich lipoproteins have recently re-emerged as risk 
factors for atherosclerosis [24]. TG-rich particles may 
directly damage the endothelium principally via oxidative 
mechanisms. Also, an important consequence of 
hypertriglyceridemia, relating to increased atherosclerotic 
risk, is a shift in the spectrum of LDL subfractions towards 
smaller, denser species, which are believed to be more 
atherogenic [25]. Moreover, raised TG levels are frequently 
associated with reduced HDL levels. In our study, we only 
observed a slight (non-significant) increase in HDLc levels, 
which seems to have a protective role in the development of 
atherosclerosis [26-28]. Reinehr et al. observed a trend to 
increase HDLc levels in patients who achieved a substantial 
BMI z-sc reduction [14]. 
 Plasma Lp(a) levels are known to be mainly genetically 
determined [29, 30]. However, it appears that plasma Lp(a) 
concentration increases with age. In our study, Lp(a) levels 
were similar betweens controls and obese individuals but, in 
the longitudinal study an increase in this lipoprotein was 
observed (Table 4). In fact, this increase achieved 
statistically significance in the group without a substantial 
reduction in BMI z-sc. Thus, our data is in agreement with 
the idea that ageing elevates plasma Lp(a) concentration, and 
that this increment might be modulated be lifestyle 
modifications. 
 Adiponectin is an adipocytokine that has been noted as 
an important antiantherogenic, antidiabetic and as an anti-
inflammatory protein [31]. Adiponectin seems to be 
inversely related to systolic blood pressure, waist 
circumference, triglycerides, and 2-hour glucose levels, 
while powsitively related to HDL [32]. These associations 
are in agreement with the results obtained in our cross-
sectional study. However, and although it was suggested that 
adolescent obesity is associated with low plasma adiponectin 
levels [33], we were unable to find statistically significant 
differences in plasma levels of adiponectin between obese 
children and controls. This may be explained by the fact that 
we defined controls as having a BMI lower than the 85
th
 
percentile adjusted for sex and age, in contrast with other 
work where control group was defined as a group of 
adolescents who had a BMI between the 50
th
 and 75
th
 
percentiles [33].  
 Regarding our longitudinal study, it is important to 
highlight that adiponectin levels decreased significantly in 
the group without BMI z-sc reduction, in contrast with a 
moderate (non-significant) increase in the group that 
presented a significant decrease in BMI z-sc. It was 
previously reported that a significant weight loss in children, 
defined as BMI z-sc reduction of 0.5 or more, is associated 
with a significant increase in adiponectin [34]. Considering 
the protective effects of adiponectin, it seems reasonable to 
hypothesize that the increase in adiponectin is likely to 
explain, at least in part, some of modifications in the lipid 
profile (namely the reduction in triglycerides) and in glucose 
metabolism associated with BMI z-sc reduction. 
 The concern with childhood obesity must begin in 
overweight children and not only in severe obese children as 
it is easier to intervene in an early phase. Besides, there are 
studies that point that the majority of the diseases appear in 
individuals with moderated elevated risk factors [35].  
 Further studies involving a standardized physical activity 
and diet programs together with the assessment of important 
variables as CRF, at baseline and through the study period, 
could help to better understand the process involved in 
weight loss differences found among children and, also, the 
relation between the changes in adiposity and variations in 
CVD risk markers. 
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 In summary, our data demonstrates that lifestyle 
modifications in obese children and adolescents, even 
associated with small reductions in BMI z-sc, improve the 
CV risk profile, namely lipid profile and insulin resistance. 
This may be important in motivating patients as health 
changes can appear earlier than the esthetical ones. 
Furthermore, patients with higher BMI and/or insulin 
resistance seem to experience a greater relative reduction in 
their BMI after lifestyle improvements, probably due to a 
physiologic adaptation favoring weight loss.  
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Abstract 
Background: Adiponectin circulates as low, medium and high molecular weight multimers 
(LMW, MMW and HMW) and influences lipid profile and insulin resistance (IR), being 
HMW considered the most biological-active form. We aimed to study the relation between 
adiponectin and markers of metabolic syndrome, in paediatric obesity, and the impact of 
physical exercise.  
Methods: The study consisted of a cross-sectional part and an 8-months physical 
exercise program. Lipid profile, insulin, glucose, C-reactive protein (CRP), total 
adiponectin (TA), and homeostasis model assessment insulin resistance (HOMA) were 
measured. Adiponectin multimers were studied in a pre-pubertal group. 
Results: Obesity associated with increased dyslipidaemia, IR and inflammation. TA 
correlated inversely with adiposity, triglycerides, HOMA and CRP, and positively with 
HDLc/Total Cholesterol (TC) ratio. HMW mimicked TA associations. The intervention 
program led to a reduction of TC, LDLc, insulin, HOMA and trunk percentage of fat, and 
an increase of HDLc/TC ratio, in the obese group. BMI improvements prevented 
adiponectin reduction and correlated with increments in HMW and MMW.  
Conclusions: Obesity-related increase in MS features might be linked to lower 
adiponectin. HMW and MMW were the multimers that most explained MS features. The 
intervention program improved the lipid profile and IR, and prevented the reduction of 
adiponectin. 
 
Keywords: childhood obesity, Metabolic Syndrome, intervention program, adiponectin, 
cardiovascular risk.  
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1. Introduction  
Adiponectin is mainly secreted by adipocytes in humans,(1, 2) but total adiponectin (TA) 
levels are paradoxically lower in obese children, and even lower in obese individuals with 
metabolic syndrome (MS).(3, 4)   
Adiponectin improves lipid metabolism by lowering the synthesis of free fatty acid and 
stimulating β-oxidation.(5) Furthermore, it is inversely related with triglyceride (TG) levels 
and positively related with high-density lipoprotein cholesterol (HDLc) concentration. A 
study from our group showed that adiponectin modulates the effect of apo E genotype on 
lipid profile. (6) Adiponectin also presents an anti-inflammatory action, e.g. it inhibits pro-
inflammatory tumour necrosis factor α (TNF-α) secretion by macrophages. This activity 
might have an important role in insulin resistance (IR), as TNF-α inhibits insulin 
signalling,(7, 8) while adiponectin increases insulin sensitivity.(9) 
In pediatric ages adiponectin levels correlate negatively with age.(6) The difference 
between genders is well established, with women presenting hig her adiponectin 
concentrations.(6, 10) Sexual hormones might underlie sex-related changes as before 
puberty no differences are found between genders.(11)  
The body fat distribution influences adiponectin levels, being abdominal obesity 
associated with lower concentrations.(4, 12) The association between central adiposity 
and reduced adiponectin was seen with visceral fat accumulation in children,(13) and 
adults.(14)  
Adiponectin circulates as 3 complexes: trimer, hexamers (two trimmers), and larger 
structures of trimers – 12 to 18mers being referred as low, medium and high molecular 
weight adiponectin, respectively (LMW, MMW, and HMW).(15)  
The different multimers are suggested to present different biological functions, but results 
are still inconclusive. HMW was described as a better marker of metabolic abnormalities 
in obese children than TA or the other multimers,(16) and to be particularly related to 
improved insulin sensitivity(17) and lipid profile.(18)  
The decrease of TA in obese children appears to be due mainly to the reduction of the 
HMW multimer.(16) Controversially, another study found no difference between obese 
and lean pre-pubertal boys regarding total and HMW adiponectin.(19)  
Diet-induced weight-loss in obese adults associated with an improvement in adiponectin 
levels, with no further impact from exercise.(20) Contrarily, another study found no impact 
on TA levels after a nutritional counselling program in pre-pubertal Portuguese children, 
despite the improvement in BMI z-score (BMIzsc) and blood lipids.(21) Different results 
were found in a study involving obese adolescent boys, as improvements in adiponectin 
levels were obtained both by energy restriction and by exercise separately, moreover, 
cumulative effects were present when both approaches were combined.(22)  
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The aims of this study were: 1)Clarify changes in circulating TA and related multimers in 
obese children and adolescents; 2)Evaluate adiponectin relation with markers of MS; 
3)Study the impact of regular physical exercise (PE) in adiponectin and in MS features.  
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2. Material and methods 
2.1. Subjects 
The study consisted of a cross-sectional and a longitudinal part. 
The cross-sectional study involved a 104 children and adolescents (59 females), aged 5-
18 years, after informed and written consent of their parents. The population was recruited 
in: 1)Two paediatric obesity outpatient clinics in Oporto; 2)A school-based PE program in 
5 primary and 2 middle and high public schools from Oporto suburban setting.  
The longitudinal study consisted of an 8-month PE program. Fifty-seven individuals 
completed the intervention (27 females).  
 
2.2. Procedures and assays 
 
2.2.1. Anthropometric and clinical evaluation 
Height and weight were evaluated. Waist circumference was measured. at the superior 
border of the iliac crest.(23) Obesity was defined as BMIzsc greater than +1.65 for age 
and gender, according to 2000 Centre for Disease Control and Prevention (CDC) growth 
charts. Body composition was evaluated by dual-energy X-ray absorptiometry (DEXA). 
Development of puberty was assessed by Tanner stages.  
 
2.2.2. Physical activity program 
 Participants were involved in an 8-month PE program (October 2011 to May 2012). Five 
hours per week of moderate-to-vigorous PE were lectured divided in 3 regular physical 
education classes, and 2 PE program classes. The PE aimed to increase moderate-
vigorous PE intensities. All activities were done in indoor schools´ sports facilities and 
taught by Physical Education teachers after school time. Procedures were approved by 
the Scientific Board of the Faculty of Sports, University of Oporto. 
 
2.2.3. Blood samples 
After an overnight fast, blood was obtained by venepuncture in EDTA containing tubes 
and processed within 2 hours of collection. Aliquots of plasma were made and stored at -
80oC until assayed. 
 
2.2.4. Biochemical Analysis 
Total cholesterol (TC), TG, HDLc, glucose, insulin and C-reactive protein (CRP) were 
measured using automated technology, as described elsewhere.(24) LDLc-cholesterol 
(LDLc) and very low density lipoprotein cholesterol (VLDLc) were calculated using 
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Friedewald formula.(25) Homeostasis model assessment of insulin resistance (HOMA) 
was determinate according to Matthews.(26)  
 
2.2.5. Adiponectin 
Total adiponectin (TA) 
Plasma concentration of TA was evaluated by a commercial enzyme-linked immunoassay 
(ELISA) (e-Bioscence, San Diego, CA). 
 
Adiponectin multimers 
Absolute and relative plasma concentration of adiponectin circulating multimers (HMW, 
MMW and LMW) was determined using a commercial available kit (Alpaco, Salem, NH). 
 
2.3. Exclusion criteria and ethical approval 
Smokers, subjects under regular medication or with diabetes mellitus, endocrinology 
disorders, hereditary, inflammatory or infectious diseases were excluded from the study.  
The protocol was approved by the Hospitals Committees of Ethics and the Regional 
Education Board, and schools agreed to participate.  
 
2.4. Statistical analysis 
Statistical analysis was performed using the Statistical Package for Social Sciences 
(SPSS, version 20). Kolmogorov-Smirnov analysis was used to test if the results were 
normally distributed. Results normally distributed are presented as meanstandard 
deviation, otherwise are presented as median (interquartile range). Variables which 
distribution differed from normal were transformed for better fitting. 
Distributions were analysed using chi-squared test and Fisher’s exact test.  
Differences between groups were assessed using Student’s t-test. The strength of the 
associations was estimated by Spearman correlation coefficient.  
Significance was accepted at P less than 0.05. 
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3. Results 
3.1. Cross-sectional study 
The control and obese groups were matched for sex, age and tanner stage. The obese 
individuals presented a lipid profile with significant cardiovascular risk changes, namely, 
higher TG, LDLc and VLDLc, and lower HDLc and HDLc/TC ratio; they also presented 
increased IR (measured by HOMA) and insulin, although showing normal levels of 
glucose. A pro-inflammatory status was present in obese individuals, with lower values of 
adiponectin and CRP median being almost 5 times higher than that of the control group 
(supplemental Table 1).   
 
Supplemental Table 1. Anthropometric, nutritional and biochemical 
variables characterization of obese and control groups at the 
beginning of the study (cross-sectional study) 
 
Control (41) Obese (63) P 
Sex (female(%)) 25 (61.0)  34 (54.0) 0.546 
Tanner (pre-pub (%)) 19 (46.3) 23 (36.5) 0.414 
Age (years) 10.6 ± 3.7 10.2 ± 3.0 0.783 
Height (cm) 143.6 ± 17.2 145.9 ± 13.7 0.458 
Weight (Kg) 40.4 ± 16.3 59.6 ± 20.8 <0.001 
BMI (kg/m2) 18.6 ± 3.3 27.0 ± 4.8 <0.001 
BMI z-score 0.29 ± 0.73 2.13 ± 0.29 <0.001 
Waist (cm) 67.0 ± 12.2 88.8 ± 13.5 <0.001 
Waist/Height 46.5 ± 4.7 60.7 ± 6.0 <0.001 
Total % Fat
1)
 28.9 ± 5.1 41.7 ± 5.9 <0.001 
Trunk % Fat
1)
 24.3 ± 5.5 40.1 ± 7.2 <0.001 
Lipid Profile        
TG (mg/dl) 59.0  (46.5-73.5) 71.0  (49.0-103.0) 0.031 
TC (mg/dl) 154.0  (132.0-169.0) 164.0  (142.0-189.0) 0.116 
HDLc (mg/dl) 50.1  (42.6-60.0) 47.0  (38.8-53.7) 0.007 
LDLc (mg/dl) 88.0  (71.5-103.0) 102.0  (79.0-117.0) 0.013 
VLDLc (mg/dl) 11.8  (9.4-14.7) 14.2  (9.8-20.6) 0.030 
HDLc/TC 0.335  (0.307-0.382) 0.283  (0.236-0.337) <0.001 
Glucose Metabolism 
Glicose (mg/dl) 85.0  (79.0-91.0) 81.0  (76.0-87.0) 0.014 
Insulina (μU/ml) 7.4  (5.2-11.7) 12.0  (8.1-19.0) <0.001 
HOMA 1.60  (1.06-2.52) 2.46  (1.60-3.85) <0.001 
Inflammatory Markers 
CRP (mg/l) 0.35  (0.24-0.78) 1.71  (0.95-3.23) <0.001 
Adiponectin (µg/ml) 5.16  (3.50-6.70) 4.14  (2.88-5.94) 0.004 
Results are presented mean ± standard deviation or median (interquartile range). 
1)
, 
Control n=37, Obese n=61. Pre-pub, pre-pubertal. BMI, Body Mass Index; CRP, C 
Reactive Protein; HDLc, High Density Lipoprotein Cholesterol; HOMA, Homeotasis 
Model Assesment Insulin Resistance; LDLc, Low Density Lipoprotein Cholesterol; 
TC, Total Cholesterol; TG, triglycerides; VLDLc, Very Low Density Lipoprotein 
Cholesterol; 
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3.2. Longitudinal study 
The variation of anthropometric variables during the studied period for obese and controls 
is presented in Table 1. The groups did not differ regarding sex and tanner stage (data not 
shown). At the end of the intervention program both groups presented a significant 
decrease in BMIzsc but only the obese group presented a significant reduction of the 
trunk percentage of fat.  
The weight loss in the obese group, as shown by the reduction in BMIzsc, was 
accompanied by changes in the studied biochemical variables. Obese individuals 
improved the lipid profile, with a significant reduction of TC and LDLc concentrations, and 
an increase in the HDLc/TC ratio; IR was also improved, with a decrease in insulin levels 
and in HOMA.  
On their turn, controls did not present any significant changes in lipid profile or IR markers, 
despite the variation of BMIzsc. 
Levels of adiponectin reduced in both groups during the studied period. 
Obese and control groups were also compared for the absolute and relative variations of 
the anthropometric and biochemical variables (data not shown). No difference between 
the two groups was found when comparing changes in anthropometric data. Conversely, 
an increase in ΔHDLc/TC% and a trend for the lowering of HOMA was seen in obese 
(supplemental figures 1 and 2). 
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Table 1. Variation of anthropometric, nutritional and biochemical characterization during the 
intervention program in control and obese groups (longitudinal study) 
  Control (22)   Obese(35)   
  1st Evaluation 2nd Evaluation P 1st Evaluation 2nd Evaluation P 
Height (cm) 140.9 ± 17.5 142.4 ± 16.8 <0.001 145.7 ± 15.1 148.0 ± 14.5 <0.001 
Weight (Kg) 38.6 ± 16.5 39.1 ± 16.9 0.101 60.0 ± 23.3 61.0 ± 23.2 0.099 
BMI (kg/m2) 18.4 ± 3.4 18.3 ± 3.8 0.350 27.1 ± 5.4 26.7 ± 5.6 0.206 
BMI z-score 0.21 ± 0.79 -0.04 ± 0.96 0.002 2.1 ± 0.3 1.9 ± 0.5 0.001 
Waist (cm) 66.9 ± 12.7 66.7 ± 12.4 0.856 88.6 ± 14.9 90.2 ± 15.0 0.093 
Waist/Height 0.472 ± 0.048 0.467 ± 0.054 0.494 0.607 ± 0.065 0.608 ± 0.063 0.886 
Total % Fat
1)
 28.5 ± 4.6 28.9 ± 5.6 0.460 40.9 ± 6.7 40.7 ± 6.0 0.663 
Trunk % Fat
1)
 24.1 ± 4.8 23.5 ± 6.2 0.429 39.8 ± 8.2 38.1 ± 7.2 0.013 
Lipid Profile 
TG (mg/dl)    (46.0-72.8) 68.5   (57.5-80.2) 0.147 71.0   (52.0-108.0) 66.0   (53.0-102.0) 0.257 
TC (mg/dl) 152.0   (132.8-179.0) 155.0   (141.0-171.8) 0.874 173.0   (151.0-194.0) 157.0   (135.0-186.0) 0.022 
HDLc (mg/dl) 50.1   (43.2-60.8) 51.0   (44.1-60.5) 0.957 49.0   (39.0-53.7) 48.0   (41.0-53.6) 0.471 
LDLc (mg/dl) 91.5   (75.8-108.5) 89.0   (76.8-102.4) 0.778 108.0   (89.0-120.0) 91.0   (77.0-117.0) 0.006 
VLDLc (mg/dl) 11.6   (9.2-14.6) 13.7   (11.6-16.0) 0.145 14.2   (10.4-21.5) 13.2   (10.6-20.4) 0.255 
HDLc/TC 0.329   (0.307-0.374) 0.326   (0.294-0.392) 0.934 0.293   (0.231-0.327) 0.319   (0.251-0.348) 0.004 
Glucose Metabolism 
Glicose (mg/dl) 84.5   (77.0-90.2) 74.5   (70.0-83.2) 0.002 81.0   (76.0-85.0) 77.0   (72.0-81.0) 0.001 
Insulina (μU/ml) 6.1   (4.5-9.8) 6.5   (3.8-9.8) 0.636 12.0   (7.0-17.3) 10.7   (8.1-15.1) 0.048 
HOMA 1.18   (0.94-1.94) 1.15   (0.74-1.74) 0.796 2.46   (1.38-3.85) 1.88   (1.40-3.09) 0.014 
Inflammatory Markers 
CRP (mg/l) 0.32   (0.24-0.88) 0.60   (0.21-2.19) 0.083 2.00   (1.12-3.41) 1.42   (0.96-3.44) 0.688 
Adiponectin (µg/ml) 4.68   (3.39-5.98) 3.60   (2.78-4.63) <0.001 3.87   (2.68-4.49) 3.00   (2.16-4.03) <0.001 
Results are presented mean ± standard deviation or median (interquartile range). 
1)
, Control n=19, obese n=31. BMI, Body 
Mass Index. Results are presented. BMI, Body Mass Index; CRP, C Reactive Protein; HDLc, High Density Lipoprotein 
Cholesterol; HOMA, Homeotasis Model Assesment Insulin Resistance; LDLc, Low Density Lipoprotein Cholesterol; TC, Total 
Cholesterol; TG, triglycerides; VLDLc, Very Low Density Lipoprotein Cholesterol. 
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Supplemental Figure 1. HDL/TC relative variation in obese 
and control groups 
D, Delta; HDLc, High Density Lipoprotein Cholesterol; TC, Total Cholesterol. 
a, p=0.028. 
 
 
Supplemental Figure 2. HOMA in obese and control groups 
before and after the intervention program 
HOMA, Homeostasis Model Assessment. HOMA, Homeostasis Model 
Assessment; eva, evaluation. a, p=0.796 ; b, p=0.001 ; c, p=0.014. 
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3.3. Analysis of adiponectin multimers 
To better understand the function of adiponectin isoforms and to verify any difference 
between obese and controls we selected a pre-pubertal population, in order to minimize 
the variations caused by other factors rather than obesity (e.g. sexual hormones). The 
control (n=10) and obese (n=13) groups were adjusted for gender (50% females vs 46.2% 
females, respectively) and age (mean 7.3±1.4 vs 7.9±1.4, respectively).  
The differences in anthropometric and biochemical variables observed between obese 
and controls in the larger population tend to be kept although TG, HDLc, LDLc and 
VLDLc, became of borderline statistical significance (data not shown), and adiponectin 
lost significance.  
No differences were observed between obese and controls regarding the absolute and 
relative multimers concentrations, before and after the PE program (data not shown). 
We further analysed the impact of the PE program in TA and in its multimers by dividing 
the obese group based on having achieved, or not, a BMIzsc reduction of 0.2 (Table 2). 
The control group did not present significant changes in adiponectin during the 
intervention period. Regarding the obese participants, the group that reached the cut-off 
value also did not present any significant reduction of adiponectin. Conversely, obese 
individuals who did not reach the cut-off value presented a general reduction of TA and its 
multimers absolute concentration. The relative percentage of the different isoforms was 
maintained in all groups.  
To clarify the functions of the different adiponectin multimers several correlations were 
performed. First, we analysed associations between TA and the other studied variables 
using the entire studied population (cross-sectional study; n=104), and then we performed 
sub-analysis between changes in studied variables over the interventional study (n=57 for 
TA; n=23 for adiponectin multimers). The levels of TA (n=104) correlated inversely with 
BMI, total percentage of body fat, TG, insulin, HOMA and CRP, and positively with HDLc 
and HDLc/TC ratio (Table 3). Regarding the longitudinal analysis (n=57), changes in TA 
were inversely correlated with changes in markers of adiposity and in TG levels. The 
multimer that most mimic TA associations at the baseline, was the HMW isoform; even 
though, statistical significance was lost, probably due to the lower number of cases 
(n=23).  
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Table 2. Total adiponectin and adiponectin isoforms in the control and obese groups variation with 
the intervention program (longitudinal study) 
  Obese 
  Control (10) BMI z-score reduction < 0.2 (8) BMI z-score reduction ≥ 0.2 (5) 
  
  
1st Evaluation 
  
  
2nd Evaluation 
  
P 
  
1st Evaluation 
  
  
2nd Evaluation 
  
P 
  
1st Evaluation 
  
  
2nd Evaluation 
  
P 
Adipo (µg/ml) 4.36 ± 1.79 3.87 ± 1.25 0.185 4.18 ± 1.41 3.31 ± 1.34 0.008 4.05 ± 1.33 3.58 ± 0.94 0.133 
HMW (µg/ml) 2.37 ± 1.34 2.16 ± 0.98 0.442 2.15 ± 0.86 1.74 ± 0.95 0.015 2.00 ± 0.99 1.88 ± 0.58 0.648 
MMW (µg/ml) 1.03 ± 0.40 0.94 ± 0.25 0.484 1.11 ± 0.33 0.93 ± 0.28 0.140 1.07 ± 0.38 0.99 ± 0.27 0.512 
LMW (µg/ml) 0.96 ± 0.40 0.76 ± 0.16 0.146 0.93 ± 0.30 0.64 ± 0.26 0.023 0.98 ± 0.22 0.72 ± 0.22 0.149 
% HMW 52.1 ± 7.7 53.5 ± 9.8 0.476 50.6 ± 3.9 50.3 ± 7.7 0.897 48.1 ± 8.1 51.8 ± 4.0 0.372 
% MMW 24.4 ± 5.5 25.0 ± 3.4 0.700 26.8 ± 3.2 29.2 ± 4.6 0.155 26.2 ± 6.0 27.8 ± 3.1 0.708 
% LMW 23.5 ± 7.8 21.5 ± 7.9 0.452 22.6 ± 4.7 20.5 ± 7.1 0.455 25.6 ± 7.4 20.4 ± 4.6 0.233 
Results are presented mean ± standard deviation. BMI, Body Mass Index; Adipo, adiponectin; HMW, High Molecular Weight 
adiponectin; MMW, Medium Molecular Weight adiponectin; LMW, Low Molecular Weight adiponectin. 
 
12
Inflammation and atherogenic risk in obese children and adolescents 
 
 
 
 
Table 3. Associations between total adiponectin and 
relative adiponectin isoforms with biochemical and 
anthropometric data, at the beginning of the study and 
respective variation after the intervention program 
Cross-sectional Study 
  Adipo
3)
 % HMW
4)
 % MMW
4)
 % LMW
4)
 
Age -0.071 -0.239 -0.198 0.465* 
BMI -0.322** -0.240 0.105 0.085 
BMI z-score -0.306** -0.144 0.163 -0.109 
Total % fat
1)
 -0.200* -0.186 0.129 -0.010 
Trunk % fat
1)
 -0.276** -0.300 0.207 0.040 
TG -0.195* -0.509* 0.122 0.436* 
TC -0.086 -0.159 0.508* -0.170 
HDLc 0.257** 0.055 0.186 -0.129 
LDLc -0.181 -0.145 0.497* -0.178 
HDLc/TC 0.323** 0.135 -0.166 0.000 
HOMA -0.200* -0.308 0.206 0.076 
CRP -0.202* -0.065 -0.105 0.175 
Longitudinal Study 
  D Adipo
5)
 D % HMW
4)
 D % MMW
4)
 D % LMW
4)
 
D BMI -0.415** -0.406 -0.052 0.391 
D BMI z-score -0.350** -0.332 -0.076 0.368 
D Total % fat
2)
 -0.333* 0.399 -0.269 -0.206 
D Trunk % fat
2)
 -0.299 0.107 -0.179 -0.009 
D TG -0.213 -0.191 0.272 -0.040 
D TC 0.070 -0.174 0.528** -0.233 
D HDLc 0.188 0.023 0.021 0.001 
D LDLc 0.090 -0.140 0.476* -0.237 
D HDLc/TC 0.076 0.055 -0.371 0.257 
D HOMA 0.084 0.244 -0.167 -0.171 
D CRP -0.176 0.119 -0.117 0.020 
Presented associations were calculated using Spearman rank test. 
Adipo, adiponectin; HMW, High Molecular Weight adiponectin; MMW, 
Medium Molecular Weight adiponectin; LMW, Low Molecular Weight 
adiponectin, BMI, Body Mass Index; TG, Triglycerides; TC, Total 
Cholesterol; HDLc, High Density Lipoprotein Cholesterol; LDLc, Low 
Density Lipoprotein Cholesterol; HOMA, Homeostasis Model 
Assessment Insulin Resistance; CRP, C Reactive Protein. D, delta (2
nd
 
evaluation – 1
st
 evaluation). 
3)
, n=104; 
4)
, n=23; 
5)
 n=57. 
1)
 n=98 for 
Adipo; 
2)
 n=50 for D Adipo.  *, P<0.05; **, P<0.01. 
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Improvements in adiposity variables at pre-pubertal stages, especially BMI, correlated 
with increments in circulating levels of HMW and MMW forms (Figure 1). Moreover, by 
multiple regression analysis, the parameter that best explained changes in HMW isoform 
was the delta BMIzsc (R2=0.299, standardized coefficient/beta: -0.547, P=0.013).  
 
 
Figure 1. Variation of high and medium molecular weight adiponectin (HMW and 
MMW, respectively) with changes in body mass index (BMI) after the intervention 
program 
 
The increase in HMW relative percentage was related with lower levels of circulating TG. 
In contrast, despite the negative correlation with adiposity, an increased relative 
percentage of MMW was associated with increased levels of TC and LDLc (p<0.01 and 
0.05, respectively).  
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4. Discussion 
4.1. Cross-sectional study 
Childhood obesity was accompanied by worsening of MS markers(3, 4) In our study the 
obese group presented a worse lipid profile, increased IR (measured by HOMA) and 
inflammation, as seen in supplemental Table 1. 
The obese group presented increased IR, although showing normal levels of glucose, 
pointing at an unbalanced glucose metabolism. In children, the insulin levels seem to be 
an early indicator of metabolic changes, appearing first than anomalies in glycaemia.  
 
4.2. Longitudinal study 
Although both obese and controls reduced BMI-score following the intervention program, 
only the obese group presented clear changes in the body composition, with a significant 
reduction of the trunk percentage of fat. The body fat distribution influences the 
metabolism; actually, a central accumulation of adiposity has been associated with an 
increase in CVD risk.(4, 12, 13) The reduction of the central adiposity in the obese group 
is an important indicator of the positive impact of the PE program. 
Accompanying the decrease in adiposity in obese individuals, were improvements in 
biochemical variables, namely lipid profile and insulin. Obese individuals presented with 
an improved lipid profile as seen by a decrease in ΔHDLc/TC% ratio. Actually, more than 
75% of the obese individuals presented a decrease in that atherogenic index, while only 
less than 50% of the controls. This is an important finding as this ratio is an accepted 
marker of atherosclerotic risk.(6) As well, the trend to an improvement in HOMA in obese 
patients indicated a better glucose homeostasis; a particularly relevant point as IR 
continues to explain most, if not all, of MS.(27) Together, these changes demonstrate a 
global improvement in lipid and glucose metabolisms following the intervention program.  
The lack of changes seen for controls, regarding lipid profile or IR, is probably due to the 
fact that these variables were already at good levels and, although the practice of exercise 
improved the nutritional status, their metabolism was previously balanced and no further 
changes could be detected. 
Considering that the metabolism of obese individuals is unbalanced, the BMIzsc reduction 
observed in this group, with a particular decrease in central adiposity, likely contributed to 
lead the biochemical variables to the desirable levels. In fact, changes in body fat 
distribution might be the key factor behind the metabolic improvement. 
The PE program was unable to increase TA values in any of the groups, contrarily to other 
studies.(22) This might be related with a lower reduction of BMIzsc presented by our 
participants, despite the significant changes in anthropometric variables. Additionally, 
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adiponectin is negatively correlated with age in children and adolescents, meaning that it 
might be necessary greater BMIzsc reductions to oppose this physiological trend.(6) 
 
4.3. Analysis of adiponectin multimers 
For the study of adiponectin isoforms we selected a pre-pubertal population in order to 
minimize the variations caused by other factors rather than obesity. Despite the 
differences in anthropometric and biochemical variables between obese and controls in 
the larger population were, somehow, maintained, no significant changes were observed 
between the two groups regarding TA and absolute and relative multimers concentrations, 
both before and after the PE program (data not shown). Oppositely, some studies have 
pointed to an increase in HMW following intervention.(16, 28) The lack of significant 
differences might be related to a small sample size, however it can also indicate that the 
differences previously found could be due to confounding factors, present later in life, or, 
that differences in TA concentrations seen at older ages, might be caused by a cumulative 
effect, still not evident at early ages. So, acting early might be the best strategy to avoid 
obesity impact later in life.  
TA and its multimers absolute concentrations did not vary both in controls and in the 
obese group that reached the cut-off value for BMIzsc reduction (0.2), however in the 
obese individuals who did not reach that cut-off, there was noted a general reduction. 
Interestingly the relative percentage of the different isoforms was maintained in all groups.  
Other studies have reported that BMIzsc reduction is related to an increase in TA, 
particularly in the HMW form.(16, 28) In children, adiponectin decreases with aging (6), 
therefore, a small reduction of BMIzsc (0.2), might not be enough to raise the TA levels, 
but it seems to be enough to slow the process as age-related adiponectin reduction 
seems to be accelerated in obese individuals. Moreover, previous data from our group 
demonstrated that small reductions in BMIzsc are associated with significant 
improvements in lipid profile and IR, markers of MS inversely related to adiponectin 
levels.(24) 
Increased TA, at baseline, was correlated with lower adiposity, inflammation and IR and 
with a better lipid profile (Table 3). Additionally, the longitudinal analysis showed that 
increases in TA are related to decreases in adiposity and TG. These results are in 
agreement with previous studies, showing that higher values of TA are associated with 
reduced body weight and improved lipid profile, inflammatory status and insulin sensitivity. 
(6, 9)   
An important finding of our longitudinal study was that improvements in the adiposity 
variables, at pre-pubertal stages, correlated with increments in circulating HMW. In fact, 
when multiple regression analysis was used, variations of HMW were explained by 
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changes in BMIzsc (negative association). HMW is proposed to be the most biological-
active form of adiponectin, being lower adiposity associated with higher circulating 
HMW.(16)  
HMW adiponectin has been reported to correlate closer with IR than with adiposity, 
however, the association between TA and HMW with IR in pre-pubertal children is not so 
clear and is said to appear only between the ages of 2 and 6 years.(29) Despite the age 
of our pre-pubertal group fell outside those limits, we did not find any association of HMW 
with IR. Nevertheless, the increased levels of HMW relative percentage were associated 
with lower TG levels. HMW relation with a better lipid profile is probably explained by the 
influence of this multimer in liver insulin sensitivity.(18)  
Thus, it seems that HMW mimic the associations of TA with adiposity and lipid profile, and 
is possible that this adiponectin fraction explains most of those associations. 
Another multimer, MMW, presented ambiguous results. Although the increase of MMW 
adiponectin was associated with the improvement of body weight (Figure 1), it was also 
linked with a worse lipid profile. More studies are necessary to verify these relations.  
The impact of the other multimers rather than HMW in obesity has been poorly 
explored;(16) actually we are, to the best of our knowledge, the first group to describe 
associations between the worsening of lipid profile and increasing MMW.  
The study has some weakness: 1)The sample size is not very large and some differences 
might have been underestimated; 2)Adiponectin multimers were analysed only in pre-
pubertal individuals, an age period when the relation between adiponectin and MS is still 
not clear.  
Despite these limitations, the study of adiponectin multimers in pediatric patients before 
and after an interventional study is rare and, thus, we think our work may offer some 
important information. Moreover, this is, as far as we know, the first study on this subject 
in Portugal.   
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5. Conclusion 
Childhood obesity is accompanied by an increase in MS features (worse lipid profile and 
increased IR) and a pro-inflammatory state. Lower adiponectin levels in obese patients 
are likely to be related with most of these deleterious changes; however, differences are 
not evident at pre-pubertal stages. The adiponectin multimers that mostly explained MS 
features at pre-pubertal stages were HMW and MMW.  
Insulin is an early indicator of IR and should be used as a routine measurement in 
pediatric obesity. 
The PE program helped to improve the lipid profile and to decrease IR in obese 
individuals, though with no significant variation of TA or adiponectin multimers. 
Nevertheless, pre-pubertal patients that reduced the BMIzsc maintained adiponectin 
levels, contrarily to individuals who did not. 
Understanding how total adiponectin and its oligomers influence the metabolism is an 
important issue, particularly for children, in who an early intervention can present relevant 
impact in the future. Thus, our work highlights that the different circulating forms of 
adiponectin might present different, or even opposite effects, in MS features. On its turn, 
weight loss helped to sustain what appears to be a positive profile of adiponectin isoforms. 
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Abstract 
Introduction: Obesity, particularly central obesity, associates with dyslipidemia, insulin 
resistance and hypertension, to form a cluster of risk factors of cardiovascular disease 
called metabolic syndrome (MS). Different criteria are used to define body mass index 
(BMI) z-score, a variable used to evaluate the nutritional status, in children and 
adolescents. In this study we aimed to evaluate the differences in BMI z-scores 
determined using the criteria of the Center for Disease Control and Prevention (CDC), and 
that of the World Health Organization (WHO), and their relation with MS and its features.  
Methods: 246 obese adolescents (10-18 years, 122 females) participated in the study. 
Anthropometric variables, systolic (SBP) and diastolic blood pressure (DBP), plasmatic 
triglycerides, HDLc, glucose, insulin, HOMAIR, adiponectin and C-reactive protein (CRP) 
were determined. 
Results: Using the International Diabetes Federation (IDF) criteria, obese individuals with 
MS presented (as a group) increased adiposity markers, dyslipidaemia (increased 
triglycerides, and reduced HDLc), blood pressure (increased SBP and DBP) and insulin 
resistance (increased insulin, glucose and HOMAIR) than those without MS. MS patients 
also presented lower adiponectin values (p< 0.001) and a trend to higher CRP values 
(p=0.072). By linear regression analysis, the factors that better predicted MS were SBP, 
triglycerides and HDLc. When only anthropometric data was analysed, CDC BMI z-score 
was an independent predictor of MS (p< 0.001).   
Conclusion: In our adolescent population, BMI z-score determined using the CDC 
reference showed higher specificity to predict MS than the WHO reference. Furthermore, 
the measurement of SBP should be highly encouraged in routine appointments, as we 
found that this low-cost and non-invasive measurement has a high predictive value for 
MS. 
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1. Introduction 
Obesity is a chronic inflammatory disease that is spreading worldwide, particularly in 
pediatric ages. This is an important problem in Portugal, as our country has a high 
prevalence of weight excess, with almost one third of overweight or obese children
 and adolescents (1, 2). Obesity, together with dyslipidaemia, hypertension and 
insulin resistance (IR), form a cluster of risk factors for the development of cardiovascular 
disease (CVD), known as the metabolic syndrome (MS) (3).  
In adults, obesity is defined by a body mass index (BMI) higher than 30 kg/m2. During 
childhood, BMI evolution is not linear and must be adjusted for age and gender. The two 
most used criteria to define obesity are from the Centre for Disease Control and 
Prevention (CDC) and from the World Health Organization (WHO) (4). These two 
references were built based on different populations. The WHO criterion is based on a 
multi-ethnic population, while the CDC criterion used only values from the United States. 
This fact led to the construction of different anthropometric growth curves and cut-offs 
regarding the nutritional status in pediatrics: according to 2000 CDC growth charts obesity 
is defined by a BMI z-score higher than +1.65 (5), while WHO defines obesity by a BMI z-
score higher than +2 (1). If the same population is studied using both criteria, different 
outputs are obtained: WHO reference associates with a lower prevalence of thinness and 
a higher prevalence of obesity and overweight, while CDC criterion gives lower 
prevalence of overweight and obesity and increased rates of thinness (1). 
In Portugal the CDC criterion was used for a long time, as it was recommend by the 
Portuguese Ministry of Health. However, the current recommended criterion is that from 
the WHO (6). The aim of this study was to evaluate the impact of this change, by 
comparing the relation between the BMI z-score, calculated according to the CDC and to 
the WHO criteria, with MS features, in a Portuguese obese pediatric population. 
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2. Material and methods 
 
2.1. Subjects 
Obese adolescents, aged 10-18 years, were identified from medical records, at the 
outpatient clinics of pediatric obesity from two hospitals in Porto - Portugal. The study 
protocol was approved by the Committees on Ethics of the two hospitals.  
A total of 246 obese adolescents participated in the study after informed and written 
consent of their parents. Smokers, subjects with diabetes mellitus, endocrine disorders, 
hereditary diseases, inflammatory or infectious diseases or under any therapy that could 
interfere with our results were excluded from the study. 
 
2.2. Procedures and assays 
 
2.2.1 Anthropometric characterization and clinical evaluation 
All participants were subjected to clinical examination. Height, weight and waist 
circumference (at the level of the iliac crest) were measured. BMI z-score was determined 
according to CDC and WHO criteria and children were classified as normal weight, 
overweight or obese (7, 8). Only obese individuals entered in this study. 
 
2.2.2. Blood samples 
Blood was collected by venipuncture in ethylenediaminetetraacetic acid (EDTA) 
containing tubes, after overnight fasting (10-12h) and processed within 2h of collection. 
Aliquots of plasma were made, and immediately stored at -80ºC until assayed. 
The plasma levels of C-reactive protein (CRP) were determined by immunoturbidimetry 
[CRP (latex) High-Sensitivity, Roche Diagnostics]. 
The determination of circulating levels of glucose and insulin was performed by using 
routine automated technology (ABX Diagnostics). Homeostasis model assessment of 
insulin resistance (HOMAIR) was determined by using the following formula: HOMAIR = 
fasting insulin (μU/ml) × fasting glucose (mg/dl) / 405.  
Plasma lipids and lipoprotein analysis were performed in an auto-analyser (Cobas Mira S, 
Roche) using commercially available kits. Triglycerides concentrations were determined 
by enzymatic colorimetric tests (GPO-PAP methods, Roche). HDLc was measured using 
an enzymatic colorimetric test (Direct HDLcholesterol, Roche). 
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2.2.3 Definition of metabolic syndrome 
The MS was defined according to the International Diabetes Federation (IDF) worldwide 
criterion.  Briefly, the MS is defined by the presence of at least 3 risk factors, of which the 
presence of abdominal obesity, as defined by a waist circumference higher than the 90th 
percentile, adjusted for age and sex, is mandatory. The other risk factors cut-offs are: pre-
diagnosed hypertension or type 2 diabetes mellitus; triglycerides ≥ 150mg/dl; high density 
lipoprotein cholesterol (HDLc) <40 mg/dl (or 50mg/dl if female and older than 16 years); 
systolic blood pressure (SBP) ≥ 130 mmHg; diastolic blood pressure (DBP) ≥ 85 mmHg; 
fasting glucose ≥100 mg/dl (9). 
 
2.3. Statistical analysis 
The distributions of continuous variables were analysed using Kolmogorov-Smirnov tests 
to assess significant departures from normality. Normally distributed variables are 
presented as mean±SD. Variables non-normally distributed are presented as median 
(interquartile range) and were log transformed before further analyses. Comparisons 
between two groups were performed using Student’s unpaired t-test. Adjustment of 
statistical differences for confounding factors was performed using ANCOVA. The 
association between categorical variables was analysed using chi-squared test. 
The strength of the association between the variables was estimated by Pearson 
correlation coefficient. To evaluate the contribution of the different variables to detect MS, 
multiple regression analysis was performed, using stepwise selection, with an entry 
criteria of p <0.05.  
Statistical analysis was performed using the Statistical Package for Social Sciences 
(SPSS), version 20.0 (IBM, Armonk, NY, USA). Statistical significance was accepted at p 
less than 0.05. 
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3. Results 
The anthropometric data, blood pressure, glucose metabolism, lipid profile and 
inflammatory data of the obese children and adolescents, according to the presence or 
not of MS, are presented in Table 1. 
The groups were adjusted for gender and Tanner stage of pubertal development (data not 
shown). Obese patients with MS presented increased adiposity, a worst lipid profile 
(increased triglycerides and reduced HDLc), higher blood pressure (increased SBP and 
DBP), increased insulin resistance (increased insulin, glucose and HOMAIR) and lower 
adiponectin values. CRP levels were also higher in MS patients, though this result only 
reached borderline statistical significance (p=0.072). 
Table 1 also presents the correlations between the different markers of metabolic risk and 
the BMI z-score, as determined by the WHO and CDC criteria. The correlations were 
similar for both criteria, however the CDC criterion presented, in general, a stronger 
correlation with the different variables (exception made for CRP and DBP). 
To clarify the predictive value of the studied factors to identify MS, a logistic regression 
analysis was performed involving all the variables presented in Table 1 and the Tanner 
stage. The best predictive marker of MS was the SBP, followed by triglycerides and HDLc 
(p<0.001 for all). The used model presented a sensitivity of 67.4% and a specificity of 
94.1%.  
In order to evaluate which clinical anthropometric data were more closely associated with 
MS, we performed a logistic regression considering only waist circumference, weight, 
BMI, and BMI z-score (adjusted for gender, age and Tanner stage) calculated using the 
two criteria. CDC BMI z-score was the only independent predictor of MS (p< 0.001).   The 
model presented a sensitivity of 19.7% and a specificity of 96.0%. 
6
Inflammation and atherogenic risk in obese children and adolescents  
 
 
 
 
 
 
 
Table 1. Clinical and biochemical data of obese children and adolescents based 
on the presence of metabolic syndrome and the correlation with BMI z-score 
according to CDC or WHO criteria 
p WHO CDC
Number of participants (%) 185 (75.2) 61 (24.8) - -
Females, n (%) 97 (52.4) 25 (41.0) 0.141 - -
Age (years) 12.7 ± 1.8 13.4 ± 2.1 0.017 0.057 0.122
Height (cm) 158.5 ± 8.9 162.8 ± 9.9 0.002 0.189** 0.277**
Weight (kg) 78.0 (68.0-89.0) 90.2 (76.0-113.5) <0.001 0.673** 0.726**
BMI (kg/m²) 30.55 (28.15-34.08) 34.52 (30.20-39.14) <0.001 0.848** 0.865**
BMI z-score (CDC) 2.20 ± 0.29 2.43 ± 0.31 <0.001 0.933** -
BMI z-score (WHO) 3.00 ± 0.62 3.51 ± 0.86 <0.001 - 0.933**
Waist circumference (cm) 99.0(91.8-106.5) 105.0 (96.5-118.0) <0.001 0.736** 0.778**
Blood pressure1)
Systolic  (mm Hg) 116.5 ± 11.6 135.0 ± 13.2 <0.001 0.323** 0.360**
Diastolic  (mm Hg) 63.4 ± 8.3 69.9 ± 12.2 0.001 0.267** 0.218**
Lipid profile
TG (mg/dL) 71.0 (53.1-100.6 126.7 (81.5-181.5) <0.001 0.186** 0.185**
HDLc (mg/dL) 43.0 (38.3-49.0) 35.0 (32.0-38.4) <0.001 -0.215** -0.223**
Glucose metabolism
Glucose (mg/dl) 83.0 (77.0-89.6) 88.0 (80.0-93.8) 0.005 0.043 0.046
Insulin (µU/ml) 15.9 (12.2-22.1) 23.3 (14.6-33.3) <0.001 0.421** 0.440**
HOMAIR 3.18 (2.43-4.52) 4.94 (3.34-7.06) <0.001 0.410** 0.429**
Inflammatory mediators
CRP (mg/L)2) 1.61 (0.84-4.05) 2.30 (1.00-4.59) 0.072 0.326** 0.302**
Adiponectin3) 5.92 (4.14-8.36) 4.25 (2.82-5.70) <0.001 -0.073 -0.124
Without MS With MS
Correlatio with BMI z-score
 
*, p<0.05; **, p<0.001. 1) With MS n=45, without MS n= ; 2) With MS n=60, without MS, n=180. 3) With 
MS n=60, without MS, n=177. BMI, Body mass index; CDC, Center for Disease Control; C-reactive 
protein; TG, Triglycerides; HDLc, High Density Lipoprotein cholesterol; MS, metabolic syndrome, 
WHO, World Health Organization. 
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Figure 1 illustrates the relation between the BMI z-score obtained using the two criteria.  
The relation presents an exponential behaviour, with WHO criteria presenting a wider 
range of BMI z-score values. 
 
 
Figure 1. Distribution of BMI z-score values of obese 
children and adolescents using CDC and WHO criteria.  
BMI, body mass index; CDC, Center for Disease Control and Prevention; 
WHO, World Health Organization. 
 
R2 = 0.905 
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4. Discussion 
Obesity, particularly central obesity, is associated with a worse metabolic profile and an 
increased risk of presenting MS, a cluster of risk factors for CVD. The fact that almost one 
quarter of the subjects in our population presented MS is in accordance with other studies, 
reporting a high prevalence of MS for obese individuals; lean individuals presented no 
cases of MS (10). 
 In our population, the factors that better predicted MS were SBP, triglycerides and HDLc. 
Interestingly abdominal obesity, as defined by the waist circumference, a sine qua non 
condition for MS, according to IDF, did not enter the model (although closely associated 
with most of the variables (data not shown). Furthermore, when only anthropometric data 
was analysed by linear regression analysis, CDC BMI z-score was an independent 
predictor of MS. Thus, the evaluation of SBP and BMI z-score should be encouraged as 
they can be cost effective determinations for identifying individuals with increased 
metabolic derangement.  
We verified that the BMI z-score calculated using the criteria of CDC had a better 
correlation with metabolic and anthropometric variables, when compared to WHO criteria. 
As a result, CDC BMI z-score was a better predictor of the presence of MS.  
Although the WHO criteria is based on a multi-ethnic population, and the CDC criteria 
uses only values from the United States, it appears that, in what metabolic risk is concern, 
the CDC criteria is more sensible. Moreover, the widening of the BMI z-score scale in the 
WHO criteria (Figure 1), especially for higher values, does not seem to add much to the 
capacity of BMI z-score to identify individuals in increased metabolic risk. 
In conclusion, although the BMI z-score is not the most sensible marker for MS, the 
values defined by the CDC criteria correlated better with other risk markers and were able 
to predicted (amongst all anthropometric data) the presence of MS. SBP has a high 
predictive value for MS for our population and, thus, this low-cost and non-invasive 
measurement should be used in routine appointments. 
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15. Discussion 
Obesity is increasing worldwide both in adults and in children. In Portugal the prevalence 
of pediatric obesity is high, with almost one third of the children and adolescents 
presenting overweight or obesity (1, 12, 183).  
Childhood obesity is a serious public health problem, as obese children have an increased 
prevalence of a large number of comorbidities (e.g. T2DM, dyslipidemia and 
hypertension), increasing the risk for CVD and for mortality later in life (5, 20, 179). 
Moreover, obese-related complications represent great costs to our society, both at 
human and financial levels.   
With this work we aimed to clarify the changes in classical and new CVD risk factors in 
obese children and adolescents, and the impact of two different approaches in those risk 
factors and in obesity itself: a lifestyle modification program and an interventional program 
involving physical exercise. In this way we performed a cross-sectional analysis and a 
longitudinal analysis. 
 
CROSS-SECTIONAL ANALYSIS 
Obese Portuguese children and adolescents presented altered CV risk markers, namely 
worsening of MS features (glucose metabolism, lipid profile and blood pressure), 
inflammation and oxidative stress, when compared to normal weight controls (Papers V, 
VI and VII). 
 
Glucose metabolism 
IR is reported to underlie many of the CV risk changes observed in obesity. We found that 
obese children and adolescents present increased HOMAIR and insulin levels, despite the 
normal values of glucose (Papers VI e VII). In fact, hyperinsulinemia has been reported as 
the earlier marker of metabolic derangement and insipient IR in obese children (4, 25). 
The peripheral resistance to insulin leads to the accumulation of glucose in the blood, 
triggering the secretion of more insulin by the pancreas, in order to normalize glucose 
levels. Through this feedback mechanism, the body is able to keep normal glucose levels 
and enables its normal uptake and utilization by peripheral tissues. On the other hand, a 
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continuous exposition of organs and tissues to increased insulin concentrations would 
further increase IR, contributing to a vicious cycle that, if not counterbalanced, will 
progress until the pancreas achieves its maximum secretory capacity and, therefore, the 
peripheral IR is no longer compensated by increasing insulin secretion. The development 
of T2DM is the final step of this pathway (5, 33, 179). 
Our data suggest that it is important to measure insulin in pediatric obesity, in order to 
detect early metabolic changes, especially in children with increased risk factors (family 
history of early CVD, diabetes and obesity, or personal history of obesity and 
comorbidities commonly associated with IR, such as dyslipidemia, hypertension and 
acanthosis nigrican) (197, 218). Portugal has a program for diabetes screening, however, 
it focus only on the importance to determine glycemia (18).  The inclusion of insulin 
measurement, adapted for age and gender, as a part of the diabetes screening protocol, 
would be valuable. HOMAIR is a good indicator of the degree of IR, even in children, and 
has a positive correlation with oral glucose tolerance test (OGTT); thus, HOMAIR could 
also be useful, as a routine marker of IR, in pediatric populations (197, 218). By doing so, 
we could promote early detection of children at increased risk of developing diabetes and, 
therefore, to prevent its associated complications. 
 
Lipid profile 
Concerning the lipid profile, we found that obese children and adolescents presented risk 
changes in the lipid profile, with higher TG, TC, LDLc, apo B, and lower HDLc and apo A-
1 levels, as compared to normal weight individuals. The ratios TC/HDLc and apo B/apo A-
1, known markers of atherogenic risk, were increased as well (Paper VI and VII). A 
worsening of the lipid risk profile can be directly linked to an increase in IR, both at hepatic 
and peripheral levels (4, 25).  The increase in IR causes the increase in the hepatic 
production of VLDL, leading to increased circulating levels of TG and LDLc. Moreover, the 
LpL activity is reduced in the presence of peripheral IR, further increasing the plasmatic 
TG, and reducing HDLc, by increasing its degradation and reducing its synthesis (4, 5, 25, 
179).   
In obese individuals, the atherogenic changes in blood lipids seem to be present since 
early in life. The chronic exposition of the vasculature to atherogenic lipids and 
lipoproteins leads to the deposit of lipids in the subendothelial space of the vessels walls, 
to the formation of foam cells and atherosclerotic plaques and to vascular remodeling. 
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Hyperinsulinemia will also contribute to an increase in smooth muscle cell proliferation 
and, thus, to atherosclerosis. These changes are cumulative and increase the risk for 
CVD in the adult life (197, 218). 
Increased blood pressure in obese individuals is, in part, a direct effect of the 
atherosclerotic changes, which lead to less elastic blood vessels. Moreover, higher insulin 
concentration contributes to hypertension, by increasing sympathetic activity and 
promoting sodium retention by the kidneys (4, 25). 
 
Inflammation and oxidative stress 
Besides the study of classical markers, our work focused on inflammatory mediators as 
new markers of CVD. Inflammatory processes are reported to be linked to the genesis of 
IR.  In fact, inflammatory mediators, such as TNF-α, inhibit insulin signaling, while the anti-
inflammatory adipokine adiponectin increases insulin sensitivity (5, 31) (Paper I). 
We found that obese children and adolescents presented an increased inflammatory 
condition. Actually, CRP, a sensitive marker of inflammation, was 3-5 fold higher in obese 
individuals (Paper VI and VII), when compared with lean controls, while adiponectin was 
decreased (Paper VII). CRP is known to be secreted by the liver, in response to VAT IL-6. 
Thus, an increase in VAT, and therefore in central obesity, is associated with an increase 
in inflammatory mediators (95, 123) (Paper I). 
The observed increase in inflammatory markers in obese children and adolescents was 
closely linked to changes in other markers of CVD risk, namely increased adiposity, 
particularly central adiposity, increased IR and risk changes in the lipid profile (Papers II, 
IV, V, VI and VII).  
Leukocytosis and an increase in neutrophil/lymphocyte ratio have been associated with 
obesity (175, 247). In our study obese individuals presented an increase in neutrophil 
percentage, and neutrophil count was positively correlated with adiposity, namely with 
central adiposity markers (WC and WC/height ratio). Moreover, a positive correlation was 
observed between CRP and neutrophil count (Paper V). Neutrophils are able to secrete a 
large number of inflammatory mediators in response to WAT adipokines. The WAT 
adipokines, IL-6 and IL-1, are able to induce an increase in hepatic CRP synthesis and in 
circulating neutrophils, via demargination of neutrophils from the marginal pool (248-250). 
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The increase in the neutrophil/lymphocyte ratio, in the absence of another cause for 
neutrophilia, suggests an unbalance towards an inflammatory response (173). Regarding 
this finding, the leukogram, a non-expensive routine analysis, might be used as an obese-
related inflammation indicator. 
Worsening of the metabolic profile was closely associated to increased adiposity. In fact, 
when considering only the obese individuals, those with increased BMI z-score, or with 
increased percentage of body fat, presented a worsening of the lipid profile and higher 
levels of inflammatory markers (Papers II and IV). Furthermore, the obese individuals with 
MS presented a general worsening of the majority of the anthropometric and biochemical 
risk factors (Paper VIII).  
Inflammation and oxidative stress are tightly connected and we found relevant to study 
some oxidative stress markers. Bilirubin, a molecule with important antioxidant and anti-
inflammatory properties, was inversely correlated with BMI z-score, body and trunk fat 
percentages and with CRP in the obese population, but not in controls (Paper IV). 
Although obese individuals presented increased erythrocyte count, hemoglobin 
concentration and hematocrit, no differences were observed in bilirubin levels between 
obese and controls. Moreover, we found that obese individuals with increased body fat 
percentage presented decreased bilirubin and increased CRP. The reduction of bilirubin in 
the obese individuals is likely to be caused by a “consumption” of this antioxidant factor, 
due to the increased inflammation and oxidative stress in obesity. 
 
Genetic polymorphisms 
Obesity is a multifactorial disease involving both environmental and genetic factors. We 
studied some genetic polymorphisms associated with obese-related comorbidities, namely 
dyslipidemia and increased oxidative stress, and verified that individuals presenting 
specific genotypes are at increased metabolic risk: 
 Apo E polymorphism: obese individuals with the E4 allele presented a worst lipid 
profile, with higher TC, LDLc, apoB and TC/HDLc ratio and lower apo A-I/apo B 
ratio, when compared to E2 carriers and E3/3 subjects (Paper II).  
 Apo (a) PNR polymorphism: obese individuals with a lower number of repeats of 
the apo (a) pentanucleotide (TTTAT)n polymorphism presented increased Lp(a) 
levels and, consequently, an increased CV risk (Paper III).  
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 Bilirubin UGT1A1*28 polymorphism: 6/6 homozygous obese individuals presented 
a worst metabolic profile, including lower levels of bilirubin, increased IR and 
dyslipidemia, when compared with 6/7 and 7/7 subjects (Paper IV). 
Nevertheless, and because obesity is multifactorial, other factors can influence the impact 
of a certain polymorphism in the metabolism. In fact, the worsening of the lipid profile 
observed in E4 (apo E) and 6/6 (UGT1A1*28) obese individuals might benefit from BMI 
reductions, as leaner individuals, for the same risk genotypes, presented a lower lipid risk 
profile (Paper II and IV). Furthermore, adiponectin also modulated the effect of apo E 
polymorphism, as obese individuals presenting increased adiponectin had a better lipid 
profile, regardless of the apo E genotype (Paper II). Thus, considering that adiponectin 
concentration increases with BMI improvement, it appears particularly important to focus 
on the control of adiposity to manage an increased genetic risk. Although the distribution 
of the studied genetic polymorphisms (associated with CVD risk markers) did not differ 
between obese and lean controls, the use of genetic studies could help to identify 
individuals who are at increased metabolic risk that may, therefore, deserve a closer 
follow-up by health professionals.  
 
Criteria used to classify obesity in Portugal: impact on MS diagnosis 
The prevalence of MS is much greater in obese individuals when compared to lean 
subjects. In fact, normal weight is considered a protection against the appearance of MS 
(148, 179). Our obese adolescent population presented a high prevalence of MS – 24.8% 
(Paper VIII). This prevalence was higher than those found in Greek obese children (7.7%, 
10-14 years, IDF criterion) (56) and in another Portuguese overweight and obese children 
cohort (16%, children 7-9 years, NCEP criterion) (148). However, it was similar to the 
prevalence found in German obese children (25%, 6-19 years, IDF criterion) (70).  The 
differences in the prevalence among different studies are mainly related to the 
characteristics of the studied population, particularly with the degree of obesity, and with 
the used criterion.   
MS is a cluster of CVD risk factors (4, 5, 197). In agreement, obese adolescents with MS 
in our population presented, as expected, with worsening in all markers of MS: increased 
adiposity (BMI, WC, WC/H), BP (both SBP and DBP) and IR (insulin, glucose and 
HOMAIR), when compared to obese adolescents without MS. A worst inflammatory status, 
with decreased adiponectin and a trend to increased CRP, was also present in individuals 
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with MS. High BP was the most common MS feature in the obese adolescents, besides 
the mandatory increase in WC stipulated by the IDF criterion. In agreement, the SBP was 
the best predictor of MS in this population (Paper VIII). 
In the present work, as we have finished our recruitment of participants in July 2012, 
children were still classified regarding their nutritional status according to the CDC 2000 
growth charts, as recommended by the Portuguese Ministry of Health. The CDC growth 
charts are based in the American population (USA), a population known to have increased 
anthropometrics measures (height and weight) when compared to Portuguese subjects. 
This fact probably led to an underestimation of obesity and overweight in our study. In 
fact, the WHO criterion (the reference that is now recommended)  is associated with lower 
prevalence of thinness and increased prevalence of overweight and obesity, when 
compared to CDC criterion (6, 17). We found that, for obese Portuguese children and 
adolescents, the association of CDC criterion with MS features and other markers of CV 
risk is stronger than those found with the WHO criterion. Consequently, it seems that the 
CDC criterion has a higher sensitivity to identify individuals with increased metabolic risk 
(Paper VIII). 
 
LONGITUDINAL ANALYSIS 
In the second part of this work, we studied the impact of two different approaches on 
tackling obesity: a lifestyle intervention program (Paper VI) and an exercise based 
program (Paper VII).  
Both approaches achieved very similar results. Actually, the percentage of obese 
individuals presenting significant weight loss was not very different. The weight 
improvements with both intervention programs were not very marked, and the majority of 
the individuals who lost weight presented only moderate weight reductions (Papers VI and 
VII).  
Nevertheless, these small weight reductions were already associated with significant 
improvements in several risk factors, namely in the lipid profile and IR. The improvements 
in adiposity, however, were not associated to significant changes in the inflammatory 
markers, such as in CRP and adiponectin (Paper VI and VII). Actually, other studies have 
reported that higher improvements in BMI are necessary to observe beneficial effects on 
inflammation (42, 234). It is important to highlight, though, that the protective changes that 
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we observed in lipid profile and insulin sensitivity were closely linked to weight reduction 
and to central adiposity in particular (WC and % trunk fat) (Paper VI and VII). Thus, the 
magnitude of adiposity reduction might be the limiting factor for the improvement in 
inflammation.  
Regarding the exercise interventional program (Paper VII), we found a greater beneficial 
metabolic effect in obese patients than in controls. Although after the intervention program 
similar changes in adiposity and nutritional markers were observed in both groups, the 
obese group presented a higher improvement in lipid profile and IR. Some of the 
beneficial effects in the metabolic risk might be related to changes in the body fat 
distribution as the obese group reduced central adiposity, and central obesity was 
associated with a worst lipid profile, IR and inflammation, at baseline. 
In both program studies, an increase in circulating adiponectin levels was associated to a 
reduction in adiposity, inflammation and IR. Moreover, an increase of total adiponectin 
following exercise therapy was associated with improvements in lipid profile (reduction in 
TG) and with a decrease in adiposity (Paper VII). 
Concerning adiponectin multimers, the HMW multimer was the one that better mimic the 
relations of total adiponectin with other variables, at pre-pubertal stages. HMW 
adiponectin levels were also inversely correlated with TG levels, and with an improvement 
in adiposity, following the exercise program (Paper VII).  
MMW adiponectin multimer presented more ambiguous results. In the longitudinal study, 
the increase in MMW was associated with improvements in body weight, but it was also 
linked to a worst lipid profile. 
The changes in adiponectin before puberty are not well established, as there are 
controversial results (Paper I). In our study, total adiponectin and the absolute and relative 
concentrations of adiponectin multimers did not differ, before and after the exercise 
interventional program, between obese and control pre-pubertal individuals (Paper VII). 
Nevertheless, controls and obese children who improved their BMI z-score did not present 
a reduction in total adiponectin following the interventional study, as occurred with obese 
participants who did not improve their body weight. Regardless of that, the multimer 
relative percentage was maintained in all groups (Paper VII). 
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Studies with larger populations of both pre-pubertal and pubertal individuals are needed to 
clarify how adiponectin multimers vary in obese pediatric populations, their relation with 
other metabolic risk markers and the influence of weight reduction.  
Although with both interventional programs the improvement in adiposity was not very 
striking (Papers VI and VII), it is important to highlight that a considerable percentage of 
obese children stabilized their weight, breaking the positive caloric balance and the 
increase of obesity. Although this is not the final target of the program, it is an important 
achievement for the children. Also, the fact that metabolic improvements, occur before 
esthetical modifications is particularly important, and must be used to motivate children, 
care-takers and health professionals involved in the fight against obesity. 
The fact that both approaches presented similar effects must be further explored, in order 
to understand which variables limit, and which increase, the success rates. Moreover, 
some other strategies to improve the success of obesity treatment can be considered, 
such as: 
1. An interventional approach focused on the family environment, aiming to educate 
parents and care takers on healthy habits and avoidance of an obesogenic 
environment. The inclusion of parents in the interventional programs would also be 
of great importance; 
2. A closer participation of a nutritionist in the interventional programs. A nutritional 
re-education of parents and children is crucial to obtain the best results and to their 
maintenance; 
3. The inclusion of a psychologist in the team. Personal appointments with a 
psychologist, and the use of questionnaires to clarify psychological and 
motivational issues that could block the treatment, might increase the success and 
prevent drop-outs; 
4. To evaluate different exercise and activity protocols. An interesting option would 
be to randomly address to each school a different protocol; 
5. Increase the number of check points, to evaluate child progress and to detect 
individuals that are not improving weight, or that significantly reduced the 
improvement rate. 
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16. Concluding remarks 
Portuguese obese children and adolescents presented an increased metabolic risk profile, 
including dyslipidemia, IR, inflammation and oxidative stress, when compared to their lean 
counterparts.  
Abdominal obesity, inflammation, IR and oxidative stress are at the basis of the metabolic 
derangement caused by obesity, and as they present a very close interrelation, it is 
difficult to find causality relations.  
The use of insulin and HOMAIR as early markers of IR in routine clinical analyzes of 
pediatric obesity could help to identify individuals with increased risk of developing T2DM 
and other comorbidities.  
Adiponectin has a central role in obesity-related metabolic changes. The different 
circulating forms of adiponectin might present different, or even opposite effects on MS 
features. Our data suggest that the HMW adiponectin might be particularly important in 
pre-pubertal individuals, being the adiponectin form with more beneficial effects, 
particularly in lipid profile and IR. BMI improvement helps to prevent adiponectin reduction 
in children and adolescents. Understanding how total adiponectin and its multimers 
influence the metabolism, before and after puberty, is important, particularly in pediatric 
populations.  
Bilirubin, an anti-oxidant molecule, is positively correlated with BMI and inversely 
correlated with body and trunk fat percentages and with CRP, in obese children and 
adolescents. In fact, individuals who are more obese have reduced bilirubin, probably due 
to its consumption in increased metabolic stress. Furthermore, we demonstrated that 
adiposity is a major determinant of bilirubin levels, independently of UGT1A1 
polymorphism, a major determinant of bilirubin levels in general population.  
Neutrophil count, a routine clinical analysis, can be used as a cost effective obesity-
related inflammation marker, as it is positively related with adiposity markers and CRP 
levels (a high sensitive marker of inflammation).  
Genetic polymorphisms in the apo E, apo (a) and UGT genes were associated with 
increased metabolic derangement. Nevertheless, the effect of a less favorable genetic 
profile on risk markers can be modulated by improvements in adiposity and inflammatory 
mediators (e.g. adiponectin).  
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More studies are needed to understand the causality and the mechanistic of obese related 
inflammation and metabolic disturbances. The study of genetic polymorphisms of 
inflammatory mediators and of their influence on the plasmatic levels of those markers, 
and on other routine clinical parameters, could help to identify individuals at increased 
risk, who would benefit of an early intervention. 
School and community based interventional approaches are good options to reduce 
weight gain and to improve metabolic status of obese children and adolescents. In fact, 
we verified that even small reductions in body weight are associated to improvements in 
CV risk profile, although the improvements in inflammatory mediators might need greater 
reductions. The study of different, family based, protocols with the support of a 
multidisciplinary team, could enhance the success of the treatment of obesity in children 
and adolescents.  
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